WO2016198749A1

WO2016198749A1 - Diagnostic biomarkers, clinical variables, and techniques for selecting and using them

Info

Publication number: WO2016198749A1
Application number: PCT/FI2016/050417
Authority: WO
Inventors: Matti Poutanen; Taija SALONIEMI; Kaisa Huhtinen; Antti PERHEENTUPA; Pia SUVITIE; Tero AITTOKALLIO; Harri Siitari; Daniel LAAJALA
Original assignee: University of Turku
Current assignee: University of Turku
Priority date: 2015-06-12
Filing date: 2016-06-10
Publication date: 2016-12-15
Anticipated expiration: 2017-12-12

Abstract

The present disclosure relates to the field of in vitro diagnostics. More specifically the present disclosure relates to non-invasive means and methods for determining a subject's diagnostic state. In particular, novel combinations of biomarkers and/or clinical variables, and processes for selecting or identifying them for determining a subject's diagnostic state are disclosed. The presently disclosed techniques for selecting and combining the biomarkers and clinical variables are applicable to determining a subject's diagnostic state of not only endometriosis but also other diseases particularly diseases associated with lower abdominal pain.

Description

DIAGNOSTIC BIOMARKERS, CLINICAL VARIABLES, AND TECHNIQUES FOR

SELECTING AND USING THEM

FIELD OF THE INVENTION

BACKGROUND OF THE INVENTION

Some specific use cases of the present disclosure relate to endo- metriosis. Endometriosis is a chronic estrogen-dependent gynecological disorder characterized by the presence and growth of endometrial tissue outside of the uterus. Globally, the disease affects up to 10% of women (176 to 181 million worldwide). Patients with endometriosis commonly complain of progressive and debilitating dysmenorrhea that begins already before menstruation. The pain may range from mild to severe, and is characteristically dull and aching. Dyspareunia, dysuria and painful defecation are also commonly associated with endometriosis. The experienced pain correlates poorly with the observed severity of the disease, although advanced endometriosis is strongly associated with infertility. The disease primarily affects women of reproductive age, and the associated pain and infertility symptoms have a significant impact on physical and mental well-being. Consequently, the health burden and social cost associated with endometriosis are very high with a recent estimate of over 9000€ per woman per year in the EU due to loss of productivity and direct health care costs.

Patients with endometriosis have significant unmet needs due to the lack of non-invasive diagnostics and the lack of approved treatment options that could provide both continuous efficacy and a favorable long-term safety profile. Suspicion of endometriosis arises from the presenting symptoms. Despite typical symptoms and clinical findings the diagnostic delay is several years. This delay is mostly a consequence of ineffective suspicion of endome- triosis despite the presenting symptoms. A typical finding in endometriosis is the presence of painful nodules on the uterosacral ligaments. Limited mobility of the uterus is also common. When endometriosis is suspected, additional investigations are needed for definitive diagnosis. Laparoscopy is the gold standard, resulting in a correct diagnosis in -90% of cases. It is also useful for the staging of disease. However, only 20-50% of women who undergo exploratory laparoscopy are found to have endometriosis. Currently, the most widely used staging system of the American Fertility Society relies on visualization and identification of endometriotic lesions. Even with the confirmed diagnosis there are currently no predictive tools to evaluate the response to medical treatment, rate of progression, risk of reoccurrence, risk of malignant transformation and effect on fertility.

Several serum markers have been studied for using in the diagnostics of endometriosis. Serum CA125 is elevated in the serum of -60% of stage III and IV endometriosis patients. However, only 33% of stage l/l I patients have elevated concentrations. Therefore, the assay is not considered to be sufficiently sensitive as a screening test. In addition, several other serum markers have also been studied, while none of the studies have been able to identify a set of serum markers clinically useful for identifying endometriosis. Thus, the diagnosis of endometriosis is currently mostly based on clinical signs and symptoms, physical examination and imaging techniques, such as ultrasound or MR imaging. However, as many of the clinical signs and symptoms of the disease, such as lower abdominal pain, are relatively unspecific and do not directly allow reliable diagnosis of endometriosis, incontrovertible proof of dis- ease requires histological examination of specimens collected during laparoscopy. Due to the invasiveness of laparoscopic intervention, symptomatic women suspected of having endometriosis are often treated symptomatically with analgesics and hormonal medication prior to a definitive laparoscopic diagnosis.

Thus, there is an identified need for non-invasive and accurate methods for diagnosing and monitoring endometriosis. Furthermore, there is a need for enhanced computer-assisted processes for selecting effective bi- omarkers, clinical variables and/or combinations of these for a computer- implemented method for determining a subject's diagnostic state or condition. BRIEF DESCRIPTION OF THE INVENTION

One aspect of the present disclosure is directed to a computer- implemented in vitro method of determining a subject's diagnostic state, as defined in claim 1. As used herein, determination of a subject's diagnostic state shall be interpreted in a slightly broader sense compared with unequivocal confirmation or exclusion of a disease. In the present disclosure, determination of the subject's diagnostic state shall also comprise processes whose outcome is a computed risk for the subject to have or develop a disease, although a conclusive diagnosis is not made. Other aspects of the present disclosure are directed to a processor specially adapted to carry out the method of claim 1 , and to a tangible non-transitory memory, which comprises program code instructions as defined in the independent claim directed to the processor.

In a still further aspect, the present disclosure is directed to a method of determining a subject's endometriosis state, said method comprising:

a) assessing levels of biomarkers comprising human cancer antigen

125 (CA125), Midkine (MDK), and Elastin microfibril interfacer 1 (EMILIN1 ) in a sample obtained from said subject,

b) comparing the determined biomarker levels and corresponding control levels, and

c) responsive to the comparison, determining the subject's endometriosis state,

wherein increased levels of CA125 and MDK, and decreased level of EMILIN1 in said sample are indicative of endometriosis.

In some embodiments, said the biomarkers may further comprise at least one biomarker selected from the group consisting of Granulocyte- macrophage colony-stimulating factor (GM-CSF), phosphatidylcholine acyl- alkyl C38:1 (PC ae C38:1 ), phosphatidylcholine acyl-alkyl C38:2 (PC ae C38:2), and any combination thereof.

In some further embodiments, said biomarkers may additionally comprise at least one biomarker selected from the group consisting of epidermal growth factor (EGF), interleukin-1 receptor antagonist (IL-1 Ra), interleukin- 17 (IL-17), and any combination thereof.

In some still further embodiments, said biomarkers may further comprise human epididymal secretory protein E4 (HE4).

In some embodiments, the method further comprises assessing at least one clinical variable selected from the group consisting of the subject's general information, surgical information, medical history, obstetric history, and pain symptoms. Preferably, the method comprises assessing at least one pain symptom selected from the group consisting of menstrual pain, intercourse pain, and defecation pain.

In some embodiments, determination of a subject's endometriosis state includes diagnosing, testing for, prognosing or monitoring endometriosis state, risk of endometriosis, response to treatment of endometriosis, recurrence or relapse of endometriosis, or risk of recurrence or relapse of endometriosis.

In some embodiments, the presence of endometriosis is determined on the basis of an increased level of said at least one biomarker as compared with a corresponding control level.

In some embodiments, said determining the presence or absence of endometriosis in step c) includes determining or prognosing any possible re- lapse of the disease or response to treatment.

In some further embodiments, the method is used for excluding the presence or risk of a lower abdominal pain-associated disease other than endometriosis, such as disease selected from the group consisting of endometrial can-cer, ovarian cancer, colon cancer, ulcerative colitis, irritable bowel dis- ease, irritable bowel syndrome and Crohn's disease.

In another aspect, the present disclosure provides an in vitro screening kit comprising reagents for determining a biological sample for the level of biomarkers comprising CA125, MDK, and EMILIN1.

In some embodiments, the kit may further comprise reagents for de- termining the level of at least one biomarker selected from the group consisting of GM-CSF, PC ae C38:1 , PC ae C38:2, and any combination thereof.

In some further embodiments, the kit may additionally comprise reagents for determining the level of at least one biomarker selected from the group consisting of EGF, IL-1 Ra, IL-17, and any combination thereof.

In some still further embodiments, the kit may additionally comprise one or more reagents for determining the level of HE4.

In a further aspect, the present disclosure is directed to use of a biomarker combination comprising CA125, MDK, and EMILIN1 for determining a subject's endometriosis state.

In accordance with other aspects of the present disclosure, said use may further comprise use of at least one biomarker selected from the group consisting of GM-CSF, PC ae C38:1 , PC ae C38:2, and any combination thereof.

In some embodiments, said use may further comprise use of at least one biomarker selected from the group consisting of EGF, IL-1 Ra, IL-17, and any combination thereof.

In some further embodiments, said use may additionally comprise use of HE4.

Other objectives, aspects, embodiments, details and advantages of the present invention will become apparent from the following figures, detailed description, examples, and dependent claims.

BRIEF DESCRIPTION OF THE DRAWINGS

In the following section, specific embodiments of the present disclosure will be described in greater detail in connection with illustrative but non-restrictive examples. Reference is made to the following drawings:

Figure 1 shows an overview of a feature selection and classification process in prediction of endometriosis;

Figure 2 generally illustrates the concept of a decision-making process in which a subject's diagnosis of endometriosis is either confirmed or excluded;

Figure 3 is a more detailed process flow chart;

Figures 4A and 4B depict sample screens (pages) of a tool view, which is used to obtain clinical variables concerning patients;

Figure 4C depicts a sample screen relating to risk assessment;

Figure 5 shows examples of decision trees with clinical variables and bi- omarkers; typically large numbers of such decision trees generated to fit the patient information provided;

Figure 6A depicts ranking of the importance of features (clinical variables and biomarkers) used in the model;

Figure 6B depicts AUC (area under curve), sensitivity and specificity of the endometriosis diagnosis obtained by using the tool with the three most important clinical variables and three most informative biomarkers included; and

Figure 7 depicts progress of AUC versus additional features, and maximum and minimum values obtained after 100 different repeats of the algorithm. DETAILED DESCRIPTION OF SOME SPECIFIC EMBODIMENTS

As used herein, the term "biomarker" refers to a molecule whose measurement provides information regarding a disease state of a subject and is a distinctive indicator of a pathologic condition or its absence. The term "bi- omarker of endometriosis" refers to a biomarker selected from the set of bi- omarkers provided by the present invention and which is indicative of endometriosis. The terms "biomarker" and "marker" are used herein interchangeably and they include, but are not limited to, protein markers, nucleic acid bi- omarkers (e.g. mRNA or cDNA) corresponding to or encoding said protein markers, and lipid markers.

As used herein, the term "assessing a biomarker level", and any corresponding expressions, refer to quantifying a biomarker. The term "level" is interchangeable with the terms "amount" and "concentration", and can refer to an absolute or relative quantity. Assessing a biomarker may also include de- termining the absence or presence of the biomarker. Absolute or relative quantities of one or more biomarkers may also be referred to as "an expression profile" or "an expression pattern".

The level of a biomarker in a biological sample may be determined by a variety of techniques as is readily apparent to a skilled person. Non- limiting examples of suitable methods include mass spectrometry, immunoassays, spectrophotometry, enzymatic assays, ultraviolet assays, kinetic assays, electrochemical assays, colorimetric assays, turbidimetric assays, atomic absorption assays, flow cytometry, liquid chromatography such as high performance/pressure liquid chromatography (HPLC), gas chromatography, nuclear magnetic resonance spectrometry, and any combinations thereof.

As used herein, the term "sample" refers to a biological sample, typically a clinical sample which may be, for example, a tissue sample, such as a biopsy or a laparoscopy sample, or a sample of a bodily fluid, such as urine, blood, plasma, or serum, obtained from a subject. Generally, obtaining the sample to be analyzed from a subject is not part of the present method of determining a subject's state. Serum samples and plasma samples are the most preferred sample types to be used in the present method.

In some embodiments, biological samples may be obtained from the subject at various time points before, during, or after treatment. The expression levels of the present biomarker combinations in the biological sample are then determined and compared with those in a biological sample obtained from the same subject at a different time point, or with a control level obtained, for example, from a reference sample derived from an individual whose endometriosis state is known and/or who has not been exposed to said treatment. In some embodiments, predetermined reference values obtained from a pool of apparently healthy individuals may be used as control levels in said comparisons.

In some embodiments, clinical variables obtained from a subject may be used with or without biomarker data to determine the subject's diagnostic state. The clinical variables may be obtained at various time points be- fore, during, or after treatment and compared with those obtained from the same subject at a different time point.

As used herein, the term "clinical variable" includes various objective or subjective variables concerning a subject's health or general condition. For instance, the term includes, but is not limited to, general information such as the subject's age, height, weight, menopausal status, and features of the menstrual cycle. The term also includes the subject's surgical history including status, reason, location, and number of previous abdominal surgery or surgeries, procedures used during previous abdominal surgery or surgeries, possible removal of the ovary and/or the Fallopian tube, and hysterectomy history. The term also includes the subject's obstetric history including gravidity history and parity, ectopic pregnancies and treatments, history of miscarriage and medical abortions, history of infertility treatments, number of in vitro fertilizations (IVF, ICSI), history of insemination and ovulation induction, number of ovulation induction procedures, normality of partner's sperm, success of infertility treat- ments, and current desire for pregnancy (trying for more than a year without success). Furthermore, the term includes other history information such as the subject's medication history (especially concerning hormonal medication), diagnostic history, and history of disorders associated with lower abdominal pain in close family member. The term also includes various pain-associated symp- toms, such as menstrual pain (duration, frequency, and severity of menstrual pain; type of medication required for alleviating menstrual pain); intercourse pain (description of pain, frequency and severity of pain, avoidance of intercourse because of pain), urinary pain i.e. pain associated with urinary bladder function (duration, frequency, and severity of pain, occasions of experienced pain symptoms, association with menstrual cycle, and previously diagnosed bladder related diseases); chronic abdominal pain, i.e. history of recurrent pain in the abdominal area lasting at least 6 months wherein the pain is other that menstrual pain, pain during intercourse, and defecation or urination associated pain (frequency of pain symptom, length of recurrent pain in the abdominal area, association with the menstrual period and severity of pain); and symp- toms associated with the digestive tract, particularly defecation-related symptoms (duration, frequency and severity of defecation-associated pain, obstipation, diarrhea, association of the symptoms with menstruation, frequency of defecation previous diagnosis of haemorrhoid or anal fissure, previous diagnosis of a bowel related disease or symptoms, lactose intolerance, celiac dis- ease. The severity of pain symptoms may be evaluated on a scale such as the one from 0 to 10, wherein 0 denotes no pain and 10 denotes the strongest imaginable pain. Typically, the clinical variables are obtained from the subject by a questionnaire comprising any number of relevant questions. As is evident to those skilled in the art, the clinical variables to be taken into account, and thus the questions to be comprised in the questionnaire, may vary and depend on the disease in question.

The herein-disclosed techniques and methods for determining a subject's diagnostic state may be applied to any diseases, disorders, or conditions. Some embodiments concern diseases associated with lower abdominal pain including, but not limited to urinary, disorders, such as bladder or kidney problems, bowel disorders, such as Crohn's disease, colon cancer, ulcerative colitis, irritable bowel disease (IBD) or irritable bowel syndrome (IBS), disorders of the reproductive system, such as endometriosis, endometrial cancer, ovarian cancer, or any other gynecological disease.

As used herein, the term "subject" refers to an animal, preferably to a mammal, more preferably to a human, and in connection with gynecological diseases, most preferably to a woman. Depending on an embodiment in question, said subject may suffer from endometriosis with or without diagnosis, be suspected to suffer from endometriosis, be at risk of endometriosis, or may have already been treated for endometriosis. Accordingly, said subject may also suffer from, be suspected to suffer from, be at risk of, or may have already been treated for a disease other than endometriosis, especially another disease associated with lower abdominal pain. Herein, the terms "human subject", "patient" and "individual" are inter-changeable.

As used herein, the term "diagnostic state" refers any distinguishable manifestation of a disease, including non-disease. For example, the term includes, without limitation, information regarding the presence or absence of the disease, the risk of the disease, the stage of the disease, progression or remission, relapse or recurrence of the disease over time, and the severity of the disease.

Accordingly and by way of example, the term "endometriosis state" refers any distinguishable manifestation of endometriosis, including non- disease. For example, the term includes, without limitation, information regarding the presence or absence of endometriosis, the risk of endometriosis, the stage of endometriosis, progression or remission, relapse or recurrence of en- dometriosis over time, and the severity of endometriosis. As is apparent to those skilled in the art, corresponding terminology may be applied to any other disease, disorder, or condition as well, including but not limited to those associated with lower abdominal pain. As used herein, the term "determining a subject's diagnostic state" refers, without limitation, to diagnosing, testing for, prognosing or monitoring state of a disease, progression of said disease, risk of said disease, response to treatment, remission, relapse or recurrence of said disease, or a risk of remission, relapse of recurrence of said disease.

Accordingly and by way of example, the term "determining a subject's endometriosis state" refers, without limitation, to diagnosing, testing for, prognosing or monitoring endometriosis state, progression of endometriosis, risk of endometriosis, response to treatment, remission, relapse or recurrence of endometriosis, or a risk of remission, relapse of recurrence of endometriosis. Again, corresponding terminology may be applied to any other disease, disorder, or condition including but not limited to those associated with lower abdominal pain.

As used herein, the term "diagnosing" refers, without limitation, to a process aimed at determining whether or not a subject is afflicted with a disease such as endometriosis or any other disease associated with lower abdominal pain. This is also meant to include instances where the presence or a stage of said is not finally determined but that further diagnostic testing is warranted. In such embodiments, the method is not by itself determinative of the presence or absence of said disease, or the stage of said disease in the subject but can indicate that further diagnostic testing is needed or would be beneficial. Therefore, the present method may be combined with one or more other diagnostic methods for the final determination of the presence or absence of said disease , or the stage of said disease in the subject. Such other diagnostic methods are well known to a person skilled in the art, including but not limited to, laparoscopy.

In accordance with the above, the techniques disclosed herein may be used not only for diagnostic purposes but also for prognosis or predicting the outcome of or risk of a disease such as endometriosis or any other disease associated with lower abdominal pain, or monitoring the subject's disease state over time, any possible remission, recurrence or relapse of the disease, or response to treatment. Monitoring of a subject's disease state can be performed by continuously measuring certain parameters and/or performing a medical test repeatedly. In some embodiments of the present invention, a subject's disease state is monitored by obtaining bodily fluid samples repeatedly, assaying the samples using the method disclosed herein and comparing assay results with one another and with a reference value to identify any change in the subject's disease state.

Furthermore, the techniques disclosed herein may be used for differential diagnostics, i.e. for distinguishing of a particular disease, disorder, or condition from others that present similar clinical features. In some embodiments, the techniques are particularly suitable for differentiating various abdominal pain-associated diseases from each other.

As used herein, the term "indicative of a disease", when applied to a biomarker, refers to an expression pattern or profile which, using routine statistical methods setting confidence levels at a minimum of 95%, is diagnostic of said disease or a stage of said disease such that the expression pattern is found significantly more often in subjects with said disease or a stage of said disease than in subjects without said disease or another stage of said disease. Preferably, an expression pattern which is indicative of a disease is found in at least 80% of subjects who have the disease and is found in less than 10% of subjects who do not have the disease. More preferably, an expression pattern which is indicative of said disease is found in at least 90%, at least 95%, at least 98%, or more in subjects who have the disease and is found in less than 10%, less than 8%, less than 5%, less than 2.5%, or less than 1 % of subjects who do not have the disease. In some embodiments, said disease is associated with lower abdominal pain. In some further embodiments, said disease is endometriosis.

For the sake of simplicity, as used herein, the terms "expression profile" and "expression pattern" refer not only to an expression level of a pro- tein or nucleic acid biomarker or but also to a level of a lipid biomarker, although it is understood that lipids are not expressed through translation but synthetized in a series of defined steps in the cytoplasm.

To determine whether an expression profile of a biomarker is indica- tive of a disease, the expression profile of the biomarker in a relevant control has to be determined. Once the control levels are known, the determined marker levels can be compared therewith and the significance of the difference can be assessed using standard statistical methods. In some embodiments of the present disclosure, a statistically significant difference between the deter- mined biomarker level and the control level is indicative of a disease such as endometriosis or any other disease associated with lower abdominal pain. In some further embodiments, before to be compared with the control, the biomarker levels are normalized using standard methods.

As used herein, the term "control" may refer to a control sample ob- tained from an apparently healthy individual or a pool of apparently healthy individuals, or it may refer to a predetermined threshold value which is indicative of the presence or absence of a disease in question. Statistical methods for determining appropriate threshold values will be readily apparent to those of ordinary skill in the art. The control or threshold values may have been de- termined, if necessary, from samples of subjects of the same age, demographic features, and/or disease status, etc. The threshold value may originate from a single individual not affected by a disease in question or be a value pooled from more than one such individual.

As used herein, the term "apparently healthy" refers to an individual or a pool of individuals who show no signs of a disease in question and thus are believed not to be affected by said disease in question and/or who are predicted not to develop said disease in question.

As used herein, the term "increased expression" refers to an increase in the amount of a biomarker in a sample as compared with a corre- sponding control sample. Said increase can be determined qualitatively and/or quantitatively according to standard methods known in the art. The expression is increased if the amount or level of the biomarker in the sample is, for instance, at least about 1.5 times, 1.75 times, 2 times, 3 times, 4 times, 5 times, 6 times, 8 times, 9 times, time times, 10 times, 20 times or 30 times the amount of the same biomarker in the control sample. In some embodiments, the term "increased expression" refers to a statistically significant increase in the level or amount of the biomarker as compared with that of a relevant control.

As used herein, the term "decreased expression" refers to a decrease in the amount of a biomarker in a sample as compared with a corre- sponding control sample. Said decrease can be determined qualitatively and/or quantitatively according to standard methods known in the art. The expression is decreased if the amount of the biomarker in the sample is, for instance, at least about 1.5 times, 1.75 times, 2 times, 3 times, 4 times, 5 times, 6 times, 8 times, 9 times, time times, 10 times, 20 times or 30 times lower than the amount of the same biomarker in the control sample. In some embodiments, the term "decreased expression" refers to a statistically significant decrease in the level or amount of the biomarker as compared with that of a relevant control.

As used herein, "sensitivity" is a measure of the ability of a marker to detect the disease. In other words, sensitivity represents the probability of a positive test result in subjects with the disease.

As used herein, "specificity" is a measure of the ability of a marker to detect the absence of the disease. In other words, specificity represents the probability of a negative test result in a subject without the disease.

As used herein, the term "false positive" (FP) refers to a test result which classifies an unaffected subject incorrectly as an affected subject, i.e. a subject having or predicted to develop a disease. Likewise, "false negative" (FN) refers to a test results which classifies a subject who has or will develop a disease incorrectly as an unaffected subject.

As used herein, the term "true positive" (TP) refers to a test result which classifies a subject who has or will develop a disease correctly as a subject having or predicted to develop a disease. Likewise, "true negative" (TN) refers to a test result which classifies an unaffected subject correctly as an unaffected.

In accordance with the above, the term "success rate" refers to the percentage-expressed proportion of affected individuals with a positive result, while the terms "false positive rate" and "false detection rate" (FDR) refer to the percentage-expressed proportion of unaffected individuals with a positive result.

As used herein, the term "accuracy", also called "diagnostic effectiveness", refers to a proportion of correctly classified subjects (TP+TN) among all subjects (TP+TN+FP+FN).

Receiver Operation Characteristic (ROC) curves may be utilized to demonstrate the trade-off between the sensitivity and specificity of a marker, as is well known to skilled persons. The horizontal X-axis of the ROC curve represents 1 -specificity, which increases with the rate of false positives. The vertical Y-axis of the curve represents sensitivity, which increases with the rate of true positives. Thus, for a particular cut-off (i.e. threshold) selected, the values of specificity and sensitivity may be determined. In other words, data points on the ROC curves represent the proportion of true-positive and false- positive classifications at various decision boundaries. Optimum results are obtained as the true-positive proportion approaches 1.0 and the false-positive proportion approaches 0.0. However, as the cut-off is changed to increase specificity, sensitivity usually is reduced and vice versa.

The area under the ROC curve, often referred to as the AUC, is a measure of the utility of a marker in the correct identification of disease subjects, i.e. subjects who are affected by a disease. Thus, the AUC values can be used to determine the effectiveness of the test. An area of 1.0 represents a perfect test; an area of 0.5 represents a worthless test. A traditional rough guide for classifying the accuracy of a diagnostic test is the following: AUC val- ues 0.9 to 1.0 represent a test with excellent diagnostic power, AUC values 0.80 to 0.90 represent a test with good diagnostic power, AUC values 0.70 to 0.80 represent a test with fair diagnostic power, AUC values 0.60 to 0.70 represent a test with poor diagnostic power, and AUC values 0.50 to 0.60 represent a test with failed diagnostic power. AN ALGORITHMIC APPROACH FOR DETERMINING A SUBJECT'S DIAGNOSTIC STATE

Figure 1 shows an overview of a feature selection and classification process in prediction of a subject's classification into one of diagnostic states, such as patient or control group. The following description and the associate drawings relate to an environment used for developing an algorithm for diagnosing endometriosis. Those skilled in the art will understand, however, that the algorithmic classification approach is applicable to other diseases or conditions for which the classification is based on combinations of clinical variables and biomarkers. After combining clinical variables and biomarkers from patients, wrapper feature subset selection methodology (Kohavi, 1997) was used to select the best discriminating features (clinical variables and biomarkers) for the prediction problem, namely disease versus control classification. In this disclo- sure, "best" discriminating features means those that maximize the ratio of correct classifications to all classifications. In some implementations, sensitivity vs. (1 -specificity) is plotted as a normalized curve, ie, a curve whose x- and y- axes are normalized to the range of {0, 1}, and the area under the curve (AuC) is used as the metrics. Sensitivity can be expressed as the ratio true positives /(true positives + false negatives) and specificity as the ratio true nega- tives/(true negative + false positives) of prediction.

The size of the search space for n features grows with 2ⁿ, which means that exhaustive searches over typical clinical data sets are impractical or impossible. Instead, a heuristic function guides the search to find feature subsets with the highest-scoring evaluator functions. In "wrapper" selection methods the actual accuracy is not known, but an accuracy estimate is often used as both the heuristic function (which guides the search) and the evaluator function (which evaluates the goodness of a candidate subset). The inventors used repeated cross-validation as the evaluator function.

Each filtering approach emphasizes certain benefits. Wrapper feature subset selection methodology is one of several filtering approaches described by Kohavi et al. The inventors found wrapper feature subset selection attractive because it forces the accuracy estimation to execute cross-validation more times on small datasets than on large datasets. Because small datasets require less time to learn, the overall accuracy estimation time, which is the sum of the induction algorithm running time and the cross-validation time, does not grow too fast. This means that small datasets will be cross-validated many times to overcome the high variance resulting from small amounts of data. The inventors experimented with the wrapper subset selection strategy in a repeat- ed cross-validation setting and assembled the results across different repeats of the cross-validation. In a feature selection phase, 200 repeats of cross- validation were performed. Special consideration was taken in encoding variables for clinical data because most of the variables were categorical. Finally, the results from the repeated cross-validations were assembled into a final list of features to be used for classification. After the most discriminating features were selected, a similar repeated five-fold cross-validation was used to train the machine learning classifier for final classification as shown in Figure 1. As the machine-learning classifier, a version of bootstrap aggregation ("bagging") with a random subset of features was used. A readily available software package is the Random forest package in R (Liaw, 2012). Some of the parameters used were also learned in the cross-validation setting (e.g. mtry parameter which is the number of variables randomly sampled as candidates at each split), while some others were default parameters of the Random forest package (e.g. ntree which determines the number of trees to grow). Repeated cross-validation was used to search for the best parameters of random forest and to quantify the predictive power of the machine learning model. The final results reported are averaged over all the repeats of the cross-validation. In final classification, 100 repeats of cross- validation were executed. Each repeat was randomly seeded at each iteration in both feature selection and final classification for variation in different random parameters (e.g. division of data into test and training set in cross-validation). The reported results are averages of different repeats.

Feature Selection

For the purposes of the present disclosure, the biomarker discovery can be formulated as:

Let X = {X(i ), X(2), X(D)} be a set of predictors (features, i.e., biological measurements) and T be the target variable (i.e., the disease status we want to predict). The task of feature selection is to find a minimal subset X'={X(i), X(2), X(d)} of X such that it achieves maximum classification perfor- mance of T (for a given classifier and a given classification metric) and d«D.

Classification: Bootstrap aggregation with random subset of features

Decision trees are excellent modelling tools which have found usage in many application domains. However, a major drawback of decision trees is that they are prone to overfitting to their training sets. Several tech- niques exist that address the overfitting problem. For instance, bootstrap aggregating of decision trees - abbreviated "tree bagging" - is a class of methods, in which the bagging algorithm repeatedly selects (B times) a random sample with replacement of the training set and fits trees to these samples. Such algorithms improve the performance of the model by decreasing its variance without increasing bias.

The inventors have experimented with multiple different classification schemes and discovered that algorithms based on "Random forest" mod- els are particularly effective for identifying effectively predictive biomarkers, at least for endometriosis. However, use of "Random forest" is registered as US trademark number 3185828, which is why the technically descriptive term "bootstrap aggregation with random subset of features" (or its shorter version "bagging with a random feature subset") is preferred in this disclosure.

Bagging with a random feature subset is thus a technique which address the tendency of decision-tree-based decision algorithms to overfit to their training data sets. It uses a collection of decision trees, each of which is trained on different random permutations of the data as well as the predictive features. Finally, the results from these different decision trees are combined (typically, averaged) to get the final unbiased prediction, which ameliorates the disadvantages of a single decision tree and provides better and more robust generalization capabilities.

Bagging with a random feature subset

"Bagging" (bootstrap aggregation of) a decision tree with a random subset of features involves an ensemble of multiple decision trees that are useful for classification, regression, and also missing value imputation. In the presently disclosed application to endometriosis diagnosis, bagging is used to arrive at a classification setting which models a binary response (Patient or Control) as a function of predictor variables (biomarkers with or without clinical variables concerning patients). Generally, decision tree algorithms create a binary tree by repeatedly splitting the features in the dataset into two groups. At each branching point (a node in the tree), any feature can be divided into two groups (children) which results in the best separation between the categorical response. The splitting is performed until a criterion for stopping the split- ting is completed. Typically the splitting is stopped when a minimum number of nodes nmin is reached of the tree needs no further splitting because its leaves contain observations of a single class

One of the major challenges in decision tree learning is how to determine the procedure to split the trees. A Gini impurity index (G) of the parents and its prospective child is often used as the splitting criterion. If the current node consists of n observations in P classes, let n_p be the number of observations in the p^th class. We can now mathematically formulate the Gini impurity index as:

In the equation 1 (eq. 1 ) above, the value of G is at minimum (=0) when all the observations in a node are of the same class. Similarly, the Gini index G increases when observations from different classes are accumulated in the same node. Similar to the Gini index, other potential candidates for split- ting criterion are: information gain, variance reduction, and other statistical tests.

The process of constructing of the tree is begun by computing the

Gini index in the parent node. Then for all the predictors, different unique binary partitions are considered, first splitting between the first and second lowest values and continuing with the second and third lowest values and so on. At each split, samples with a value lower than or equal to the threshold of split is assigned to the one of the two children of the node (e.g. left child of the binary tree) and the samples with values larger than the threshold of split is assigned to the other child of the node (e.g. right child of the binary tree). We then com- pute the Gini index for each of the child node, and the final Gini index is the average of these two Gini index. Considering all the variables and value splits, we choose the split that leads to the largest reduction in the Gini index. We continuously split all the nodes until the Gini index is 0, i.e., all the samples in the child node are of the same class.

A simplified algorithm for bagging with a random feature subset can be described in the form of pseudocode as follows:

For a number of trees (b) in 1 to B

do

1. Use bootstrapping (bootstrap aggregating, or "bagging") to draw a bootstrap sample Z^* of size N from the training data- analysis;

2. Train a decision tree T_b to the bootstrapped data sample D^* recursively by:

a) Selecting I predictors at random from a total of p predic- tors; b) Picking the threshold to split the variable among all m variables (Gini index);

c) Splitting the node to two child nodes until the minimum number of nodes nmin is reached or the tree requires no further splits (e.g. Gini index is zero); and

3. Output ensemble of trees: ^osl

Finally, to make a prediction at a new point x:

Let U {x) be the prediction from both decision tree in the set of bootstrap-aggregated decision trees with random feature subsets. Then the final prediction from the set of such trees is given by @Tf( ) - majority vote { _b(_X)}^

The two-way arrows in Figure 1 indicate that feature selection and/or classification may be performed iteratively, to reduce the influence of random artefacts on final results.

Figure 2 generally illustrates the concept of an in vitro decisionmaking process in which a subject's risk of having or developing endometriosis is determined. As shown in Figure 2, features from one or two classes are obtained from the subject, namely biomarkers and/or clinical variables. Bi- omarkers, which are measurable indicators of some biological state or condi- tion, can be obtained via well-known methods, which are beyond the scope of the present disclosure. It should be noted that the decision-making process described herein does not use physical samples obtained from subjects but data elements describing the physical samples.

Clinical variables are information elements which objectively and/or subjectively describe the subject. Examples of objective descriptors include the subject's age, weight, menopausal status, or the like. Examples of subjective descriptors include the subject's own evaluation of various pains. The features obtained from the subject are inputted to a computer-implemented model, which is based on the above-described machine-learning process. In that pro- cess, candidate sets of decisions trees are filtered to yield an optimized set of decisions trees, which is used to process the features obtained from the subject. The result of the in vitro decision-making process shown in Figure 2 may be a qualitative diagnosis (eg endometriosis or not) or a quantitative risk assessment (eg x% likelihood of having endometriosis, with y% confidence and z% accuracy). Figure 3 is a more detailed flow chart of an overall process, which comprises model creation (shown as phase A) and diagnostic decision-making (shown as phase B). The model-creation phase comprises step 3-2, in which clinical variables describing large numbers of samples are obtained. In the preset context, large numbers of samples means sample sizes large enough to draw scientifically solid conclusions, such as correlations between feature sets and diagnostic status.

In some embodiments the clinical variables are obtained via computerized user interfaces, which present one or more questionnaires. Each questionnaire comprises multiple questions, whose answers will form the set of clinical variables concerning one sample. The set of clinical variables is optimized in the Feature selection phase described in connection with Figure 1. In this disclosure, we assume that biomarkers describing the same samples are also available, which is why the test 3-4 is answered positively and the flow proceeds to step 3-6, in which the computer-implemented model (see Figure 2) is trained on both clinical variables and biomarkers obtained from the same samples. This model-training step 3-6 includes the feature-selection phase described in connection with Figure 1.

In phase B, the model trained in step 3-6 will be used in an in vitro diagnostic phase (or risk-assessment phase) concerning an individual subject (prospective patient). Phase B begins in step 3-12, in which biomarkers and clinical variables of the subject are obtained. This step is analogous with steps 3-2 and 3-6 described above, apart from the fact that the steps of phase A were performed with respect to a large number of samples. In step 3-14 the model trained in step 3-6 (namely the filtered sets of decision trees) is used to assess the subject's diagnostic status. In step 3-16 the result of step 3-12 are outputted from the computerized model. For instance, the results can be shown to a physician and/or the subject, but what the physician does with the results is beyond the scope of the present disclosure.

Figures 4A and 4B depict sample screens (pages) of a tool view, which is used to obtain clinical variables concerning patients. By way of example, the screen shown in Figure 4A is used to obtain objective information, but similar screens can be used to obtain subjective information, such as the subject's own assessment of various pains. The screen shown in Figure 4B may be used to combine biomarker data with clinical variables obtained by screens analogous with the one shown in Figure 4A. Figure 4C depicts a sample screen relating to risk assessment. The exemplary screen indicates a 94.06% risk for a disease (eg endometriosis), and its inverse value, namely 5.94% likelihood of not having that disease. Instead of indicating a risk (or likelihood) for a subject to currently have a dis- ease, a risk for having that disease in a future period of time may be calculated and shown. The two rightmost columns indicate an estimated confidence (97.30%) and estimated accuracy (87,78%).

Figure 5 shows examples of decision trees with clinical variables and biomarkers; typically large numbers of such decision trees generated to fit the patient information provided. Reference number 5-10 is one exemplary decision tree. The decision tree 5-10 has a root node 5-11 , which is associated with a feature (clinical variable or biomarker) 5-12, herein menstrual pain strength, which may be entered via a user interface analogous with the one shown in Figure 4A. The feature 5-12 has a threshold value 5-13 (here: a value of 4 for subjective assessment of menstrual pain strength). Still further parameters may be associated with the feature 5-12, such as a confidence value 5-14. Use of the decision tree 5-10 begins at the root node 5-11. Its associated feature and threshold are used to retrieve the corresponding feature obtained from the subject, which is compared with the threshold. If, say, the feature ob- tained from the subject (menstrual pain) is less than or equivalent to the threshold, traversal of the decision tree 5-10 proceeds to intermediate node 5-15, which is associated with feature (biomarker) MDK and threshold 0.316. If the corresponding feature (level of MDK) obtained from the subject is less than or equivalent to the threshold 0.316, the threshold, traversal of the decision tree proceeds to 5-21 , which is one of the leaf nodes 5-21 ... 5-25 of the decision tree 5-10. Leaf node 5-21 indicates an (approximately) 43% likelihood for classification as patient. Other decision trees, of which two exemplary ones are depicted by reference numbers 5-30 and 5-40 will be used to improve the confidence and accuracy of classification (prediction).

The nodes of decision trees, which are not leaf nodes, have associated features and threshold values, which the features are to be compared with. Several efficient features and feature sets will be given later in this disclosure, particularly for endometriosis. As regards determining the threshold values, the same threshold values that were used to create the decision trees in the machine-learning phase can also be used in the diagnostic or risk assessment phase. Figure 6A depicts ranking of the importance of features (clinical variables and biomarkers) used in the model, while Figure 6B depicts AUC (area under curve), sensitivity and specificity of the endometriosis diagnosis obtained by using the tool with the three most important clinical variables and three most informative biomarkers included. Figure 7 depicts progress of AUC versus additional features, and maximum and minimum values obtained after 100 different repeats of the algorithm. More information will be given in the Tables section at the end of this description.

CLINICAL VARIABLES

In some embodiments, any available clinical variables may be sub- jected to the algorithm disclosed herein for determining a subject's diagnostic state. The number of the clinical variables to be utilized may vary from an embodiment to embodiment, and may include at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, at least ten, etc. clinical variables selected independently from each other among various variable categories such as the subject's general information, surgical information, medical history, obstetric history, and various pain symptoms including but not limited to, menstrual pain, intercourse pain, and pain associated with defecation or urination. In some embodiments, menstrual pain, intercourse pain, and defecation pain are the most relevant clinical variables for determining a subject's endometriosis state.

BIOMARKERS

Serum concentrations of human cancer antigen 125 (CA125) are known to be elevated in patients with ovarian cancer, advanced endometriosis with peritoneal or deep lesions, or ovarian endometriomas. However, lack of sensitivity and specificity of CA125 has significantly hampered its use as a diagnostic tool. Furthermore, the classical cut-off value of CA125 (35 U/ml) used for diagnostics of ovarian cancer is far too high for diagnosing endometriosis. Nevertheless, CA125 may be used as a biomarker for determining a subject's state of a disease associated with lower abdominal pain, especially endometri- osis or ovarian cancer.

With reference to endometriosis and Example 1 , determination of CA125 levels alone with a cut-off value of 35 U/ml provided a sensitivity value of 39.1 , a specificity value of 100, and an accuracy value of 56.5. Reducing the cut-off value to 13 U/ml improved the sensitivity and accuracy values to 76.5 and 80.1 , respectively, while lowered the specificity value to 89.1. At its high- est, the accuracy value was 0.82 as shown in Table 1 below. Deternnination of CA125 levels alone provided an AUC value of 0.87.

Performance of the present method of determining a subject's endometriosis state was improved clearly when the levels of both CA125 and Midkine (MK or MDK), also known as neurite growth -promoting factor 2 (NEGF2), were assessed. With a CA125 cut-off value of 35 U/ml combined analysis of CA125 and MDK provided a sensitivity value of 76.3, a specificity value of 82.7, and an accuracy value of 78.2. Reducing the CA125 cut-off value to 13 U/ml improved the sensitivity, specificity, and accuracy values to 81.2 and 87, and 82.8, respectively. At its highest, the accuracy value was 0.861 as shown in Table 2 below. Overall, the combined analysis of CA125 and MDK provided an AUC value of 0.91 as shown in Table 7.

In some embodiments, performance of the present method was improved even further when the level of human epididymal secretory protein E4 (HE4, also known as WAP four-disulfide core domain protein 2) was assessed together with the levels of CA125 and MDK. Such a combined analysis provided an AUC value of 0.90 and, at its highest, an accuracy value of 0.886.

HE4 is a known biomarker whose expression is markedly increased in ovarian cancer, especially the stage I disease, and in endometrial cancer. Thus, another advantage associated with the use of HE4 in combination with CA125 and MDK is the differentiation of endometriosis from endometrial cancer and ovarian cancer.

In some embodiments, performance of the present method was improved further also when the level of any one of Elastin microfibril interfacer 1 (EMILIN1 ), Granulocyte-macrophage colony-stimulating factor (GM-CSF), and phosphatidylcholine acyl-alkyl C38:1 (lipid metabolite PC ae C38:1 ) or phosphatidylcholine acyl-alkyl C38:2 (lipid metabolite PC ae C38:2) were assessed together with the levels of CA125 and MDK. To be more specific, combined assessment of CA125, MDK, and EMILIN1 levels provided an accuracy value of 0.862 at its highest. Combined assessment of CA125, MDK, and GM-CSF levels, in turn, provided an accuracy value of 0.916, while combined assessment of CA125, MDK, and PC ae C38:1 and/or PC ae C38:2 levels provided, at its highest, an accuracy value of 0.928. Corresponding AUC values are shown in Table 7.

In addition to a combined determination of CA125, MDK and any one or any combination of EMILIN1 , GM-CSF, PC ae C38:1 , and PC ae C38:2, the present method may, in some embodiments, further comprise determination of the level of HE4, particularly for differentiating endometriosis from endometrial cancer and ovarian cancer.

In some embodiments, the present method may further comprise determination of any one or any combination of epidermal growth factor (EGF), interleukin-1 receptor antagonist (IL-1 Ra), and interleukin-17 (IL-17).

The endometriosis-associated biomarkers disclosed herein, namely CA125, MDK, EMILIN1 , GM-CSF, PC ae C38:1 , PC ae C38:2, EGF, IL-1 Ra, IL-17, and HE4 were identified among over 50 serum markers including for instance various cytokines, steroids, peptide hormones, and serum metabolites. In some embodiments, these biomarkers are used in the present technique or method depending on availability of reagents for assessing their expression levels. The expression levels of PC.ae.C38.1 , PC.ae.C38.2, IL-17, and EMILIN1 were decreased or down-regulated in patients with endometriosis while CA125, IL1 RA, HE4, EGF, GMCSF, and MDK were increased or upregu- lated in patients with endometriosis.

In one aspect, the present disclosure provides a method of determining a subject's endometriosis state on the basis of assessing the level of CA125, MDK, and EMILIN1 in a sample obtained from said subject. Optionally, the level of at least one further marker selected from GM-CSF, PC ae C38:1 , PC ae C38:2, EGF, IL-1 Ra, IL-17, and HE4 may be used in the analysis. As is apparent to a skilled person, measurements of the present biomarkers may be used alone or combined with other data obtained regarding the subject whose endometriosis state is to be determined. However, in the present aspect, the method per se does not involve analyzing any other data, such as clinical variables.

In accordance with the above, the present disclosure also provides use of the disclosed biomarker combinations in determining a subject's endometriosis state.

In a further aspect, the present disclosure provides a method of determining a subject's diagnostic state by obtaining at least three features from said subject, wherein at least one of the features is a clinical variable, and at least two of the features are biomarker levels, such as levels of biomarkers selected from CA125, MDK, EMILIN1 , GM-CSF, PC ae C38:1 , PC ae C38:2, EGF, IL-1 Ra, IL-17, and HE4, or vice versa. In some specific embodiments concerning endometriosis, said clinical variables are selected from menstrual pain, intercourse pain, and defecation pain, the presence of which together with the increased level of any one of CA125, IL1 RA, HE4, EGF, GM-CSF, and MDK and/or decreased level of any one of PC.ae.C38.1 , PC.ae.C38.2, IL-17 and EMILIN1 are indicative of endometriosis. In some other embodiments, in- creased level of at least CA125 and/or HE4 together with the presence of relevant clinical variables may be indicative of ovarian cancer. On the other hand, normal level of any one of CA125, MDK, EMILIN1 , GM-CSF, PC ae C38:1 , PC ae C38:2, EGF, IL-1 Ra, IL-17, and HE4 together with the presence of relevant clinical variables may indicate that the subject has or is at risk of developing a lower abdominal pain-associated disease other than endometriosis or ovarian cancer.

In some embodiments of the above aspect, i.e. of a method of determining a subject's endometriosis state on the basis of both clinical variables and biomarkers, the method comprises assessing any one, two or three clinical variables are selected from menstrual pain, intercourse pain, and defecation pain, and assessing the expression level of any one, two, or three biomarkers selected from CA125, MDK, and EMILIN1. The combined presence of the assessed one, two, or three pain symptoms, and increased expression of CA125 or MDK, and decreased expression of EMILIN1 are indicative of the presence of or risk of developing endometriosis.

As used herein, the term "presence of a pain symptom" may refer to a pain score X, on an intuitive scale, such as from 0 to 10. Thus, in some embodiments, the pain score of at least X is considered indicative of endometriosis. In some embodiments the threshold value X may be determined as the value that, based on available data, maximizes the AUC value of the feature or feature combination which depends on the pain score. In some embodiments the threshold value for the pain score may be set to an explicit value, such as at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine or at least 10. Different diseases and/or different pains may have different threshold values.

The present disclosure also provides a kit for use in determining a subject's endometriosis state. Said kit may comprise any reagents or test agents necessary for assessing the level of biomarker combinations disclosed herein. A person skilled in the art can easily determine the reagents to be in- eluded depending on the biomarker combination in question and a desired technique for carrying out said assessment. In some embodiments, an appro- priate control sample or a threshold value may be comprised in the kit. The kit may also comprise a computer readable medium, comprising computer- executable instructions for performing any of the methods of the present disclosure.

As is apparent to a skilled person any embodiments, details, advantages, etc. of the present disclosure regarding the method of determining a subject's endometriosis state apply accordingly to other aspects of the present disclosure, including use of the disclosed biomarker combinations in determining a subject's endometriosis state and a kit for use in said determination, and vice versa.

It will be apparent to a person skilled in the art that, as the technology advances, the inventive concept can be implemented in various ways. The invention and its embodiments are not limited to the examples described below but may vary within the scope of the claims. EXAMPLE 1

All biological samples were obtained with appropriate permissions and informed consents in accordance with the ethical guidelines of the Hospital District of Southwest Finland.

Methods

Serum of altogether 102 women with known or suspected endometriosis, and from 45 women with neither history nor suspicion of endometriosis seeking laparoscopic sterilization were prospectively enrolled, and serum was obtained. The exclusion criteria included acute pelvic infection, pregnancy and suspicion of malignancy. Women with suspected endometriosis but no ob- served lesions and women with unexpected asymptomatic endometriosis among controls were also excluded. The operations were carried out in random phase of the menstrual cycle. The serum samples from all participants were collected within 24 hours prior to the operation into non-heparinized tubes and centrifuged for 15 min at 800 g after being kept at room temperature for 30 minutes. The serum was stored at -20°C until analyzed. Serum CA125 concentrations (U/ml) were evaluated using ELISA analysis (Fujirebio Diagnostics Inc, Malvern, PA, USA) according to the manufacturer's instructions. The concentration of Midkine (MDK) was carried out using a sandwich enzyme immunoassay according to the instructions of the manufacturer (Biovendor Reaearch and Diagnostic Products, Czech Republic). Elastin microfibril interfacer 1 (EMILIN) was measured with an in-house sandwich immunoassay using commercially available antibodies. The granulocyte-macrophage colony-stimulating factor (GMCSF) was measured as part of the LINCOplex Kit (HCYTO-60K-PMX29, LINCO Research Inc., St. Charles, Missouri, USA) according to the manufacturer's instructions. The lipid metabolites (PC.ae.C38.0 and PC.ae.C38.1 ) being phospatidylcolines were analysed using targeted ESI-FIA-MS/MS by AbsolutelDQ p150 kit (BIOCRATES Life Sciences AG, Innsbruck, Austria).

Performance data of the assay combinations

To provide an unbiased estimate of the prediction performance of the multi-assay panel, we use nested five-fold cross-validation, as shown in Figure 1 , to train our machine learning classifier. We used Random Forrest as the machine learning classifier (Breiman, Machine learning 45.1 (2001 ): 5-32) via the randomForest Package (Liaw, "Documentation for R package random- Forest" (PDF), http://cran.r-project.org/web/packages/randomForest/ran- domForest.pdf, 16 October 2012, retrieved 18 August 2015). The parameters used were the default parameters in the package except for node and ntree (node =3 and ntree=100). First, we divided the data into five training and validation sets in order to avoid selection bias (Varma and Simon, BMC bioinfor- matics 7.1 (2006): 91 ). Only the training data was then again split into five different folds to tune the parameters of the classification model. The model that produced best results on the test data in the inside cross-validation setup was then again evaluated on the validation dataset in the outer cross-validation setup. The final results reported are the mean of the models on outer validation sets.

Results

Results obtained from different assay combinations are summarized in Tables 1 to 5 below. Table 6 shows biomarker levels before and after treatment. Further assay combinations and their respective AUC values will be giv- en in Table 7. Table 1. Sensitivity, specificity and accuracy analysed for CA125 alone

Threshold Sensitivity Specificity Accuracy

5: 0,9565217; 0,173913; 0,7329193;

7 0,8956522: 0,5; 0,7826087;

9 0,8695652: 0,6956522; 0,8198758

11 0,826087: 0,7608696; 0,8074534;

13 0,7652174i 0,8913043; 0,8012422;

17 0,6347826; 0,9565217; 0,7267081 ;

21 0,5652174; 0,9565217; 0,6770186;

35 0,3913043; 1 0,5652174;

37 0,3652174; 1 0,5465839;

40 0,3391304; 1 0,5279503;

AUC 0,8687;

Table 2. Sensitivity, specificity and accuracy analysed for CA125 bination with MDK

Threshold Sensitivity Specificity Accuracy

0.05 1 ; 0,022222222; 0,718818681 ;

0,2; 0,98; 0,308888889; 0,787953297;

0.4 0,95312253; 0,661111111 0,87157967;

0.55 0,911093544; 0,723333333; 0,859793956;

0.6 0,902397892; 0,748333333; 0,861236264

0.65 0,889064559; 0,788333333; 0,861236264

0.75 0,855924462; 0,828333333; 0,847293956;

0.85 0,795924462; 0,868333333; 0,814217033;

0.9 0,756504172; 0,912777778; 0,797967033;

1 0,410171278; 0,96; 0,565728022 ;

AUC 0,9

Table 3. Sensitivity, specificity and accuracy analysed for CA125 bination with MDK and EMILIN1

Threshold Sensitivity Specificity Accuracy

0.2 1 ; 0,308333333; 0,786511439;

0.3 0,959615385; 0,469444444; 0,806444894;

0.4 0,919230769; 0,616111111 0,822433729;

0.45 0,919230769; 0,674444444; 0,841293378;

0.5 0,903846154; 0,772777778; 0,862126712

0.6 0,829895105; 0,835; 0,829788814;

0.7 0,754213287; 0,875; 0,789480559;

0.75 0,711031469; 0,897222222; 0,765695292 ;

0.85 0,61208042; 0,977777778; 0,723050377;

1 0,161748252; 1 0,420693092 ;

AUC 0,92

Table 4. Sensitivity, specificity and accuracy analysed for CA125 bination with MDK and GMCSF

Threshold Sensitivity Specificity Accuracy

0.35 1 ; 0,377222222; 0,813899064;

0.45 0,981818182; 0,541111111 0,849488706;

0.5 0,981818182; 0,743333333; 0,911507937;

0.55 0,95959596; 0,808333333; 0,916030729

0.6 0,877747729; 0,866666667; 0,876035307;

0.65 0,799092989; 0,891666667; 0,82785409;

0.7 0,751373691 ; 0,925; 0,803515466;

0.8 0,696789404; 0,95; 0,771967847;

0.85 0,578917782; 0,975; 0,69656339;

1 0,181151561 ; 1 0,424707468;

AUC 0,946

Table 5. Sensitivity, specificity and accuracy analysed for CA125 bination with MDK, and PC ae C38:1 and/or PC ae C38:2

Threshold Sensitivity Specificity Accuracy

0.2 0,986666667; 0,384285714; 0,809062771 ;

0.35 0,977971014; 0,584285714; 0,862255411 ;

0.45 0,966859903; 0,682857143; 0,882601732;

0.5 0,966859903; 0,702857143; 0,888662338;

0.55 0,948678085; 0,831428571 j 0,915222944;

0.6 0,928871322; 0,926666667; 0,928209957

0.65 0,869064559; 0,926666667; 0,885577922;

0.8 0,719367589; 0,946666667; 0,785495671 ;

0.85 0,662169521 1 ; 0,760612554;

AUC 0,954 EXAMPLE 2. CASE STUDIES

The following case examples demonstrate that the algorithm disclosed herein provide a correct diagnosis of endometriosis. In these non- limiting examples, clinical variables obtained by a questionnaire were used either alone or in combination with biomarker data to obtain a risk prediction.

Case 1

32-year-old patient was presented with a 2-year history of infertility. Menstruation was still regular but she had 2-3 days of spotting before her menses are due. She also complained of pain with intercourse and pelvic pain. In reviewing the patient's history, over the past year the patient was repeatedly treated with antibiotics for recurrent microscopic hematuria.

The patient had no history of sexually transmitted infections. She had no urinary urgency, dysuria, nocturia, dyschezia or pain with defecation. Her physical examination was normal.

The patient took the endometriosis symptom-based questionnaire to assess the risk of endometriosis. Subjecting the clinical variables to the algorithm disclosed herein gave an assessment of 82.4% chance of the disease with a 94% confidence, which result equated to a high predicted risk.

Laparotomy performed confirmed the presence of endometriosis. Case 2

19-year-old null gravida was presented for treatment of chronic pelvic pain. She had the onset of severe dysmenorrhea at 15 years of age. Soon after that she was started on cyclical combined oral contraceptives (OCs) by her pediatrician as a treatment for dysmenorrhea. Over time, her dysmenor- rhea worsened, despite continuous treatment with combined OCs. Soon after she started experiencing pelvic pain throughout the month, rather than only with menstruation. She rated her pelvic pain at an intensity of 4 to 6 on a scale of 10 on most days, and as a 10 of 10 during menses. Additionally, she became sexually active about 6 months ago and over the past 3 months has had severe pain with intercourse.

The patient had no history of sexually transmitted infections. She had no urinary urgency, dysuria, nocturia, diarrhea, constipation, dyschezia or pain with defecation. Her physical examination was normal except for mild uterine and adnexal tenderness. Patient took the endometriosis symptom-based questionnaire to assess the risk of endometriosis an assessment of 75% risk of disease with a 95% confidence of result which equates to high risk was predicted.

Biomarker measurements added for CA125 u/ml - 18.73 and HE4 pmol/l - 34.5 increased the risk of disease from 75% - 77.4% with a confidence of result of 97.14%

Laparotomy performed confirmed the presence of endometriosis there was removal of bilateral endometriomas (6cm & 3cm): ~ 50% left ovary and 80% right ovary retained. Case 3

26-year-old primigravida, para 1 with a history of dysmenorrhea from an early age was put on oral contraceptive pill till she decided to get pregnant. All symptoms were alleviated during pregnancy and while breast feeding. Once breast feeding stopped and her menstrual period returned, the symptoms also returned. She has also been experiencing mild pain with intercourse, diarrhea, and constipation.

The patient has no history of sexually transmitted infections. She has no urinary urgency, dysuria, nocturia, dyschezia or pain with defecation. Her physical examination was normal.

Patient took the endometriosis symptom-based questionnaire to assess the risk of endometriosis with a prediction of 46% risk of disease with a 94% confidence of result which equates to intermediate risk.

Biomarker measurements added for CA125 - 13.4 u/ml, MDK ng/ml - 0.511 , EMILIN ng/ml - 0.85 gave a risk assessment of 49% risk of disease with 98% confidence of result.

Laparotomy performed confirms the presence of endometriosis lesion on the peritoneum and Uterosacral nodularity.

Case 3 is presented as an example wherein the subject's computed risk of having endometriosis was 49%. Because the computed risk alone was very close to 50%, it was insufficient for a definite diagnosis but was sufficient for triggering additional procedures, which then confirmed the presence of endometriosis.

Case 4

21 -year-old null gravida with regular menstruation but has 2-3 days of spotting before her menses are due. Complained of persistent abdominal pain, which is alleviated during menstruation, menstrual pain lasting 3-4 days, with an intensity of 7 on a scale of 10, mild pain with intercourse and severe pelvic pain. Patient history showed no history of sexually transmitted infections, repeated treatment for recurrent microscopic hematuria with antibiotics, she had no urinary urgency but persistent dysuria and pain with defecation.

Patient took the endometriosis symptom-based questionnaire to assess the risk of endometriosis an intermediate risk was predicted with a 49.2% chance of disease with a 94% confidence of result.

Laparotomy performed confirmed no endometriosis.

Similarly to the previous case, case 4 is presented as an example wherein the computed risk of having endometriosis (49.2%) was very close to 50%. This finding triggered additional procedures, which in this case excluded endometriosis.

EXAMPLE 3. RESPONSE TO TREATMENT

Three randomly selected laparotomy-treated endometriosis patients out of the initial 102 women of Example 1 were assessed for the level CA125, IL-1 Ra, EGF, GM-CSF, and HE4 expression both before and after laparotomy. Owing to a temporary shortage of reagents, the expression levels of no other biomarkers were tested at this point. Nevertheless, the results shown in Table 6 demonstrate that the present biomarkers are suitable not only for diagnosing endometriosis but also for monitoring endometriosis, especially monitoring response to treatment.

TABLE 6. Biomarker levels before and after treatment

Biomarker P049 Before P049 After P088 Before P088 After P101 Before P101 After

CA125 38.27 15.72 57.2 40.44 16.73 12.41

HE4 37.7 27.7 31.3 38.6 56.2 44.8

EGF 191.707 184.337 172.196 80.256 301.939 168.386

GMCSF 87.741 19.341 4.163 4.013 6.331 4.041

IL1 RA 574.366 479.932 269.009 209.152 1040.946 796.545

IL-17 72.921 33.217 1.74 2.195 1.455 2.506 Table 7: AUC Values for Combinations of Clinical Variables and Bi- omarkers

The following abbreviations have been used to conserve space:

ips=intercourse pain strength

mps=nnenstrual pain strength

dps=defecation pain strength

^*1 =PC.ae.C38.1

^*2=PC.ae.C38.2

Index Feature combination AUC,% 39 EMILIN, MDK 80.771

1 ips, mps 91.797 40 EMILIN, Ί 75.799

2 ips, dps 84.588 41 EMILIN, EGF 67.933

3 ips, CA125 96.094 42 EMILIN, GMCSF 70.65

4 ips, EMILIN 88.707 43 EMILIN, IL1 RA 73.366

5 ips, MDK 89.737 44 EMILIN, HE4 71.786

6 ips, 88.192 45 EMILIN, *2 72.71

7 ips, EGF 79.883 46 MDK, 82.386

8 ips, GMCSF 83.274 47 MDK, EGF 73.793

9 ips, IL1RA 82.173 48 MDK, GMCSF 73.118

10 ips, HE4 79.155 49 MDK, IL1 RA 73.828

11 ips, *2 81.392 50 MDK, HE4 71.52

12 mps, dps 88.832 51 MDK, *2 75.391

13 mps, CA125 95.206 52 *1 , EGF 64.311

14 mps, EMILIN 94.247 53 Ί , GMCSF 62.766

15 mps, MDK 92.614 54 *1 , IL1 RA 63.21

16 mps, 88.53 55 Ί . ΗΕ4 65.98

17 mps, EGF 84.925 56 68.679

18 mps, GMCSF 82.99 57 EGF, GMCSF 49.006

19 mps, IL1 RA 89.169 58 EGF, IL1 RA 51.456

20 mps, HE4 84.712 59 EGF, HE4 51.545

21 mps, *2 87.891 60 EGF, *2 47.869

22 dps, CA125 92.756 61 GMCSF, IL1 RA 50.178

23 dps, EMILIN 88.281 62 GMCSF, HE4 56.605

24 dps, MDK 86.328 63 GMCSF, *2 58.984

25 dps, 86.293 64 IL1 RA, HE4 50.533

26 dps, EGF 81.25 65 IL1 RA, *2 56.445

27 dps, GMCSF 75.71 66 HE4, *2 53.729

28 dps, IL1 RA 79.936 67 ips, mps, dps 93.484

29 dps, HE4 76.563 68 ips, mps, CA125 97.124

30 dps, *2 82.209 69 ips, mps, EMILIN 95.455

31 CA125, EMILIN 89.826 70 ips, mps, MDK 94.886

32 CA125, MDK 91.122 71 ips, mps, 93.253

33 CA125, 86.417 72 ips, mps, EGF 92.152

34 CA125, EGF 85.227 73 ips, mps, GMCSF 91.3

35 CA125, GMCSF 84.996 74 ips, mps, IL1 RA 93.342

36 CA125, IL1 RA 88.885 75 ips, mps, HE4 91.3

37 CA125, HE4 83.345 76 ips, mps, *2 90.749

38 CA125, *2 86.328 77 ips, dps, CA125 96.52 ps, dps, EMILIN 92.152 130 mps, dps, *2 89.773 ps, dps, MDK 92.933 131 mps, CA125, EMILIN 96.982 ps, dps, 91.548 132 mps, CA125, MDK 95.739 ps, dps, EGF 89.293 133 mps, CA125, 93.928 ps, dps, GMCSF 87.784 134 mps, CA125, EGF 94.247 ps, dps, IL1 RA 87.109 135 mps, CA125, GMCSF 93.928 ps, dps, HE4 86.239 136 mps, CA125, 1 LI RA 94.78 ps, dps, *2 89.116 137 mps, CA125, HE4 94.673 ps, CA125, EMILIN 95.987 138 mps, CA125, *2 94.815 ps, CA125, MDK 96.733 139 mps, EMILIN, MDK 95.17 ps, CA125, 95.277 140 mps, EMILIN, Ί 94.212 ps, CA125, EGF 95.49 141 mps, EMILIN, EGF 91.726 ps, CA125, GMCSF 95.028 142 mps, EMIUN. GMCSF 92.045 ps, CA125, IL1 RA 95.17 143 mps, EMILIN, IL1 RA 94.567 ps, CA125, HE4 94.247 144 mps, EMILIN, HE4 93.111 ps, CA125, *2 95.028 145 mps, EMILIN, *2 93.111 ps, EMILIN, MDK 89.915 146 mps, MDK, Ί 94.07 ps, EMILIN, Ί 88.885 147 mps, MDK, EGF 91.584 ps, EMILIN, EGF 87.18 148 mps, MDK, GMCSF 92.418 ps, EMILIN, GMCSF 87.695 149 mps, MDK, IL1 RA 93.075 ps, EMILIN, IL1 RA 87.429 150 mps, MDK, HE4 91.353 ps, EMILIN, HE4 87.198 151 mps, MDK, *2 92.223 ps, EMILIN, *2 86.754 152 mps, , EGF 88.956 ps, MDK, Ί 91.868 153 mps, , GMCSF 87.482 ps, MDK, EGF 88.672 154 mps, , I LI RA 90.447 ps, MDK, GMCSF 89.258 155 mps, , HE4 88.192 ps, MDK. IL1 RA 88.263 156 mps, , *2 89.631 ps, MDK, HE4 87.109 157 mps, EGF, GMCSF 85.884 ps, MDK, *2 89.276 158 mps, EGF, IL1 RA 88.601 ps, *1 , EGF 86.967 159 mps, EGF, HE4 84.57 ps, *1 , GMCSF 87.056 160 mps, EGF, *2 86.719 ps, *1 , IL1 RA 86.523 161 mps, GMCSF, IL1 RA 87.145 ps, *1 , HE4 85.387 162 mps, GMCSF, HE4 83.825 ps, *1 , *2 87.997 163 mps, GMCSF, *2 85.334 ps, EGF, GMCSF 84.553 164 mps, IL1 RA, HE4 89.151 ps, EGF, IL1RA 82.227 165 mps, I LI RA, *2 89.879 ps, EGF, HE4 82.386 166 mps, HE4, *2 84.677 ps, EGF, *2 82.937 167 dps, CA125, EMILIN 93.75 ps, GMCSF, IL1 RA 82.28 168 dps, CA125, MDK 94.212 ps, GMCSF, HE4 82.227 169 dps, CA125, *1 92.188 ps, GMCSF, *2 85.121 170 dps, CA125, EGF 93.501 ps, IL1RA, HE4 80.54 171 dps, CA125, GMCSF 91.619 ps. IL.1RA, *2 83.168 172 dps, CA125, IL1 RA 92.827 ps, HE4, *2 77.752 173 dps, CA125, HE4 91.229 mps, dps, CA125 94.815 174 dps, CA125, *2 93.253 mps, dps, EMILIN 94.07 175 dps, EMILIN, MDK 88.459 mps, dps, MDK 92.347 176 dps, EMILIN, Ί 87.571 mps, dps, 91.371 177 dps, EMILIN, EGF 85.263 mps, dps, EGF 89.631 178 dps, EMIUN. GMCSF 83.842 mps, dps, GMCSF 86.648 179 dps, EMILIN, IL1 RA 86.825 mps, dps, IL1 RA 90.661 180 dps, EMILIN, HE4 86.009 mps, dps, HE4 88.246 181 dps, EMILIN, *2 87.145 182 dps, MDK, Ί 90.376 234 EMILIN, MDK, IL1RA 81.783

183 dps, MDK, EGF 86.009 235 EMILIN, MDK, HE4 79.972

184 dps, MDK, GMCSF 85.866 236 EMILIN, MDK, *2 81.126

185 dps, MDK, IL1RA 84.837 237 EMILIN, Ί, EGF 75.178

186 dps, MDK, HE4 83.771 238 EMILIN, Ί, GMCSF 75.746

187 dps, MDK, *2 88.352 239 EMILIN, *1, IL1RA 76.332

188 dps, *1, EGF 88.175 240 EMILIN, Ί, HE4 75.604

189 dps, , GMCSF 83.558 241 EMILIN, Ί,*2 76.705

190 dps, *1, IL1RA 85.582 242 EMILIN, EGF, GMCSF 68.697

191 dps, *1, HE4 84.411 243 EMILIN, EGF, IL1RA 69.602

192 dps,*1,*2 86.399 244 EMILIN, EGF, HE4 68.626

193 dps, EGF, GMCSF 78.391 245 EMILIN, EGF,*2 67.915

194 dps, EGF, IL1RA 81.605 246 EMILIN, GMCSF, IL1RA 73.793

195 dps, EGF, HE4 80.362 247 EMILIN, GMCSF, HE4 72.266

196 dps, EGF,*2 83.061 248 EMILIN, GMCSF, *2 72.585

197 dps, GMCSF, IL1RA 77.486 249 EMILIN, IL1RA, HE4 73.58

198 dps, GMCSF, HE4 75.923 250 EMILIN, IL1RA, *2 73.651

199 dps, GMCSF, *2 81.729 251 EMILIN, HE4,*2 70.881

200 dps, IL1RA, HE4 77.344 252 ΜϋΚ,Ί, EGF 80.948

201 dps, IL1RA, *2 83.345 253 MDK, Ί, GMCSF 82.138

202 dps, HE4, *2 78.693 254 MDK, *1, IL1RA 80.895

203 CA125, EMILIN, MDK 91.371 255 ΜϋΚ,Ί, HE4 81.428

204 CA125, EMILIN, Ί 90.874 256 MDK,*1,*2 80.895

205 CA125, EMILIN, EGF 88.512 257 MDK, EGF, GMCSF 73.26

206 CA125, EMIUN.GMCSF 89.4 258 MDK, EGF, IL1RA 74.112

207 CA125, EMILIN, IL1RA 90.412 259 MDK, EGF, HE4 72.781

208 CA125, EMILIN, HE4 89.169 260 MDK, EGF, *2 74.254

209 CA125, EMILIN, *2 90.341 261 MDK, GMCSF, IL1RA 73.047

210 CA125, MDK, 91.016 262 MDK, GMCSF, HE4 71.875

211 CA125, MDK, EGF 90.589 263 MDK, GMCSF, *2 75.533

212 CA125, MDK, GMCSF 89.968 264 MDK, IL1RA, HE4 74.254

213 CA125, MDK, I LIRA 91.193 265 MDK, I LIRA, *2 74.183

214 CA125, MDK, HE4 90.163 266 MDK, HE4, *2 73.793

215 CA125, MDK, *2 90.803 267 , EGF, GMCSF 64.364

216 CA125,*1,EGF 86.009 268 , EGF, IL1RA 64.134

217 CA125, *1, GMCSF 85.724 269 , EGF, HE4 64.56

218 CA125, *1, IL1RA 87.997 270 *1, EGF, *2 67.667

219 CA125,*1,HE4 85.014 271 , GMCSF, IL1RA 62.891

220 CA125,*1,*2 86.967 272 Ί, GMCSF, HE4 63.192

221 CA125, EGF, GMCSF 85.298 273 , GMCSF, *2 67.081

222 CA125, EGF, IL1RA 86.861 274 *1,IL1RA, HE4 63.494

223 CA125, EGF, HE4 84.411 275 *1,IL1RA, *2 63.281

224 CA125, EGF,*2 83.487 276 Ί,ΗΕ4,*2 66.886

225 CA125, GMCSF, IL1RA 86.435 277 EGF, GMCSF, IL1RA 54.084

226 CA125, GMCSF, HE4 83.913 278 EGF, GMCSF, HE4 51.598

227 CA125, GMCSF, *2 84.233 279 EGF, GMCSF, *2 55.238

228 CA125, IL1RA, HE4 86.559 280 EGF, IL1RA, HE4 51.776

229 CA125, IL1RA, *2 86.932 281 EGF, IL1RA, *2 52.947

230 CA125, HE4,*2 82.209 282 EGF, HE4, *2 51.065

231 EMILIN, MDK, 83.984 283 GMCSF, IL1RA, HE4 48.864

232 EMILIN, MDK, EGF 80.824 284 GMCSF, IL1RA, *2 57.919

233 EMILIN, MDK, GMCSF 79.794 285 GMCSF, HE4, *2 48.988 IL1 RA, HE4, *2 50.533 338 ips, dps, CA125, HE4 95.668 ps, mps, dps, CA125 97.372 339 ips, dps, CA125, *2 96.094 ps, mps, dps, EMIUN 96.236 340 ips, dps, EMIUN, MDK 93.288 ps, mps, dps, MDK 95.49 341 ips, dps, EMIUN, Ί 92.152 ps, mps, dps, 93.928 342 ips, dps, EMIUN, EGF 92.596 ps, mps, dps, EGF 93.661 343 ips, dps, EMIUN, GMCSF 91.726 ps, mps, dps, GMCSF 92.987 344 ips, dps, EMIUN, IL1 RA 92.223 ps, mps, dps, I LI RA 94.229 345 ips, dps, EMIUN, HE4 91.939 ps, mps, dps, HE4 92.347 346 ips, dps, EMIUN, *2 92.188 ps, mps, dps, *2 93.022 347 ips, dps, MDK, Ί 93.288 ps, mps, CA125, EMIUN 98.331 348 ips, dps, MDK, EGF 92.063 ps, mps, CA125, MDK 97.869 349 ips, dps, MDK, GMCSF 92.116 ps, mps, CA125, 97.372 350 ips, dps, MDK, IL1 RA 91.797 ps, mps, CA125, EGF 97.088 351 ips, dps, MDK, HE4 91.548 ps, mps, CA125, GMCSF 97.088 352 ips, dps, MDK, *2 92.259 ps, mps, CA125, 1 LI RA 97.195 353 ips, dps, , EGF 91.957 ps, mps, CA125, HE4 97.408 354 ips, dps, , GMCSF 91.246 ps, mps, CA125, *2 97.159 355 ips, dps, , I LI RA 90.696 ps. mps, EMIUN, MDK 96.626 356 ips, dps, *1 , HE4 91.033 ps. mps, EMIUN, Ί 95.526 357 ips, dps, , *2 90.554 ps, mps, EMIUN, EGF 95.384 358 ips, dps, EGF, GMCSF 89.009 ps, mps, EMIUN, GMCSF 95.49 359 ips, dps, EGF, IL1 RA 89.364 ps. mps, EMIUN, IL1 RA 96.946 360 ips, dps, EGF, HE4 89.4 ps, mps, EMIUN, HE4 95.597 361 ips, dps, EGF, *2 89.773 ps. mps, EMIUN, *2 95.099 362 ips, dps, GMCSF, IL1 RA 87.855 ps, mps, MDK, 95.135 363 ips, dps, GMCSF, HE4 87.802 ps, mps, MDK, EGF 95.064 364 ips, dps, GMCSF, *2 89.347 ps, mps, MDK, GMCSF 94.886 365 ips, dps, IL1 RA, HE4 86.293 ps, mps, MDK, IL1 RA 95.81 366 ips, dps, IL1 RA, *2 89.169 ps, mps, MDK, HE4 94.531 367 ips, dps, HE4, *2 87.003 ps, mps, MDK, *2 94.744 368 ips, CA125, EMIUN, MDK 97.159 ps, mps, , EGF 93.146 369 ips, CA125, EMIUN, Ί 95.774 ps, mps, , GMCSF 92.454 370 ips, CA125, EMIUN, EGF 96.094 ps, mps, *1 , IL1 RA 93.466 371 ips, CA125, EMIUN, GMCSF 95.597 ps, mps, , HE4 92.312 372 ips, CA125, EMIUN, IL1 RA 95.881 ps, mps, , *2 92.898 373 ips, CA125, EMIUN, HE4 96.378 ps, mps, EGF, GMCSF 91.513 374 ips, CA125, EMIUN, *2 96.307 ps, mps, EGF, I LI RA 93.572 375 ips, CA125, MDK, Ί 96.946 ps, mps, EGF, HE4 92.188 376 ips, CA125, MDK, EGF 96.839 ps, mps, EGF, *2 91.868 377 ips, CA125, MDK, GMCSF 97.053 ps, mps, GMCSF, IL1 RA 93.395 378 ips, CA125, MDK, IL1 RA 96.911 ps, mps, GMCSF, HE4 91.353 379 ips, CA125, MDK, HE4 96.626 ps, mps, GMCSF, *2 91.513 380 ips, CA125, MDK, *2 96.697 ps. mps, IL1 RA, HE4 93.466 381 ips, CA125, *1 , EGF 95.526 ps, mps, IL1 RA, *2 93.537 382 ips, CA125, *1 , GMCSF 95.241 ps, mps, HE4, *2 90.696 383 ips, CA125, *1 , IL1 RA 94.993 ps, dps, CA125, EMIUN 96.946 384 ips, CA125, *1 , HE4 94.46 ps, dps, CA125, MDK 96.839 385 ips, CA125, *1 , *2 95.17 ps, dps, CA125, *1 96.2 386 ips, CA125, EGF, GMCSF 95.17 ps, dps, CA125, EGF 96.875 387 ips, CA125, EGF, IL1 RA 95.17 ps, dps, CA125, GMCSF 95.916 388 ips, CA125, EGF, HE4 95.028 ps, dps, CA125, IL1 RA 95.987 389 ips, CA125, EGF, *2 95.526 390 ips, CA125, GMCSF, IL1 RA 94.709 442 ips, EGF, GMCSF, IL1 RA 83.203

391 ips, CA125, GMCSF, HE4 94.851 443 ips, EGF, GMCSF, HE4 84.624

392 ips, CA125, GMCSF, *2 94.957 444 ips, EGF, GMCSF, *2 84.73

393 ips, CA125, IL1 RA, HE4 94.567 445 ips, EGF, IL1 RA, HE4 81.286

394 ips, CA125, IL1 RA, *2 95.241 446 ips, EGF, I LI RA, *2 83.487

395 ips, CA125, HE4, *2 94.247 447 ips, EGF, HE4, *2 81.463

396 ips, EMILIN, MDK, *1 92.01 448 ips, GMCSF, IL1 RA, HE4 82.599

397 ips, EMILIN, MDK, EGF 90.874 449 ips, GMCSF, IL1 RA, *2 83.984

398 ips, EMILIN, MDK, GMCSF 90.891 450 ips, GMCSF, HE4, *2 82.315

399 ips, EMILIN, MDK, IL1 RA 90.945 451 ips, IL1 RA, HE4, *2 80.433

400 ips, EMILIN, MDK, HE4 90.305 452 mps, dps, CA125, EMILIN 97.195

401 ips, EMILIN, MDK, *2 91.122 453 mps, dps, CA125, MDK 96.342

402 ips, EMILIN, Ί , EGF 88.601 454 mps, dps, CA125, 95.17

403 ips, EMILIN, Ί , GMCSF 88.814 455 mps, dps, CA125, EGF 95.419

404 ips, EMILIN, *1 , IL1 RA 89.045 456 mps, dps, CA125, GMCSF 94.851

405 ips, EMILIN, Ί . ΗΕ4 89.24 457 mps, dps, CA125, 1 LI RA 95.419

406 ips, EMILIN, Ί , *2 89.205 458 mps, dps, CA125, HE4 95.526

407 ips, EMILIN, EGF, GMCSF 86.825 459 mps, dps, CA125, *2 95.668

408 ips, EMILIN, EGF, IL1 RA 88.139 460 mps, dps, EMILIN, MDK 95.313

409 ips, EMILIN, EGF, HE4 86.719 461 mps, dps, EMILIN, Ί 94.993

410 ips, EMILIN, EGF, *2 86.168 462 mps, dps, EMILIN, EGF 93.43

411 ips, EMILIN, GMCSF, IL1 RA 88.743 463 mps, dps, EMILIN, GMCSF 93.359

412 ips, EMILIN, GMCSF, HE4 88.743 464 mps, dps, EMILIN, IL1 RA 95.881

413 ips, EMILIN, GMCSF, *2 87.962 465 mps, dps, EMILIN, HE4 94.176

414 ips, EMILIN, IL1 RA, HE4 88.388 466 mps, dps, EMILIN, *2 93.945

415 ips, EMILIN, IL1 RA, *2 87.749 467 mps, dps, MDK, 94.656

416 ips, EMILIN, HE4, *2 86.79 468 mps, dps, MDK, EGF 92.862

417 ips, MDK, Ί , EGF 91.761 469 mps, dps, MDK, GMCSF 92.631

418 ips, MDK, Ί , GMCSF 92.188 470 mps, dps, MDK, IL1 RA 94.318

419 ips, MDK, *1 , IL1 RA 90.98 471 mps, dps, MDK, HE4 92.188

420 ips, MDK, *1 , HE4 90.838 472 mps, dps, MDK, *2 93.714

421 ips, MDK, *1 , *2 91.602 473 mps, dps, , EGF 91.406

422 ips, MDK, EGF, GMCSF 90.199 474 mps, dps, , GMCSF 89.08

423 ips, MDK, EGF, IL1 RA 89.844 475 mps, dps, , I LI RA 91.513

424 ips, MDK, EGF, HE4 87.784 476 mps, dps, , HE4 90.376

425 ips, MDK, EGF, *2 89.134 477 mps, dps, , *2 92.081

426 ips, MDK, GMCSF, IL1 RA 89.595 478 mps, dps, EGF, GMCSF 88.228

427 ips, MDK, GMCSF, HE4 88.814 479 mps, dps, EGF, IL1 RA 90.785

428 ips, MDK, GMCSF, *2 89.879 480 mps, dps, EGF, HE4 89.258

429 ips, MDK, IL1 RA, HE4 87.784 481 mps, dps, EGF, *2 90.359

430 ips, MDK, IL1 RA, *2 88.601 482 mps, dps, GMCSF, IL1RA 89.595

431 ips, MDK, HE4, *2 88.21 483 mps, dps, GMCSF, HE4 86.612

432 ips, *1 , EGF, GMCSF 86.257 484 mps, dps, GMCSF, *2 88.21

433 ips, , EGF, IL1 RA 85.973 485 mps, dps, IL1 RA, HE4 91.087

434 ips, , EGF, HE4 85.938 486 mps, dps, IL1 RA, *2 91.335

435 ips, *1 , EGF, *2 87.784 487 mps, dps, HE4, *2 87.731

436 ips, , GMCSF, IL1 RA 86.701 488 mps, CA125, EMILIN, MDK 97.692

437 ips, , GMCSF, HE4 85.938 489 mps, CA125, EMILIN, Ί 96.875

438 ips, , GMCSF, *2 87.678 490 mps, CA125, EMILIN, EGF 97.017

439 ips, , IL1 RA, HE4 85.316 491 mps, CA125, EMILIN, GMCSF 97.053

440 ips, *1 , IL1 A, *2 86.009 492 mps, CA125, EMILIN, IL1 RA 97.266

441 ips, *1 , HE4, *2 84.872 493 mps, CA125, EMILIN, HE4 97.159 494 mps, CA125, EMIUN, *2 97.159 546 mps, MDK, GMCSF, IL1RA 92.614

495 mps, CA125, MDK,*1 96.289 547 mps, MDK, GMCSF, HE4 92.116

496 mps, CA125, MDK, EGF 95.987 548 mps, MDK, GMCSF, *2 92.188

497 mps, CA125, MDK, GMCSF 96.307 549 mps, MDK, IL1RA, HE4 93.04

498 mps, CA125, MDK, IL1RA 96.449 550 mps, MDK, IL1RA, *2 93.963

499 mps, CA125, MDK, HE4 96.378 551 mps, MDK, HE4, *2 91.655

500 mps, CA125, MDK, *2 96.591 552 mps, , EGF, GMCSF 88.991

501 mps, CA125, *1, EGF 94.212 553 mps, , EGF, IL1RA 90.128

502 mps, CA125, *1, GMCSF 94.176 554 mps, , EGF, HE4 87.464

503 mps, CA125, *1, IL1RA 95.099 555 mps,*1,EGF,*2 90.128

504 mps, CA125,*1,HE4 94.425 556 mps, , GMCSF, IL1RA 88.565

505 mps, CA125, *1, *2 95.099 557 mps, , GMCSF, HE4 86.648

506 mps, CA125, EGF, GMCSF 94.212 558 mps, , GMCSF, *2 88.743

507 mps, CA125, EGF, IL1RA 94.425 559 mps, , IL1RA, HE4 90.305

508 mps, CA125, EGF, HE4 94.354 560 mps, , I LIRA, *2 90.803

509 mps, CA125, EGF,*2 94.389 561 mps,*1,HE4,*2 88.388

510 mps, CA125, GMCSF, IL1RA 94.531 562 mps, EGF, GMCSF, IL1RA 87.962

511 mps, CA125, GMCSF, HE4 94.496 563 mps, EGF, GMCSF, HE4 86.239

512 mps, CA125, GMCSF, *2 94.176 564 mps, EGF, GMCSF, *2 86.861

513 mps, CA125, IL1RA, HE4 95.295 565 mps, EGF, IL1RA, HE4 88.139

514 mps, CA125, IL1RA, *2 94.886 566 mps, EGF, I LIRA, *2 89.098

515 mps, CA125, HE4, *2 94.709 567 mps, EGF, HE4, *2 85.476

516 mps, EMIUN, MDK, Ί 95.916 568 mps, GMCSF, IL1RA, HE4 87.908

517 mps, EMIUN, MDK, EGF 94.638 569 mps, GMCSF, IL1RA, *2 88.21

518 mps, EMIUN, MDK, GMCSF 94.567 570 mps, GMCSF, HE4, *2 83.913

519 mps, EMIUN, MDK, IL1RA 94.78 571 mps, IL1RA, HE4, *2 89.205

520 mps, EMIUN, MDK, HE4 95.011 572 dps, CA125, EMILIN, MDK 94.318

521 mps, EMIUN, MDK, *2 95.295 573 dps,CA125, EMILIN, Ί 93.857

522 mps, EMIUN, Ί, EGF 93.75 574 dps, CA125, EMILIN, EGF 93.786

523 mps, EMIUN, Ί, GMCSF 94.407 575 dps, CA125, EMILIN, GMCSF 93.43

524 mps, EMILIN, *1, IL1RA 94.886 576 dps,CA125, EMILIN, IL1RA 94.158

525 mps, EMILIN, Ί.ΗΕ4 94.229 577 dps, CA125, EMILIN, HE4 93.963

526 mps, EMILIN, Ί,*2 94.744 578 dps,CA125, EMILIN, *2 94.46

527 mps, EMILIN, EGF, GMCSF 91.442 579 dps,CA125, MDK, 94.673

528 mps, EMILIN, EGF, IL1RA 93.732 580 dps, CA125, MDK, EGF 94.744

529 mps, EMILIN, EGF, HE4 90.838 581 dps, CA125, MDK, GMCSF 94.354

530 mps, EMILIN, EGF, *2 92.188 582 dps,CA125, MDK, IL1RA 94.496

531 mps, EMIUN, GMCSF, IL1RA 93.679 583 dps, CA125, MDK, HE4 93.892

532 mps, EMILIN, GMCSF, HE4 91.371 584 dps,CA125, MDK, *2 94.496

533 mps, EMILIN, GMCSF, *2 92.436 585 dps,CA125,*1,EGF 93.359

534 mps, EMILIN, IL1RA, HE4 94.176 586 dps, CA125,*1, GMCSF 91.531

535 mps, EMILIN, IL1RA, *2 94.691 587 dps, CA125, *1, IL1RA 92.862

536 mps, EMILIN, HE4, *2 92.436 588 dps,CA125,*1,HE4 90.98

537 mps, MDK, Ί, EGF 93.643 589 dps, CA125, *1, *2 93.075

538 mps, MDK, Ί, GMCSF 94.212 590 dps, CA125, EGF, GMCSF 93.04

539 mps, MDK, *1, IL1RA 94.318 591 dps,CA125, EGF, IL1RA 93.643

540 mps, MDK,*1,HE4 93.182 592 dps, CA125, EGF, HE4 92.738

541 mps, MDK,*1,*2 94.354 593 dps,CA125, EGF,*2 93.04

542 mps, MDK, EGF, GMCSF 91.832 594 dps, CA125, GMCSF, IL1RA 91.974

543 mps, MDK, EGF, IL1RA 92.081 595 dps, CA125, GMCSF, HE4 90.909

544 mps, MDK, EGF, HE4 91.3 596 dps, CA125, GMCSF, *2 92.294

545 mps, MDK, EGF, *2 92.223 597 dps, CA125, IL1RA, HE4 91.939 598 dps, CA125, IL1RA, *2 92.933 650 dps, EGF, IL1RA, *2 84.251

599 dps, CA125, HE4, *2 91.868 651 dps, EGF, HE4, *2 81.392

600 dps, EMIUN, MDK,*1 91.229 652 dps, GMCSF, IL1RA, HE4 77.539

601 dps, EMIUN, MDK, EGF 88.388 653 dps, GMCSF, IL1RA, *2 82.635

602 dps, EMIUN, MDK.GMCSF 87.926 654 dps, GMCSF, HE4, *2 79.634

603 dps, EMIUN, MDK, IL1RA 88.406 655 dps, IL1RA, HE4, *2 80.043

604 dps, EMIUN, MDK, HE4 88.121 656 CA125, EMILIN, MDK, 92.205

605 dps, EMIUN, MDK, *2 90.163 657 CA125, EMILIN, MDK, EGF 90.874

606 dps, EMIUN, Ί, EGF 87.145 658 CA125, EMILIN, MDK.GMCSF 90.661

607 dps, EMIUN, Ί, GMCSF 86.879 659 CA125, EMILIN, MDK, IL1RA 91.868

608 dps, EMILIN, *1, IL1RA 88.832 660 CA125, EMILIN, MDK, HE4 91.371

609 dps, EMIUN, Ί.ΗΕ4 88.53 661 CA125, EMILIN, MDK, *2 91.104

610 dps, EMILIN, Ί,*2 90.625 662 CA125, EMILIN, Ί, EGF 88.707

611 dps, EMILIN, EGF.GMCSF 82.741 663 CA125, EMILIN, Ί, GMCSF 90.092

612 dps, EMILIN, EGF, IL1RA 86.275 664 CA125, EMILIN, *1, IL1RA 90.554

613 dps, EMILIN, EGF, HE4 84.268 665 CA125, EMILIN, Ί.ΗΕ4 90.589

614 dps, EMILIN, EGF, *2 86.435 666 CA125, EMILIN, *1, *2 90.803

615 dps, EMILIN, GMCSF, IL1RA 86.364 667 CA125, EMILIN, EGF.GMCSF 87.891

616 dps, EMILIN, GMCSF, HE4 85.511 668 CA125, EMILIN, EGF, IL1RA 88.707

617 dps, EMILIN, GMCSF, *2 86.044 669 CA125, EMILIN, EGF, HE4 87.82

618 dps, EMILIN, IL1RA, HE4 87.784 670 CA125, EMILIN, EGF, *2 88.672

619 dps, EMILIN, IL1RA, *2 88.317 671 CA125, EMIUN.GMCSF, IL1RA 89.418

620 dps, EMILIN, HE4, *2 87.5 672 CA125, EMILIN, GMCSF, HE4 89.063

621 dps, MDK, Ί, EGF 90.767 673 CA125, EMILIN, GMCSF, *2 89.169

622 dps, MDK, Ί, GMCSF 91.016 674 CA125, EMILIN, IL1RA, HE4 89.702

623 dps,MDK,*1,IL1RA 91.087 675 CA125, EMILIN, IL1RA, *2 90.483

624 dps,MDK,*1,HE4 91.335 676 CA125, EMILIN, HE4, *2 89.311

625 dps,MDK,*1,*2 91.14 677 CA125, MDK, Ί, EGF 90.518

626 dps, MDK, EGF, GMCSF 85.902 678 CA125, MDK, Ί, GMCSF 91.033

627 dps, MDK, EGF, IL1RA 86.399 679 CA125, MDK, *1, IL1RA 91.584

628 dps, MDK, EGF, HE4 85.21 680 CA125, MDK,*1,HE4 90.678

629 dps, MDK, EGF, *2 88.672 681 CA125, MDK, *1,*2 91.388

630 dps, MDK.GMCSF, IL1RA 85.653 682 CA125, MDK, EGF, GMCSF 89.702

631 dps, MDK, GMCSF, HE4 85.121 683 CA125, MDK, EGF, IL1RA 90.625

632 dps, MDK, GMCSF, *2 89.311 684 CA125, MDK, EGF, HE4 89.418

633 dps, MDK, IL1RA, HE4 85.121 685 CA125, MDK, EGF,*2 89.702

634 dps, MDK, IL1RA, *2 88.814 686 CA125, MDK.GMCSF, IL1RA 89.915

635 dps, MDK, HE4, *2 88.05 687 CA125, MDK, GMCSF, HE4 89.08

636 dps, *1, EGF.GMCSF 84.624 688 CA125, MDK, GMCSF, *2 89.844

637 dps, *1, EGF, IL1RA 88.494 689 CA125, MDK, IL1RA, HE4 90.11

638 dps, , EGF, HE4 85.902 690 CA125, MDK, IL1RA, *2 91.016

639 dps, *1, EGF,*2 88.53 691 CA125, MDK, HE4,*2 90.199

640 dps, *1, GMCSF, IL1RA 84.695 692 CA125, *1, EGF, GMCSF 85.263

641 dps, , GMCSF, HE4 82.99 693 CA125, , EGF, IL1RA 87.003

642 dps, , GMCSF, *2 85.849 694 CA125, , EGF, HE4 84.411

643 dps, *1, IL1RA, HE4 84.251 695 CA125,*1,EGF,*2 85.618

644 dps, *1, IL1RA, *2 85.76 696 CA125, , GMCSF, IL1RA 86.754

645 dps, *1, HE4,*2 84.588 697 CA125, , GMCSF, HE4 84.695

646 dps, EGF.GMCSF, IL1RA 81.161 698 CA125, *1, GMCSF, *2 85.813

647 dps, EGF.GMCSF, HE4 78.356 699 CA125, , IL1RA, HE4 86.417

648 dps, EGF, GMCSF, *2 82.955 700 CA125, *1, IL1RA, *2 87.393

649 dps, EGF, IL1RA, HE4 81.108 701 CA125,*1,HE4,*2 85.192 CA125, EGF.GMCSF, IL1RA 85.476 754 MDK, *1, IL1RA, HE4 80.611

CA125, EGF, GMCSF, HE4 83.452 755 MDK, Ί, I LIRA, *2 80.291

CA125, EGF, GMCSF, *2 83.505 756 ΜϋΚ,Ί, HE4,*2 81.747

CA125, EGF, IL1RA, HE4 84.837 757 MDK, EGF.GMCSF, IL1RA 73.544

CA125, EGF, IL1RA, *2 85.263 758 MDK, EGF, GMCSF, HE4 71.839

CA125, EGF, HE4, *2 82.386 759 MDK, EGF, GMCSF, *2 74.308

CA125, GMCSF, IL1RA, HE4 84.854 760 MDK, EGF, IL1RA, HE4 72.124

CA125, GMCSF, IL1RA, *2 85.44 761 MDK, EGF, IL1RA, *2 74.112

CA125, GMCSF, HE4,*2 82.28 762 MDK, EGF, HE4, *2 73.082

CA125, IL1RA, HE4, *2 84.819 763 MDK.GMCSF, IL1RA, HE4 72.017

EMIUN, MDK, , EGF 84.588 764 MDK.GMCSF, IL1RA, *2 75.16

EMIUN, MDK, Ί, GMCSF 84.233 765 MDK, GMCSF, HE4, *2 73.509

EMIUN, MDK, *1, IL1RA 84.233 766 MDK, IL1RA, HE4,*2 72.621

EMIUN, MDK,*1,HE4 84.126 767 , EGF, GMCSF, IL1RA 64.737

EMIUN, MDK, *1,*2 84.979 768 , EGF, GMCSF, HE4 64.134

EMIUN, MDK, EGF.GMCSF 80.256 769 , EGF, GMCSF, *2 67.685

EMIUN, MDK, EGF, IL1RA 81.232 770 , EGF, IL1RA, HE4 63.778

EMIUN, MDK, EGF, HE4 80.096 771 , EGF, IL1RA, *2 64.276

EMIUN, MDK, EGF,*2 81.676 772 *1,EGF,HE4,*2 64.382

EMIUN, MDK.GMCSF, IL1RA 81.214 773 , GMCSF, IL1RA, HE4 62.695

EMIUN, MDK, GMCSF, HE4 79.51 774 , GMCSF, IL1RA, *2 65.607

EMIUN, MDK, GMCSF, *2 81.214 775 Ί, GMCSF, HE4,*2 64.489

EMIUN, MDK, IL1RA, HE4 80.788 776 *1, IL1RA, HE4,*2 62.713

EMIUN, MDK, IL1RA, *2 82.493 777 EGF.GMCSF, IL1RA, HE4 52.734

EMIUN, MDK, HE4,*2 80.753 778 EGF.GMCSF, IL1RA, *2 55.415

EMIUN, Ί, EGF.GMCSF 75.994 779 EGF, GMCSF, HE4, *2 48.633

EMIUN, Ί, EGF, IL1RA 75.746 780 EGF, IL1RA, HE4, *2 48.509

EMIUN, Ί, EGF, HE4 75.497 781 GMCSF, IL1RA, HE4, *2 52.095

EMIUN, Ί, EGF, *2 76.314 782 ps, mps, dps, CA125, EMILIN 98.26

EMIUN, Ί, GMCSF, IL1RA 77.876 783 ps, mps, dps, CA125, MDK 97.94

EMIUN, Ί, GMCSF, HE4 77.131 784 ps, mps, dps, CA125, 97.23

EMIUN, Ί, GMCSF, *2 78.8 785 ps, mps, dps, CA125, EGF 97.585

EMILIN, *1, IL1RA, HE4 78.001 786 ps, mps, dps, CA125, GMCSF 97.124

EMILIN, *1, IL1RA, *2 77.521 787 ps, mps, dps, CA125, 1 LIRA 97.159

EMILIN, Ί,ΗΕ4,*2 76.634 788 ps, mps, dps, CA125, HE4 97.479

EMILIN, EGF.GMCSF, IL1RA 71.555 789 ps, mps, dps, CA125, *2 97.195

EMILIN, EGF, GMCSF, HE4 69.957 790 ps, mps, dps, EMILIN, MDK 96.555

EMILIN, EGF, GMCSF, *2 69.762 791 ps, mps, dps, EMILIN, 95.774

EMILIN, EGF, IL1RA, HE4 70.863 792 ps, mps, dps, EMILIN, EGF 95.845

EMILIN, EGF, IL1RA, *2 70.526 793 ps, mps, dps, EMIUN.GMCSF 95.614

EMILIN, EGF, HE4, *2 69.016 794 ps, mps, dps, EMILIN, IL1RA 96.875

EMIUN.GMCSF, IL1RA, HE4 74.663 795 ps.mps, dps, EMILIN, HE4 95.739

EMIUN.GMCSF, IL1RA, *2 75.053 796 ps, mps, dps, EMILIN, *2 95.561

EMIUN.GMCSF, HE4,*2 74.432 797 ps, mps, dps, MDK, 95.455

EMILIN, IL1RA, HE4, *2 73.722 798 ps, mps, dps, MDK, EGF 95.241

ΜϋΚ,Ί, EGF.GMCSF 81.516 799 ps, mps, dps, MDK, GMCSF 95.206

MDK, , EGF, IL1RA 80.93 800 ps, mps, dps, MDK, IL1RA 95.952

ΜϋΚ,Ί, EGF.HE4 80.487 801 ps, mps, dps, MDK, HE4 94.886

ΜϋΚ,Ί, EGF,*2 80.469 802 ps, mps, dps, MDK, *2 95.295

MDK, Ί, GMCSF, IL1RA 80.948 803 ps, mps, dps, , EGF 93.679

MDK, Ί, GMCSF, HE4 81.641 804 ps, mps, dps, , GMCSF 93.253

MDK, Ί, GMCSF, *2 82.919 805 ps, mps, dps, , IL1RA 94.07 806 ips, mps, dps, , HE4 93.324 858 ips, mps, EMILIN, EGF, IL1 RA 97.053

807 ips, mps, dps, , *2 93.821 859 ips, mps, EMILIN, EGF, HE4 95.348

808 ips, mps, dps, EGF, GMCSF 93.04 860 ips, mps, EMILIN, EGF, *2 95.241

809 ips, mps, dps, EGF, I LI RA 94.212 861 ips, mps, EMILIN, GMCSF, IL1 RA 96.839

810 ips, mps, dps, EGF, HE4 93.093 862 ips, mps, EMILIN, GMCSF, HE4 95.17

811 ips, mps, dps, EGF, *2 93.324 863 ips, mps, EMILIN, GMCSF, *2 94.993

812 ips, mps, dps, GMCSF, IL1 RA 93.643 864 ips, mps, EMILIN, IL1 RA, HE4 96.875

813 ips, mps, dps, GMCSF, HE4 92.756 865 ips, mps, EMILIN, IL1 RA, *2 96.875

814 ips, mps, dps, GMCSF, *2 92.933 866 ips, mps, EMILIN, HE4J2 94.957

815 ips, mps, dps, I LI RA, HE4 93.999 867 ips, mps, MDK, Ί , EGF 95.455

816 ips, mps, dps, 1 LI RA, *2 94.194 868 ips, mps, MDK, Ί , GMCSF 95.313

817 ips, mps, dps, HE4, *2 92.205 869 ips, mps, MDK, *1 , IL1 RA 96.023

818 ips, mps, CA125, EMILIN, MDK 98.58 870 ips, mps, MDK, *1 , HE4 95.241

819 ips, mps, CA125, EMILIN, Ί 98.651 871 ips, mps, MDK, Ί , *2 95.668

820 ips, mps, CA125, EMILIN, EGF 98.473 872 ips, mps, MDK, EGF, GMCSF 94.886

821 ips, mps, CA125, EMILIN, GMCSF 98.402 873 ips, mps, MDK, EGF, IL1 RA 95.952

822 ips, mps, CA125, EMILIN, IL1 RA 98.686 874 ips, mps, MDK, EGF, HE4 94.922

823 ips, mps, CA125, EMILIN, HE4 98.615 875 ips, mps, MDK, EGF, *2 95.028

824 ips, mps, CA125, EMILIN, *2 98.58 876 ips, mps, MDK, GMCSF, IL1 RA 95.739

825 ips, mps, CA125, MDK, Ί 98.189 877 ips, mps, MDK, GMCSF, HE4 94.638

826 ips, mps, CA125, MDK, EGF 98.331 878 ips, mps, MDK, GMCSF, *2 94.851

827 ips, mps, CA125, MDK, GMCSF 98.082 879 ips, mps, MDK, IL1 RA, HE4 95.739

828 ips, mps, CA125, MDK, IL1 RA 98.011 880 ips, mps, MDK, IL1 RA, *2 95.632

829 ips, mps, CA125, MDK, HE4 98.153 881 ips, mps, MDK, HE4, *2 94.425

830 ips, mps, CA125, MDK, *2 98.047 882 ips, mps, , EGF, GMCSF 92.383

831 ips, mps, CA125, *1 , EGF 97.443 883 ips, mps, *1 , EGF JU RA 93.679

832 ips, mps, CA125, , GMCSF 96.911 884 ips, mps, , EGF, HE4 92.791

833 ips, mps, CA125, *1 , IL1 RA 97.443 885 ips, mps, , EGF, *2 93.466

834 ips, mps, CA125, . ΗΕ4 97.408 886 ips, mps, , GMCSF, IL1RA 93.111

835 ips, mps, CA125, , *2 97.266 887 ips, mps, , GMCSF, HE4 92.33

836 ips, mps, CA125, EGF, GMCSF 97.124 888 ips, mps, , GMCSF, *2 93.022

837 ips, mps, CA125, EGF, IL1 RA 97.159 889 ips, mps, *1 , IL1 RA, HE4 93.643

838 ips, mps, CA125, EGF, HE4 97.372 890 ips, mps, *1 , IL1 RA, *2 93.821

839 ips, mps, CA125, EGFJ2 97.266 891 ips, mps, Ί . ΗΕ4, *2 92.401

840 ips, mps, CA125, GMCSF, IL1 RA 96.946 892 ips, mps, EGF, GMCSF, IL1 RA 93.182

841 ips, mps, CA125, GMCSF, HE4 97.053 893 ips, mps, EGF, GMCSF, HE4 91.868

842 ips, mps, CA125, GMCSF, *2 97.07 894 ips, mps, EGF, GMCSF, *2 92.01

843 ips, mps, CA125, 1 LI RA, HE4 97.692 895 ips, mps, EGF, IL1 RA, HE4 93.217

844 ips, mps, CA125, 1 LI RA, *2 97.195 896 ips, mps, EGF, IL1 RA, *2 93.395

845 ips, mps, CA125, HE4, *2 97.337 897 ips, mps, EGF, HE4, *2 91.655

846 ips, mps, EMILIN, MDK, Ί 96.662 898 ips, mps, GMCSF, IL1 RA, HE4 93.111

847 ips, mps, EMILIN, MDK, EGF 96.839 899 ips, mps, GMCSF, IL1 RA, *2 92.969

848 ips, mps, EMILIN, MDK, GMCSF 96.449 900 ips, mps, GMCSF, HE4, *2 91.566

849 ips, mps, EMILIN, MDK, IL1 RA 97.053 901 ips, mps, IL1 RA, HE4J2 93.004

850 ips, mps, EMILIN, MDK, HE4 96.591 902 ips, dps, CA125, EMILIN, MDK 97.692

851 ips, mps, EMILIN, MDK, *2 96.378 903 ips, dps, CA125, EMILIN, 96.591

852 ips, mps, EMILIN, Ί , EGF 95.419 904 ips, dps, CA125, EMILIN, EGF 96.911

853 ips, mps, EMILIN, Ί , GMCSF 95.384 905 ips, dps, CA125, EMILIN, GMCSF 96.484

854 ips, mps, EMILIN, *1 JU RA 96.804 906 ips, dps, CA125, EMILIN, IL1 RA 97.124

855 ips, mps, EMILIN, Ί . ΗΕ4 95.455 907 ips, dps, CA125, EMILIN, HE4 97.159

856 ips, mps, EMILIN, Ί , *2 95.597 908 ips, dps, CA125, EMILIN, *2 96.964

857 ips, mps, EMILIN, EGF, GMCSF 95.17 909 ips, dps, CA125, MDK, Ί 97.266 910 ips, dps, CA125, MDK, EGF 97.159 962 ips, dps, MDK, GMCSF, *2 92.56

911 ips, dps, CA125, MDK, GMCSF 97.124 963 ips, dps, MDK, IL1RA, HE4 91.122

912 ips, dps, CA125, MDK, IL1RA 97.088 964 ips, dps, MDK, IL1RA, *2 92.188

913 ips, dps, CA125, MDK, HE4 96.662 965 ips, dps, MDK, HE4, *2 92.045

914 ips, dps, CA125, MDK, *2 96.982 966 ips, dps, *1, EGF, GMCSF 91.619

915 ips, dps, CA125, *1, EGF 96.662 967 ips, dps, , EGF, IL1RA 92.045

916 ips, dps, CA125, *1, GMCSF 95.792 968 ips, dps, , EGF, HE4 91.477

917 ips, dps, CA125, *1, IL1RA 95.881 969 ips, dps, *1, EGF, *2 91.726

918 ips, dps, CA125,*1,HE4 95.561 970 ips, dps, , GMCSF, IL1RA 91.335

919 ips, dps, CA125, *1,*2 96.236 971 ips, dps, , GMCSF, HE4 90.803

920 ips, dps, CA125, EGF, GMCSF 96.449 972 ips, dps, , GMCSF, *2 91.406

921 ips, dps, CA125, EGF, IL1RA 96.342 973 ips, dps, , IL1RA, HE4 90.341

922 ips, dps, CA125, EGF, HE4 96.52 974 ips, dps, , I LIRA, *2 90.696

923 ips, dps, CA125, EGF, *2 96.484 975 ips, dps,*1,HE4, *2 89.95

924 ips, dps, CA125, GMCSF, IL1RA 95.348 976 ips, dps, EGF, GMCSF, IL1RA 88.832

925 ips, dps, CA125, GMCSF, HE4 95.561 977 ips, dps, EGF, GMCSF, HE4 89.276

926 ips, dps, CA125, GMCSF, *2 95.952 978 ips, dps, EGF, GMCSF, *2 90.021

927 ips, dps, CA125, 1 LIRA, HE4 95.455 979 ips, dps, EGF, IL1RA, HE4 88.743

928 ips, dps, CA125, 1 LIRA, *2 95.81 980 ips, dps, EGF, IL1RA, *2 90.27

929 ips, dps, CA125, HE4, *2 95.561 981 ips, dps, EGF, HE4, *2 89.24

930 ips, dps, EMILIN, MDK, Ί 93.857 982 ips, dps, GMCSF, IL1RA, HE4 87.784

931 ips, dps, EMILIN, MDK, EGF 93.501 983 ips, dps, GMCSF, IL1RA, *2 89.915

932 ips, dps, EMILIN, MDK, GMCSF 93.182 984 ips, dps, GMCSF, HE4, *2 88.743

933 ips, dps, EMILIN, MDK, IL1RA 93.359 985 ips, dps, IL1RA, HE4, *2 87.926

934 ips, dps, EMILIN, MDK, HE4 92.969 986 ips, CA125, EMILIN, MDK, Ί 97.195

935 ips, dps, EMILIN, MDK, *2 93.786 987 ips, CA125, EMILIN, MDK, EGF 96.804

936 ips, dps, EMILIN, Ί, EGF 92.507 988 ips, CA125, EMILIN, MDK, GMCSF 97.017

937 ips, dps, EMILIN, Ί, GMCSF 92.17 989 ips, CA125, EMILIN, MDK, IL1RA 97.088

938 ips, dps, EMIUN, *1 JURA 93.253 990 ips, CA125, EMILIN, MDK, HE4 97.017

939 ips, dps, EMILIN, Ί.ΗΕ4 92.543 991 ips, CA125, EMILIN, MDK, *2 97.053

940 ips, dps, EMILIN, Ί,*2 92.933 992 ips, CA125, EMILIN, Ί, EGF 95.703

941 ips, dps, EMILIN, EGF, GMCSF 91.371 993 ips, CA125, EMILIN, Ί, GMCSF 95.81

942 ips, dps, EMILIN, EGF, IL1RA 92.116 994 ips, CA125, EMILIN, *1, IL1RA 95.881

943 ips, dps, EMILIN, EGF, HE4 91.832 995 ips, CA125, EMILIN, Ί.ΗΕ4 95.774

944 ips, dps, EMILIN, EGF, *2 91.868 996 ips, CA125, EMILIN, Ί,*2 95.81

945 ips, dps, EMILIN, GMCSF, IL1RA 92.188 997 ips, CA125, EMILIN, EGF, GMCSF 95.455

946 ips, dps, EMILIN, GMCSF, HE4 91.903 998 ips, CA125, EMILIN, EGF, IL1RA 95.739

947 ips, dps, EMILIN, GMCSF, *2 91.779 999 ips, CA125, EMILIN, EGF, HE4 95.916

948 ips, dps, EMILIN JURA, HE4 92.33 1000 ips, CA125, EMILIN, EGF, *2 95.952

949 ips, dps, EMILIN JURA, *2 92.614 1001 ips, CA125, EMILIN, GMCSF, 95.526

950 ips, dps, EMILIN, HE4J2 92.134 IL1RA

951 ips, dps, MDK, Ί, EGF 93.501 1002 ips, CA125, EMILIN, GMCSF, HE4 96.129

952 ips, dps, MDK, Ί, GMCSF 94.212 1003 ips, CA125, EMILIN, GMCSF, *2 95.774

953 ips, dps, MDK, *1, IL1RA 93.75 1004 ips, CA125, EMILIN, IL1RA, HE4 96.2

954 ips, dps, MDK,*1,HE4 93.377 1005 ips, CA125, EMILIN, IL1RA, *2 96.236

955 ips, dps, MDK,*1,*2 93.821 1006 ips, CA125, EMILIN, HE4J2 96.378

956 ips, dps, MDK, EGF, GMCSF 92.116 1007 ips, CA125, MDK, , EGF 96.857

957 ips, dps, MDK, EGF, IL1RA 92.347 1008 ips, CA125, MDK, Ί, GMCSF 97.159

958 ips, dps, MDK, EGF, HE4 91.371 1009 ips, CA125, MDK, *1, IL1RA 97.017

959 ips, dps, MDK, EGF, *2 92.33 1010 ips, CA125, MDK,*1,HE4 96.839

960 ips, dps, MDK, GMCSF, IL1RA 92.188 1011 ips, CA125, MDK,*1,*2 96.733

961 ips, dps, MDK, GMCSF, HE4 92.081 1012 ips, CA125, MDK, EGF, GMCSF 97.053 1013 ips, CA125, MDK, EGF, IL1RA 96.768 1065 ips, EMILIN, *1,IL1RA, *2 89.382

1014 ips, CA125, MDK, EGF, HE4 96.591 1066 ips, EMILIN, Ί,ΗΕ4,*2 89.205

1015 ips, CA125, MDK, EGF, *2 96.626 1067 ips, EMILIN, EGF.GMCSF, IL1RA 88.068

1016 ips, CA125, MDK.GMCSF, IL1RA 96.911 1068 ips, EMILIN, EGF, GMCSF, HE4 87.678

1017 ips, CA125, MDK, GMCSF, HE4 96.875 1069 ips, EMILIN, EGF, GMCSF, *2 86.665

1018 ips, CA125, MDK, GMCSF, *2 96.804 1070 ips, EMILIN, EGF, IL1RA, HE4 87.891

1019 ips, CA125, MDK, IL1RA, HE4 96.591 1071 ips, EMILIN, EGF, IL1RA, *2 87.429

1020 ips, CA125, MDK, IL1RA, *2 96.768 1072 ips, EMILIN, EGF, HE4,*2 85.511

1021 ips, CA125, MDK, HE4, *2 96.378 1073 ips, EMIUN.GMCSF, IL1RA, HE4 89.382

1022 ips, CA125, *1, EGF, GMCSF 94.957 1074 ips, EMIUN.GMCSF, IL1RA, *2 88.885

1023 ips, CA125, , EGF, IL1RA 94.993 1075 ips, EMIUN.GMCSF, HE4,*2 87.749

1024 ips, CA125,*1,EGF, HE4 94.851 1076 ips, EMILIN, IL1RA, HE4, *2 87.997

1025 ips, CA125, *1, EGF,*2 95.099 1077 ips, MDK, Ί, EGF, GMCSF 91.903

1026 ips, CA125, , GMCSF, IL1RA 94.851 1078 ips, MDK, , EGF, IL1RA 91.371

1027 ips, CA125, , GMCSF, HE4 95.117 1079 ips, MDK, Ί, EGF, HE4 90.874

1028 ips, CA125, *1, GMCSF, *2 95.028 1080 ips, MDK, Ί, EGF, *2 91.158

1029 ips, CA125, , IL1RA, HE4 94.531 1081 ips, MDK, Ί, GMCSF, IL1RA 92.045

1030 ips, CA125, *1, IL1RA, *2 94.815 1082 ips, MDK, Ί, GMCSF, HE4 91.69

1031 ips, CA125,*1,HE4,*2 94.602 1083 ips, MDK, Ί, GMCSF, *2 92.081

1032 ips, CA125, EGF.GMCSF, IL1RA 94.886 1084 ips, MDK, , IL1RA, HE4 90.803

1033 ips, CA125, EGF, GMCSF, HE4 95.064 1085 ips, MDK, *1, IL1RA, *2 91.158

1034 ips, CA125, EGF, GMCSF, *2 94.815 1086 ips,MDK,*1,HE4,*2 90.98

1035 ips, CA125, EGF, IL1RA, HE4 94.709 1087 ips, MDK, EGF, GMCSF, IL1RA 89.418

1036 ips, CA125, EGF, I LIRA, *2 94.94 1088 ips, MDK, EGF, GMCSF, HE4 89.169

1037 ips, CA125, EGF, HE4,*2 94.531 1089 ips, MDK, EGF, GMCSF, *2 89.844

1038 ips, CA125, GMCSF, IL1RA, HE4 94.602 1090 ips, MDK, EGF, IL1RA, HE4 88.317

1039 ips, CA125, GMCSF, IL1RA, *2 94.886 1091 ips, MDK, EGF, IL1RA, *2 89.222

1040 ips, CA125, GMCSF, HE4,*2 94.993 1092 ips, MDK, EGF, HE4, *2 88.494

1041 ips, CA125, IL1RA, HE4, *2 94.336 1093 ips, MDK.GMCSF, IL1RA, HE4 88.636

1042 ips, EMIUN, MDK, , EGF 92.188 1094 ips, MDK.GMCSF, IL1RA, *2 89.311

1043 ips, EMIUN, MDK, Ί, GMCSF 92.045 1095 ips, MDK, GMCSF, HE4, *2 88.903

1044 ips, EMIUN, MDK, , IL1RA 91.939 1096 ips, MDK, IL1RA, HE4, *2 87.891

1045 ips, EMIUN, MDK, Ί.ΗΕ4 92.01 1097 ips, , EGF, GMCSF, IL1RA 85.938

1046 ips, EMIUN, MDK, Ί,*2 92.223 1098 ips, , EGF, GMCSF, HE4 86.257

1047 ips, EMIUN, MDK, EGF.GMCSF 90.518 1099 ips, *1, EGF, GMCSF, *2 87.251

1048 ips, EMIUN, MDK, EGF, IL1RA 91.46 1100 ips, , EGF, IL1RA, HE4 85.05

1049 ips, EMIUN, MDK, EGF, HE4 90.376 1101 ips, , EGF, IL1RA, *2 86.452

1050 ips, EMIUN, MDK, EGF,*2 90.998 1102 ips, , EGF, HE4,*2 85.938

1051 ips, EMILIN.MDK.GMCSF, IL1RA 90.98 1103 ips, , GMCSF, IL1RA, HE4 86.044

1052 ips, EMILIN.MDK.GMCSF, HE4 91.122 1104 ips, , GMCSF, IL1RA, *2 86.985

1053 ips, EMIUN, MDK, GMCSF, *2 91.087 1105 ips, , GMCSF, HE4,*2 86.435

1054 ips, EMILIN, MDK, IL1RA, HE4 91.016 1106 ips, *1, IL1RA, HE4, *2 85.05

1055 ips, EMILIN, MDK, IL1RA, *2 91.122 1107 ips, EGF.GMCSF, IL1RA, HE4 83.203

1056 ips, EMILIN, MDK, HE4,*2 90.376 1108 ips, EGF.GMCSF, IL1RA, *2 83.807

1057 ips, EMILIN, Ί, EGF, GMCSF 87.713 1109 ips, EGF, GMCSF, HE4, *2 83.434

1058 ips, EMILIN, Ί, EGF, IL1RA 88.778 1110 ips, EGF, IL1RA, HE4,*2 81.587

1059 ips, EMILIN, Ί, EGF, HE4 88.494 1111 ips, GMCSF, IL1RA, HE4, *2 82.564

1060 ips, EMILIN, Ί, EGF, *2 88.956 1112 mps, dps, CA125, EMILIN, MDK 97.727

1061 ips, EMILIN, Ί, GMCSF, IL1RA 89.311 1113 mps, dps, CA125, EMILIN, Ί 97.337

1062 ips, EMILIN, Ί, GMCSF, HE4 89.169 1114 mps, dps, CA125, EMILIN, EGF 97.514

1063 ips, EMILIN, Ί, GMCSF, *2 89.542 1115 mps, dps, CA125, EMIUN.GMCSF 97.443

1064 ips, EMILIN, *1, IL1RA, HE4 90.146 1116 mps, dps, CA125, EMILIN, IL1RA 97.55 1117 mps, dps, CA125, EMIUN, HE4 97.656 1169 mps, dps, MDK, EGF, *2 93.466

1118 mps, dps, CA125, EMIUN, *2 97.727 1170 mps, dps, MDK, GMCSF, IL1RA 93.288

1119 mps, dps, CA125, MDK, *1 96.733 1171 mps, dps, MDK, GMCSF, HE4 92.33

1120 mps, dps, CA125, MDK, EGF 96.697 1172 mps, dps, MDK, GMCSF, *2 93.43

1121 mps, dps, CA125, MDK, GMCSF 96.591 1173 mps, dps, MDK, IL1 RA, HE4 93.572

1122 mps, dps, CA125, MDK, IL1 RA 96.946 1174 mps, dps, MDK, IL1 RA, *2 94.798

1123 mps, dps, CA125, MDK, HE4 96.697 1175 mps, dps, MDK, HE4, *2 93.253

1124 mps, dps, CA125, MDK, *2 96.733 1176 mps, dps, , EGF, GMCSF 90.199

1125 mps, dps, CA125, *1 , EGF 95.526 1177 mps, dps, *1 , EGF JU RA 91.815

1126 mps, dps, CA125, *1 , GMCSF 95.028 1178 mps, dps, *1 , EGF, HE4 91.406

1127 mps, dps, CA125, *1 , IL1 RA 95.792 1179 mps, dps, , EGF, *2 92.045

1128 mps, dps, CA125, *1 , HE4 95.561 1180 mps, dps, *1 , GMCSF JU RA 90.661

1129 mps, dps, CA125, , *2 95.845 1181 mps, dps, , GMCSF, HE4 89.364

1130 mps, dps, CA125, EGF, GMCSF 95.241 1182 mps, dps, , GMCSF, *2 91.264

1131 mps, dps, CA125, EGF, IL1 RA 95.526 1183 mps, dps, , IL1 RA, HE4 91.406

1132 mps, dps, CA125, EGF, HE4 95.703 1184 mps, dps, , I LI RA, *2 91.584

1133 mps, dps, CA125, EGFJ2 95.668 1185 mps, dps, . ΗΕ4, *2 91.388

1134 mps, dps, CA125, GMCSF, IL1 RA 95.241 1186 mps, dps, EGF, GMCSF, IL1 RA 90.075

1135 mps, dps, CA125, GMCSF, HE4 95.313 1187 mps, dps, EGF, GMCSF, HE4 88.21

1136 mps, dps, CA125, GMCSF, *2 95.206 1188 mps, dps, EGF, GMCSF, *2 89.311

1137 mps, dps, CA125, IL1 RA, HE4 95.668 1189 mps, dps, EGF, IL1 RA, HE4 90.589

1138 mps, dps, CA125, IL1 RA, *2 95.703 1190 mps, dps, EGF, IL1 RA, *2 90.891

1139 mps, dps, CA125, HE4, *2 95.597 1191 mps, dps, EGF, HE4, *2 89.524

1140 mps, dps, EMIUN, MDK, Ί 95.881 1192 mps, dps, GMCSF, IL1RA, HE4 89.844

1141 mps, dps, EMIUN, MDK, EGF 94.815 1193 mps, dps, GMCSF, IL1 RA, *2 90.146

1142 mps, dps, EMIUN, MDK, GMCSF 94.993 1194 mps, dps, GMCSF, HE4, *2 87.642

1143 mps, dps, EMIUN, MDK, IL1 RA 95.668 1195 mps, dps, IL1 RA, HE4, *2 90.714

1144 mps, dps, EMIUN, MDK, HE4 95.028 1196 mps, CA125, EMIUN, MDK, Ί 97.798

1145 mps, dps, EMIUN, MDK, *2 95.526 1197 mps, CA125, EMIUN, MDK, EGF 97.621

1146 mps, dps, EMIUN, Ί , EGF 94.46 1198 mps, CA125, EMIUN, MDK, 97.656

1147 mps, dps, EMIUN, Ί , GMCSF 94.371 GMCSF

1148 mps, dps, EMIUN, *1 JU RA 95.81 1199 mps, CA125, EMIUN, MDK, IL1 RA 97.727

1149 mps, dps, EMIUN, Ί . ΗΕ4 94.78 1200 mps, CA125, EMIUN, MDK, HE4 97.834

1150 mps, dps, EMIUN, Ί , *2 95.668 1201 mps, CA125, EMIUN, MDK, *2 97.869

1151 mps, dps, EMIUN, EGF, GMCSF 93.04 1202 mps, CA125, EMIUN, Ί , EGF 97.088

1152 mps, dps, EMIUN, EGF, IL1 RA 95.455 1203 mps, CA125, EMIUN, Ί , GMCSF 96.911

1153 mps, dps, EMIUN, EGF, HE4 93.395 1204 mps, CA125, EMIUN, *1 JU RA 97.372

1154 mps, dps, EMIUN, EGF, *2 93.714 1205 mps, CA125, EMIUN, Ί , HE4 96.982

1155 mps, dps, EMIUN, GMCSF, IL1 RA 95.206 1206 mps, CA125, EMIUN, Ί , *2 97.088

1156 mps, dps, EMIUN, GMCSF, HE4 93.643 1207 mps, CA125, EMIUN, EGF, 96.982

1157 mps, dps, EMIUN, GMCSF, *2 93.608 GMCSF

1158 mps, dps, EMIUN, IL1 RA, HE4 95.916 1208 mps, CA125, EMIUN, EGF, IL1 RA 97.088

1159 mps, dps, EMIUN, IL1 RA, *2 95.952 1209 mps, CA125, EMIUN, EGF, HE4 96.911

1160 mps, dps, EMIUN, HE4J2 93.874 1210 mps, CA125, EMIUN, EGF, *2 96.982

1161 mps, dps, MDK, Ί , EGF 94.283 1211 mps, CA125, EMIUN, GMCSF, 97.23

1162 mps, dps, MDK, Ί , GMCSF 94.602 IL1 RA

1163 mps, dps, MDK, *1 , IL1 RA 95.366 1212 mps, CA125, EMIUN, GMCSF, 97.088

1164 mps, dps, MDK, *1 , HE4 93.928 HE4

1165 mps, dps, MDK, Ί , *2 95.028 1213 mps, CA125, EMIUN, GMCSF, *2 96.982

1166 mps, dps, MDK, EGF, GMCSF 92.543 1214 mps, CA125, EMIUN, IL1 RA, HE4 97.443

1167 mps, dps, MDK, EGF, IL1 RA 93.928 1215 mps, CA125, EMIUN, IL1 RA, *2 97.372

1168 mps, dps, MDK, EGF, HE4 92.685 1216 mps, CA125, EMIUN, HE4, *2 97.23 1217 mps, CA125, MDK, , EGF 96.271 1268 mps, EMIUN, Ί, EGF, IL1RA 94.638

1218 mps, CA125, MDK, Ί, GMCSF 96.413 1269 mps, EMIUN, Ί, EGF, HE4 93.129

1219 mps, CA125, MDK, *1, IL1RA 96.626 1270 mps, EMIUN, Ί, EGF, *2 94.176

1220 mps, CA125, MDK,*1,HE4 96.484 1271 mps, EMIUN, Ί, GMCSF, IL1RA 94.744

1221 mps, CA125, MDK, *1,*2 96.626 1272 mps, EMIUN, Ί, GMCSF, HE4 93.501

1222 mps, CA125, MDK, EGF, GMCSF 96.094 1273 mps, EMIUN, Ί, GMCSF, *2 94.354

1223 mps, CA125, MDK, EGF, IL1RA 96.342 1274 mps, EMILIN, *1, IL1RA, HE4 94.513

1224 mps, CA125, MDK, EGF, HE4 96.378 1275 mps, EMILIN, *1, IL1RA, *2 95.153

1225 mps, CA125, MDK, EGF, *2 96.2 1276 mps, EMILIN, Ί,ΗΕ4,*2 94.496

1226 mps, CA125, MDK, GMCSF, IL1RA 96.342 1277 mps, EMILIN, EGF.GMCSF, IL1RA 93.182

1227 mps, CA125, MDK, GMCSF, HE4 96.449 1278 mps, EMILIN, EGF.GMCSF, HE4 90.696

1228 mps, CA125, MDK, GMCSF, *2 96.378 1279 mps, EMILIN, EGF, GMCSF, *2 91.584

1229 mps, CA125, MDK, IL1RA, HE4 96.697 1280 mps, EMILIN, EGF, IL1RA, HE4 93.643

1230 mps, CA125, MDK, IL1RA, *2 96.662 1281 mps, EMILIN, EGF, IL1RA, *2 93.75

1231 mps, CA125, MDK, HE4,*2 96.484 1282 mps, EMILIN, EGF, HE4,*2 91.282

1232 mps, CA125, *1, EGF, GMCSF 94.354 1283 mps, EMILIN, GMCSF, IL1RA, HE4 93.857

1233 mps, CA125, , EGF, IL1RA 94.869 1284 mps, EMILIN, GMCSF, IL1RA, *2 93.803

1234 mps, CA125, , EGF, HE4 94.318 1285 mps, EMILIN, GMCSF, HE4,*2 91.868

1235 mps, CA125,*1,EGF,*2 94.602 1286 mps, EMILIN, IL1RA, HE4, *2 94.389

1236 mps, CA125, , GMCSF, IL1RA 94.815 1287 mps, MDK, Ί, EGF, GMCSF 94.07

1237 mps, CA125,*1, GMCSF, HE4 94.247 1288 mps, MDK, , EGF, IL1RA 93.786

1238 mps, CA125,*1, GMCSF, *2 94.549 1289 mps, MDK, , EGF, HE4 93.324

1239 mps, CA125, , IL1RA, HE4 95.206 1290 mps, MDK, Ί, EGF, *2 94.105

1240 mps, CA125, *1, IL1RA, *2 95.348 1291 mps, MDK, Ί, GMCSF, IL1RA 94.141

1241 mps, CA125,*1,HE4,*2 94.78 1292 mps, MDK, Ί, GMCSF, HE4 93.786

1242 mps, CA125, EGF, GMCSF, IL1RA 94.531 1293 mps, MDK, Ί, GMCSF, *2 94.247

1243 mps, CA125, EGF, GMCSF, HE4 94.389 1294 mps, MDK, , IL1RA, HE4 94.194

1244 mps, CA125, EGF, GMCSF, *2 94.389 1295 mps, MDK, *1, IL1RA, *2 94.602

1245 mps, CA125, EGF, IL1RA, HE4 94.531 1296 mps, MDK,*1,HE4,*2 93.999

1246 mps, CA125, EGF, IL1RA, *2 94.602 1297 mps, MDK, EGF.GMCSF, IL1RA 91.85

1247 mps, CA125, EGF, HE4, *2 94.496 1298 mps, MDK, EGF, GMCSF, HE4 91.797

1248 mps, CA125, GMCSF, IL1RA, HE4 95.135 1299 mps, MDK, EGF, GMCSF, *2 92.152

1249 mps, CA125, GMCSF, IL1RA, *2 94.638 1300 mps, MDK, EGF, IL1RA, HE4 92.294

1250 mps, CA125, GMCSF, HE4,*2 94.318 1301 mps, MDK, EGF, IL1RA, *2 92.72

1251 mps, CA125, IL1RA, HE4, *2 95.135 1302 mps, MDK, EGF, HE4, *2 91.868

1252 mps, EMIUN, MDK, Ί, EGF 95.703 1303 mps, MDK, GMCSF, IL1RA, HE4 92.827

1253 mps, EMIUN, MDK, Ί, GMCSF 95.703 1304 mps, MDK, GMCSF, IL1RA, *2 93.04

1254 mps, EMIUN, MDK, *1, IL1RA 95.881 1305 mps, MDK, GMCSF, HE4, *2 92.276

1255 mps, EMIUN, MDK, Ί. ΗΕ4 95.703 1306 mps, MDK, IL1RA, HE4,*2 93.537

1256 mps, EMIUN, MDK, Ί,*2 96.342 1307 mps, , EGF, GMCSF, IL1RA 89.595

1257 mps, EMIUN, MDK, EGF.GMCSF 94.212 1308 mps, , EGF, GMCSF, HE4 88.139

1258 mps, EMIUN, MDK, EGF, IL1RA 94.425 1309 mps, , EGF, GMCSF, *2 89.684

1259 mps, EMIUN, MDK, EGF, HE4 94.496 1310 mps, , EGF, IL1RA, HE4 90.483

1260 mps, EMIUN, MDK, EGF,*2 94.673 1311 mps, , EGF, IL1RA, *2 90.803

1261 mps, EMIUN, MDK, GMCSF, 94.496 1312 mps, , EGF, HE4,*2 89.205 IL1RA 1313 mps, , GMCSF, IL1RA, HE4 89.169

1262 mps, EMIUN, MDK, GMCSF, HE4 94.46 1314 mps, , GMCSF, IL1RA, *2 89.311

1263 mps, EMIUN, MDK, GMCSF, *2 94.673 1315 mps, , GMCSF, HE4, *2 87.82

1264 mps, EMIUN, MDK, IL1RA, HE4 94.957 1316 mps,*1,IL1RA, HE4,*2 90.039

1265 mps, EMIUN, MDK, IL1RA, *2 95.348 1317 mps, EGF, GMCSF, IL1RA, HE4 88.707

1266 mps, EMIUN, MDK, HE4,*2 94.957 1318 mps, EGF, GMCSF, IL1RA, *2 88.672

1267 mps, EMIUN, Ί, EGF, GMCSF 93.732 1319 mps, EGF, GMCSF, HE4, *2 86.932 1320 mps, EGF, IL1RA, HE4, *2 88.814 1370 dps,CA125, EGF, GMCSF, *2 92.507

1321 mps, GMCSF, IL1RA, HE4,*2 88.139 1371 dps,CA125, EGF, IL1RA, HE4 92.862

1322 dps, CA125, EMIUN, MDK, Ί 95.064 1372 dps,CA125, EGF, I LIRA, *2 93.395

1323 dps, CA125, EMIUN, MDK, EGF 94.602 1373 dps,CA125, EGF, HE4J2 92.116

1324 dps, CA125, EMIUN, MDK, 94.318 1374 dps, CA125, GMCSF, IL1RA, HE4 90.412 GMCSF 1375 dps, CA125, GMCSF, IL1RA, *2 92.188

1325 dps, CA125, EMIUN, MDK, IL1RA 94.638 1376 dps, CA125, GMCSF, HE4J2 91.3

1326 dps, CA125, EMIUN, MDK, HE4 94.318 1377 dps, CA125, IL1RA, HE4, *2 92.045

1327 dps, CA125, EMIUN, MDK, *2 95.313 1378 dps, EMIUN, MDK, Ί, EGF 91.122

1328 dps, CA125, EMIUN, Ί, EGF 93.501 1379 dps, EMIUN, MDK, Ί, GMCSF 90.589

1329 dps, CA125, EMIUN, Ί, GMCSF 93.395 1380 dps, EMIUN, MDK, *1 JURA 91.158

1330 dps, CA125, EMIUN, *1 JURA 94.034 1381 dps, EMIUN, MDK, Ί. ΗΕ4 91.158

1331 dps, CA125, EMIUN, Ί.ΗΕ4 93.679 1382 dps, EMIUN, MDK, Ί,*2 92.685

1332 dps, CA125, EMIUN, Ί,*2 94.389 1383 dps, EMIUN, MDK, EGF, GMCSF 87.571

1333 dps, CA125, EMIUN, EGF, GMCSF 93.288 1384 dps, EMIUN, MDK, EGF, IL1RA 88.459

1334 dps, CA125, EMIUN, EGF, IL1RA 94.212 1385 dps, EMIUN, MDK, EGF, HE4 87.66

1335 dps, CA125, EMIUN, EGF, HE4 93.43 1386 dps, EMIUN, MDK, EGF, *2 90.341

1336 dps, CA125, EMIUN, EGF, *2 94.07 1387 dps, EMIUN, MDK, GMCSF, IL1RA 88.459

1337 dps, CA125, EMIUN, GMCSF, 93.892 1388 dps, EMIUN, MDK, GMCSF, HE4 87.962 IL1RA 1389 dps, EMIUN, MDK, GMCSF, *2 89.56

1338 dps, CA125, EMIUN, GMCSF, HE4 93.572 1390 dps, EMIUN, MDK, IL1RA, HE4 88.601

1339 dps, CA125, EMIUN, GMCSF, *2 93.679 1391 dps, EMIUN, MDK, IL1RA, *2 90.128

1340 dps, CA125, EMIUN, IL1RA, HE4 94.141 1392 dps, EMIUN, MDK, HE4, *2 90.234

1341 dps, CA125, EMIUN, IL1RA, *2 94.638 1393 dps, EMIUN, Ί, EGF, GMCSF 85.547

1342 dps, CA125, EMILIN, HE4J2 94.283 1394 dps, EMIUN, Ί, EGF, IL1RA 88.423

1343 dps, CA125, MDK, , EGF 94.602 1395 dps, EMIUN, Ί, EGF, HE4 87.5

1344 dps, CA125, MDK, Ί, GMCSF 94.673 1396 dps, EMIUN, Ί, EGF, *2 88.938

1345 dps, CA125, MDK, *1, IL1RA 95.064 1397 dps, EMIUN, Ί, GMCSF, IL1RA 88.086

1346 dps, CA125, MDK,*1,HE4 94.531 1398 dps, EMIUN, Ί, GMCSF, HE4 88.21

1347 dps, CA125, MDK,*1,*2 95.028 1399 dps, EMIUN, Ί, GMCSF, *2 88.743

1348 dps, CA125, MDK, EGF, GMCSF 94.176 1400 dps, EMIUN, *1, IL1RA, HE4 89.524

1349 dps, CA125, MDK, EGF, IL1RA 94.354 1401 dps, EMILIN, *1, IL1RA, *2 90.341

1350 dps, CA125, MDK, EGF, HE4 94.176 1402 dps, EMILIN, Ί,ΗΕ4,*2 90.11

1351 dps, CA125, MDK, EGF, *2 94.744 1403 dps, EMILIN, EGF, GMCSF, IL1RA 85.121

1352 dps, CA125, MDK, GMCSF, IL1RA 93.928 1404 dps, EMILIN, EGF, GMCSF, HE4 83.061

1353 dps, CA125, MDK, GMCSF, HE4 93.75 1405 dps, EMILIN, EGF, GMCSF, *2 84.073

1354 dps, CA125, MDK, GMCSF, *2 94.318 1406 dps, EMILIN, EGF, IL1RA, HE4 86.275

1355 dps, CA125, MDK, IL1RA, HE4 93.714 1407 dps, EMILIN, EGF, IL1RA, *2 87.926

1356 dps, CA125, MDK, IL1RA, *2 94.78 1408 dps, EMILIN, EGF, HE4, *2 86.168

1357 dps, CA125, MDK, HE4, *2 94.141 1409 dps, EMILIN, GMCSF, IL1RA, HE4 86.861

1358 dps, CA125, *1, EGF, GMCSF 92.33 1410 dps, EMILIN, GMCSF, IL1RA, *2 87.571

1359 dps, CA125, , EGF, IL1RA 93.288 1411 dps, EMILIN, GMCSF, HE4J2 86.683

1360 dps, CA125, , EGF, HE4 92.294 1412 dps, EMILIN, IL1RA, HE4, *2 89.276

1361 dps, CA125,*1,EGF,*2 93.271 1413 dps, MDK, Ί, EGF, GMCSF 90.483

1362 dps, CA125, , GMCSF, IL1RA 92.223 1414 dps, MDK, , EGF, IL1RA 91.513

1363 dps, CA125, *1, GMCSF, HE4 90.98 1415 dps, MDK, , EGF, HE4 90.483

1364 dps, CA125, *1, GMCSF, *2 92.188 1416 dps, MDK,*1,EGF,*2 91.584

1365 dps, CA125, , IL1RA, HE4 92.17 1417 dps, MDK, Ί, GMCSF, IL1RA 90.607

1366 dps, CA125, *1, IL1RA, *2 92.933 1418 dps, MDK, Ί, GMCSF, HE4 90.589

1367 dps, CA125,*1,HE4,*2 92.152 1419 dps, MDK, Ί, GMCSF, *2 92.223

1368 dps, CA125, EGF, GMCSF, IL1RA 92.933 1420 dps, MDK,*1,IL1RA,HE4 91.264

1369 dps, CA125, EGF, GMCSF, HE4 91.992 1421 dps, MDK, *1, IL1RA, *2 91.477 1422 dps,MDK,*1,HE4,*2 91.335 1471 CA125, EMILIN, *1, IL1RA, *2 90.696

1423 dps, MDK, EGF, GMCSF, IL1RA 86.754 1472 CA125, EMILIN, Ί,ΗΕ4,*2 90.128

1424 dps, MDK, EGF, GMCSF, HE4 84.339 1473 CA125, EMILIN, EGF, GMCSF, 88.352

1425 dps, MDK, EGF, GMCSF, *2 88.601 IL1RA

1426 dps, MDK, EGF, IL1RA, HE4 85.938 1474 CA125, EMILIN, EGF, GMCSF, 87.571

1427 dps, MDK, EGF, IL1RA, *2 89.063 HE4

1428 dps, MDK, EGF, HE4, *2 87.66 1475 CA125, EMILIN, EGF, GMCSF, *2 87.536

1429 dps, MDK, GMCSF, IL1RA, HE4 85.724 1476 CA125, EMILIN, EGF, IL1RA, HE4 87.713

1430 dps, MDK, GMCSF, IL1RA, *2 89.169 1477 CA125, EMILIN, EGF, IL1RA, *2 88.849

1431 dps, MDK, GMCSF, HE4, *2 88.352 1478 CA125, EMILIN, EGF, HE4, *2 87.766

1432 dps, MDK, IL1RA, HE4, *2 88.246 1479 CA125, EMILIN, GMCSF, IL1RA, 89.187

1433 dps, , EGF, GMCSF, IL1RA 86.754 HE4

1434 dps, , EGF, GMCSF, HE4 83.381 1480 CA125, EMILIN, GMCSF, IL1RA, *2 89.382

1435 dps, *1, EGF, GMCSF, *2 86.381 1481 CA125, EMILIN, GMCSF, HE4, *2 88.956

1436 dps, *1, EGF, IL1RA, HE4 86.648 1482 CA125, EMILIN, IL1RA, HE4, *2 89.808

1437 dps, *1, EGF, IL1RA, *2 87.891 1483 CA125, MDK, Ί, EGF, GMCSF 90.447

1438 dps, , EGF, HE4,*2 85.795 1484 CA125, MDK, , EGF, IL1RA 90.874

1439 dps, *1, GMCSF, IL1RA, HE4 84.215 1485 CA125, MDK, , EGF, HE4 89.631

1440 dps, *1, GMCSF, IL1RA, *2 85.547 1486 CA125, MDK,*1,EGF,*2 90.554

1441 dps, , GMCSF, HE4, *2 84.126 1487 CA125, MDK, Ί, GMCSF, IL1RA 91.016

1442 dps, *1, IL1RA, HE4, *2 84.588 1488 CA125, MDK, Ί, GMCSF, HE4 90.749

1443 dps, EGF, GMCSF, IL1RA, HE4 79.439 1489 CA125, MDK, Ί, GMCSF, *2 91.087

1444 dps, EGF, GMCSF, IL1RA, *2 83.345 1490 CA125, MDK, , IL1RA, HE4 91.158

1445 dps, EGF, GMCSF, HE4, *2 80.646 1491 CA125, MDK, *1, IL1RA, *2 91.371

1446 dps, EGF, IL1RA, HE4, *2 82.457 1492 CA125, MDK,*1,HE4,*2 90.874

1447 dps, GMCSF, IL1RA, HE4,*2 80.806 1493 CA125, MDK, EGF, GMCSF, IL1RA 89.524

1448 CA125, EMILIN, MDK, , EGF 91.939 1494 CA125, MDK, EGF, GMCSF, HE4 88.707

1449 CA125, EMILIN, MDK, Ί, GMCSF 92.17 1495 CA125, MDK, EGF, GMCSF, *2 89.027

1450 CA125, EMILIN, MDK, *1, IL1RA 92.614 1496 CA125, MDK, EGF, IL1RA, HE4 89.577

1451 CA125, EMILIN, MDK, Ί, HE4 92.152 1497 CA125, MDK, EGF, IL1RA, *2 90.092

1452 CA125, EMILIN, MDK, Ί,*2 92.294 1498 CA125, MDK, EGF, HE4, *2 88.459

1453 CA125, EMIUN.MDK, EGF, 90.341 1499 CA125, MDK.GMCSF, IL1RA, HE4 89.276 GMCSF 1500 CA125, MDK.GMCSF, IL1RA, *2 89.702

1454 CA125, EMIUN.MDK, EGF, IL1RA 91.3 1501 CA125, MDK.GMCSF, HE4, *2 88.849

1455 CA125, EMILIN, MDK, EGF, HE4 90.803 1502 CA125, MDK, IL1RA, HE4,*2 89.595

1456 CA125, EMILIN, MDK, EGF, *2 91.122 1503 CA125, , EGF, GMCSF, IL1RA 85.263

1457 CA125, EMILIN, MDK, GMCSF, 91.477 1504 CA125, , EGF, GMCSF, HE4 83.807 IL1RA 1505 CA125,*1, EGF, GMCSF, *2 84.801

1458 CA125, EMILIN, MDK, GMCSF, 90.767 1506 CA125, , EGF, IL1RA, HE4 85.21 HE4 1507 CA125, , EGF, IL1RA, *2 85.76

1459 CA125, EMILIN, MDK, GMCSF, *2 91.016 1508 CA125, , EGF, HE4, *2 83.984

1460 CA125, EMIUN.MDK, IL1RA, HE4 91.513 1509 CA125, , GMCSF, IL1RA, HE4 85.334

1461 CA125, EMIUN.MDK, IL1RA, *2 92.01 1510 CA125, , GMCSF, IL1RA, *2 86.47

1462 CA125, EMIUN.MDK, HE4,*2 91.264 1511 CA125, , GMCSF, HE4, *2 84.411

1463 CA125, EMILIN, Ί, EGF, GMCSF 88.423 1512 CA125, *1, IL1RA, HE4, *2 85.44

1464 CA125, EMILIN, , EGF, IL1RA 89.364 1513 CA125, EGF, GMCSF, IL1RA, HE4 83.878

1465 CA125, EMILIN, Ί, EGF, HE4 88.565 1514 CA125, EGF, GMCSF, IL1RA, *2 84.091

1466 CA125, EMILIN, Ί, EGF,*2 88.991 1515 CA125, EGF, GMCSF, HE4, *2 81.286

1467 CA125, EMILIN, , GMCSF, IL1RA 89.95 1516 CA125, EGF, IL1RA, HE4, *2 82.99

1468 CA125, EMILIN, , GMCSF, HE4 89.844 1517 CA125, GMCSF, IL1RA, HE4,*2 83.292

1469 CA125, EMILIN, Ί, GMCSF, *2 89.986 1518 EMILIN, MDK, Ί, EGF, GMCSF 84.197

1470 CA125, EMILIN, *1,IL1RA, HE4 90.305 1519 EMILIN, MDK, Ί, EGF, IL1RA 84.677 1520 EMIUN, MDK, , EGF, HE4 84.339 1570 , EGF, GMCSF, HE4, *2 65.181

1521 EMIUN, MDK,*1, EGF,*2 85.085 1571 , EGF, IL1RA, HE4, *2 63.157

1522 EMIUN, MDK, , GMCSF, IL1RA 83.842 1572 , GMCSF, IL1RA, HE4,*2 63.299

1523 EMIUN, MDK, Ί, GMCSF, HE4 84.233 1573 EGF.GMCSF, IL1RA, HE4,*2 47.656

1524 EMIUN, MDK, Ί, GMCSF, *2 84.659 1574 ips.mps, dps, CA125, EMILIN, 98.473

1525 EMIUN, MDK, , IL1RA, HE4 84.091 MDK

1526 EMIUN, MDK, *1, IL1RA, *2 84.766 1575 ips.mps, dps, CA125, EMILIN, Ί 98.438

1527 EMIUN, MDK,*1,HE4,*2 85.067 1576 ips.mps, dps, CA125, EMILIN, 98.438

1528 EMIUN, MDK, EGF.GMCSF, 80.824 EGF

IL1RA 1577 ips.mps, dps, CA125, EMILIN, 98.26

1529 EMIUN, MDK, EGF, GMCSF, HE4 78.942 GMCSF

1530 EMIUN, MDK, EGF, GMCSF, *2 80.717 1578 ips.mps, dps, CA125, EMILIN, 98.295

1531 EMIUN, MDK, EGF, IL1RA, HE4 80.398 IL1RA

1532 EMIUN, MDK, EGF, IL1RA, *2 81.978 1579 ips.mps, dps, CA125, EMILIN, HE4 98.438

1533 EMIUN, MDK, EGF, HE4, *2 80.504 1580 ips.mps, dps, CA125, EMILIN, *2 98.473

1534 EMIUN, MDK, GMCSF, IL1RA, 80.362 1581 ips.mps, dps, CA125, MDK, Ί 98.011 HE4 1582 ips, mps, dps, CA125, MDK, EGF 97.976

1535 EMIUN, MDK, GMCSF, IL1RA, *2 82.191 1583 ips.mps, dps, CA125, MDK, 97.869

1536 EMIUN, MDK, GMCSF, HE4, *2 80.895 GMCSF

1537 EMIUN, MDK, IL1RA, HE4,*2 81.286 1584 ips, mps, dps, CA125, MDK, I LIRA 98.011

1538 EMIUN, Ί, EGF, GMCSF, IL1RA 76.598 1585 ips, mps, dps, CA125, MDK, HE4 98.153

1539 EMIUN, Ί, EGF, GMCSF, HE4 75.639 1586 ips.mps, dps, CA125, MDK, *2 97.976

1540 EMIUN, Ί, EGF, GMCSF, *2 76.989 1587 ips.mps, dps, CA125, *1,EGF 97.372

1541 EMIUN, Ί, EGF, IL1RA, HE4 76.971 1588 ips, mps, dps, CA125, , GMCSF 96.946

1542 EMIUN, Ί, EGF, IL1RA, *2 76.527 1589 ips.mps, dps, CA125, , I LIRA 97.266

1543 EMIUN, Ί, EGF, HE4,*2 75.906 1590 ips.mps, dps, CA125, .ΗΕ4 97.408

1544 EMIUN, Ί, GMCSF, IL1RA, HE4 78.445 1591 ips.mps, dps, CA125, ,*2 97.159

1545 EMIUN, Ί, GMCSF, IL1RA, *2 79.35 1592 ips, mps, dps, CA125, EGF, 96.839

1546 EMIUN, Ί, GMCSF, HE4, *2 78.853 GMCSF

1547 EMILIN, *1, IL1RA, HE4, *2 78.232 1593 ips, mps, dps, CA125, EGF, IL1RA 97.337

1548 EMIUN, EGF.GMCSF, IL1RA, HE4 71.573 1594 ips.mps, dps, CA125, EGF, HE4 97.514

1549 EMILIN, EGF.GMCSF, IL1RA, *2 71.839 1595 ips.mps, dps, CA125, EGF, *2 97.443

1550 EMILIN, EGF, GMCSF, HE4, *2 70.508 1596 ips.mps, dps, CA125, GMCSF, 97.088

1551 EMILIN, EGF, IL1RA, HE4, *2 71.129 IL1RA

1552 EMILIN, GMCSF, IL1RA, HE4, *2 75.355 1597 ips.mps, dps, CA125, GMCSF, 97.124

1553 MDK, Ί, EGF, GMCSF, IL1RA 80.469 HE4

1554 MDK, Ί, EGF, GMCSF, HE4 80.291 1598 ips, mps, dps, CA125, GMCSF, *2 96.804

1555 ΜϋΚ,Ί, EGF, GMCSF, *2 81.818 1599 ips.mps, dps, CA125, 1 LIRA, HE4 97.408

1556 MDK, *1, EGF, IL1RA, HE4 79.723 1600 ips.mps, dps, CA125, 1 LIRA, *2 97.088

1557 MDK, *1, EGF, IL1RA, *2 79.794 1601 ips.mps, dps, CA125, HE4, *2 97.266

1558 MDK, *1, EGF, HE4, *2 79.83 1602 ips.mps, dps, EMILIN, MDK, Ί 96.378

1559 MDK, Ί, GMCSF, IL1RA, HE4 80.611 1603 ips.mps, dps, EMILIN, MDK, EGF 96.449

1560 MDK, Ί, GMCSF, IL1RA, *2 81.072 1604 ips.mps, dps, EMILIN, MDK, 96.449

1561 MDK, Ί, GMCSF, HE4, *2 81.481 GMCSF

1562 MDK, *1, IL1RA, HE4, *2 80.078 1605 ips.mps, dps, EMILIN, MDK, IL1RA 97.266

1563 MDK, EGF.GMCSF, IL1RA, HE4 72.088 1606 ips.mps, dps, EMILIN, MDK, HE4 96.342

1564 MDK, EGF.GMCSF, IL1RA, *2 74.006 1607 ips.mps, dps, EMILIN, MDK, *2 96.591

1565 MDK, EGF, GMCSF, HE4, *2 72.94 1608 ips.mps, dps, EMILIN, Ί, EGF 95.561

1566 MDK, EGF, IL1RA, HE4, *2 72.301 1609 ips.mps, dps, EMILIN, Ί, GMCSF 95.632

1567 MDK, GMCSF, IL1RA, HE4,*2 73.295 1610 ips.mps, dps, EMIUN, *1 JURA 96.768

1568 , EGF, GMCSF, IL1RA, HE4 63.991 1611 ips.mps, dps, EMILIN, Ί.ΗΕ4 95.579

1569 , EGF, GMCSF, IL1RA, *2 64.95 1612 ips.mps, dps, EMILIN, Ί,*2 95.881

1613 ips.mps, dps, EMILIN, EGF, 95.49 GMCSF GMCSF

1614 ips, mps, dps, EMIUN, EGF, IL1RA 96.982 1661 ips, mps, CA125, EMIUN, MDK, 98.899

1615 ips, mps, dps, EMIUN, EGF, HE4 95.561 IL1RA

1616 ips, mps, dps, EMIUN, EGF, *2 95.526 1662 ips, mps, CA125, EMIUN, MDK, 98.757

1617 ips, mps, dps, EMIUN, GMCSF, 96.733 HE4

IL1RA 1663 ips, mps, CA125, EMIUN, MDK, *2 98.828

1618 ips, mps, dps, EMIUN, GMCSF, 95.241 1664 ips, mps, CA125, EMIUN, Ί, EGF 98.509 HE4 1665 ips, mps, CA125, EMIUN, Ί, 98.438

1619 ips, mps, dps, EMIUN, GMCSF, *2 95.384 GMCSF

1620 ips, mps, dps, EMIUN, IL1RA, HE4 96.911 1666 ips, mps, CA125, EMIUN, Ί, 98.615

1621 ips, mps, dps, EMIUN, IL1RA, *2 96.662 IL1RA

1622 ips, mps, dps, EMIUN, HE4, *2 95.17 1667 ips, mps, CA125, EMIUN, Ί.ΗΕ4 98.793

1623 ips, mps, dps, MDK, Ί, EGF 95.437 1668 ips, mps, CA125, EMIUN, Ί,*2 98.651

1624 ips, mps, dps, MDK, Ί, GMCSF 95.597 1669 ips, mps, CA125, EMIUN, EGF, 98.402

1625 ips, mps, dps, MDK, Ί, IL1RA 96.2 GMCSF

1626 ips, mps, dps, MDK, Ί, HE4 95.703 1670 ips, mps, CA125, EMIUN, EGF, 98.58

1627 ips, mps, dps, MDK, , *2 95.952 IL1RA

1628 ips, mps, dps, MDK, EGF, GMCSF 95.135 1671 ips, mps, CA125, EMIUN, EGF, 98.651

1629 ips, mps, dps, MDK, EGF, I LIRA 95.952 HE4

1630 ips, mps, dps, MDK, EGF, HE4 95.277 1672 ips, mps, CA125, EMIUN, EGF, *2 98.473

1631 ips, mps, dps, MDK, EGF, *2 95.384 1673 ips, mps, CA125, EMIUN, GMCSF, 98.651

1632 ips, mps, dps, MDK, GMCSF, 95.81 IL1RA

IL1RA 1674 ips, mps, CA125, EMIUN, GMCSF, 98.686

1633 ips, mps, dps, MDK, GMCSF, HE4 95.17 HE4

1634 ips, mps, dps, MDK, GMCSF, *2 95.028 1675 ips, mps, CA125, EMIUN, GMCSF, 98.402

*2

1635 ips, mps, dps, MDK, IL1RA, HE4 95.845

1636 ips, mps, dps, MDK, IL1RA, *2 95.845 1676 ips, mps, CA125, EMIUN, IL1RA, 98.793

1637 7 HE4

ips, mps, dps, MDK, HE4, *2 94.95

638 ips, mps, dps, , EGF, GMCSF 1677

1 93.43 ips, mps, CA125, EMIUN, IL1RA, 98.651

*2

1639 ips, mps, dps, , EGF, IL1RA 94.46

1678 ips, mps, CA125, EMIUN, HE4,*2 98.615

1640 ips, mps, dps, , EGF, HE4 93.217

1679 ips, mps, CA125, MDK, , EGF 98.224

1641 ips, mps, dps, , EGF, *2 93.874

1680 ips, mps, CA125, MDK, Ί, GMCSF 98.295

1642 ips, mps, dps, , GMCSF, IL1RA 94.034

GMCSF, HE4 93.217 1681 ips, mps, CA125, MDK, *1, IL1RA 98.224

1643 ips, mps, dps, ,

1682

1644 ips, mps, CA125, MDK,*1,HE4 98.295 ips, mps, dps, , GMCSF, *2 93.786

1683 ips, mps, CA125, MDK,*1,*2 98.26

1645 ips, mps, dps, *1, IL1RA, HE4 94.07

1684 ips, mps, CA125, MDK, EGF, 98.295

1646 ips, mps, dps, *1, IL1RA, *2 94.425

GMCSF

1647 ips, mps, dps, , HE4, *2 93.501

1685 ips, mps, CA125, MDK, EGF, 98.331

1648 ips, mps, dps, EGF, GMCSF, 93.857

IL1RA

1686 ips, mps, CA125, MDK, EGF, HE4 98.295

1649 ips, mps, dps, EGF, GMCSF, HE4 92.915

1687 ips, mps, CA125, MDK, EGF,*2 98.26

1650 ips, mps, dps, EGF, GMCSF, *2 93.111

1688 ips, mps, CA125, MDK, GMCSF, 98.082

1651 ips, mps, dps, EGF, IL1RA, HE4 94.141

IL1RA

1652 ips, mps, dps, EGF, IL1RA, *2 94.052

1689 ips, mps, CA125, MDK, GMCSF, 98.402

1653 ips, mps, dps, EGF, HE4, *2 93.004

HE4

1654 ips, mps, dps, GMCSF, IL1RA, HE4 93.714

1690 ips, mps, CA125, MDK, GMCSF, *2 98.26

1655 ips, mps, dps, GMCSF, IL1RA, *2 93.857

1691 ips, mps, CA125, MDK, IL1RA, HE4 98.331

1656 ips, mps, dps, GMCSF, HE4, *2 92.791

1692 ips, mps, CA125, MDK, IL1RA, *2 98.26

1657 ips, mps, dps, IL1RA, HE4, *2 93.608

1693 ips, mps, CA125, MDK, HE4, *2 98.26

1658 ips, mps, CA125, EMIUN, MDK, Ί 98.651

1694 ips,mps,CA125,*1, EGF, GMCSF 97.159

1659 ips, mps, CA125, EMIUN, MDK, 98.793

1695 ips,mps,CA125,*1, EGF, IL1RA 97.443 EGF

1696 ips,mps,CA125,*1, EGF, HE4 97.372

1660 ips, mps, CA125, EMIUN, MDK, 98.793 1697 ips.mps, CA125, *1, EGF,*2 97.408 1737 ips.mps, EMILIN, Ί, IL1RA, *2 96.626

1698 ips.mps, CA125, *1,GMCSF, 97.23 1738 ips.mps, EMILIN, Ί, HE4,*2 95.206 IL1RA 1739 ips.mps, EMILIN, EGF.GMCSF, 97.017

1699 ips.mps, CA125, , GMCSF, HE4 97.301 IL1RA

1700 ips.mps, CA125,*1, GMCSF, *2 97.195 1740 ips.mps, EMILIN, EGF.GMCSF, 95.028

1701 ips.mps, CA125, , IL1RA, HE4 97.621 HE4

1702 ips.mps, CA125, *1, IL1RA, *2 97.408 1741 ips.mps, EMILIN, EGF, GMCSF, *2 95.028

1703 ips.mps, CA125,*1,HE4,*2 97.372 1742 ips.mps, EMILIN, EGF, IL1RA, 96.982

1704 ips, mps, CA125, EGF, GMCSF, 97.177 HE4

IL1RA 1743 ips.mps, EMILIN, EGF, IL1RA, *2 96.982

1705 ips, mps, CA125, EGF, GMCSF, 97.408 1744 ips.mps, EMILIN, EGF,HE4,*2 94.851 HE4 1745 ips.mps, EMILIN, GMCSF, IL1RA, 96.875

1706 ips, mps, CA125, EGF, GMCSF, *2 97.053 HE4

1707 ips.mps, CA125, EGF, IL1RA, HE4 97.621 1746 ips.mps, EMILIN, GMCSF, IL1RA, 96.555

*2

1708 ips.mps, CA125, EGF, IL1RA, *2 97.124

1709 ips.mps, CA125, EGF, HE4,*2 97.479 1747 ips.mps, EMILIN, GMCSF, HE4,*2 94.886

1710 ips.mps, CA125, GMCSF, IL1RA, 97.337 1748 ips.mps, EMILIN, IL1RA, HE4, *2 96.555 HE4 1749 ips.mps, MDK, Ί, EGF, GMCSF 95.419

1711 ips.mps, CA125, GMCSF, IL1RA, 96.946 1750 ips.mps, MDK, , EGF, IL1RA 96.058

*2 1751 ips.mps, MDK, , EGF, HE4 95.384

1712 ips, mps, CA125, GMCSF, HE4, *2 97.195 1752 ips.mps, MDK,*1,EGF,*2 95.81

1713 ips.mps, CA125, 1 LIRA, HE4, *2 97.443 1753 ips.mps, MDK, Ί, GMCSF, IL1RA 95.845

1714 ips.mps, EMIUN, MDK,*1, EGF 96.733 1754 ips.mps, MDK, Ί, GMCSF, HE4 95.099

1715 ips.mps, EMIUN, MDK,*1, 96.555 1755 ips.mps, MDK, Ί, GMCSF, *2 95.632 GMCSF 1756 ips.mps, MDK, , IL1RA, HE4 95.703

1716 ips.mps, EMILIN, MDK, *1, IL1RA 97.159 1757 ips.mps, MDK, *1, IL1RA, *2 95.952

1717 ips.mps, EMILIN, MDK, Ί.ΗΕ4 96.626 1758 ips.mps, MDK,*1,HE4,*2 95.241

1718 ips.mps, EMILIN, MDK, Ί,*2 96.946 1759 ips, mps, MDK, EGF, GMCSF, 95.739

1719 ips, mps, EMILIN, MDK, EGF, 96.413 IL1RA

GMCSF 1760 ips, mps, MDK, EGF, GMCSF, HE4 94.922

1720 ips, mps, EMILIN, MDK, EGF, 97.159 1761 ips, mps, MDK, EGF, GMCSF, *2 94.78 IL1RA 1762 ips.mps, MDK, EGF, IL1RA, HE4 95.881

1721 ips, mps, EMILIN, MDK, EGF, HE4 96.662 1763 ips.mps, MDK, EGF, IL1RA, *2 95.845

1722 ips.mps, EMILIN, MDK, EGF, *2 96.52 1764 ips, mps, MDK, EGF, HE4, *2 94.673

1723 ips, mps, EMILIN, MDK, GMCSF, 97.124 1765 ips.mps, MDK, GMCSF, IL1RA, 95.455 IL1RA HE4

1724 ips, mps, EMILIN, MDK, GMCSF, 96.307 1766 ips.mps, MDK, GMCSF, IL1RA, *2 95.135 HE4 1767 ips, mps, MDK, GMCSF, HE4, *2 94.318

1725 ips, mps, EMILIN, MDK, GMCSF, 96.307 1768 ips.mps, MDK, IL1RA, HE4,*2 95.419

*2

1769 ips, mps, , EGF, GMCSF, IL1RA 93.395

1726 ips.mps, EMILIN, MDK, IL1RA, 97.301 1770 ips, mps, , EGF, GMCSF, HE4 92.081 HE4 1771 ips, mps, , EGF, GMCSF, *2 93.146

1727 ips.mps, EMILIN, MDK, IL1RA, *2 97.053 1772 ips, mps, , EGF, IL1RA, HE4 93.75

1728 ips, mps, EMILIN, MDK, HE4, *2 96.342 1773 ips, mps, , EGF, IL1RA, *2 94.212

1729 ips.mps, EMILIN, Ί, EGF.GMCSF 95.419 1774 ips, mps, , EGF, HE4, *2 92.72

1730 ips.mps, EMILIN, Ί, EGF, IL1RA 96.768 1775 ips, mps, , GMCSF, IL1RA, HE4 93.075

1731 ips.mps, EMILIN, Ί, EGF, HE4 95.277 1776 ips, mps, , GMCSF, IL1RA, *2 93.288

1732 ips.mps, EMILIN, Ί, EGF, *2 95.739 1777 ips, mps, , GMCSF, HE4,*2 92.631

1733 ips.mps, EMILIN, Ί, GMCSF, 96.449 1778 ips, mps, *1, IL1RA, HE4, *2 93.608 IL1RA 1779 ips.mps, EGF.GMCSF, IL1RA, 93.359

1734 ips.mps, EMILIN, Ί, GMCSF, HE4 95.17 HE4

1735 ips.mps, EMILIN, Ί, GMCSF, *2 95.685 1780 ips.mps, EGF.GMCSF, IL1RA, *2 93.182

1736 ips.mps, EMILIN, *1, IL1RA, HE4 96.768 1781 ips, mps, EGF, GMCSF, HE4, *2 91.761 1782 ips.mps, EGF, IL1RA, HE4,*2 93.075 1820 ips, dps, CA125,*1, EGF, GMCSF 96.271

1783 ips, mps, GMCSF, IL1RA, HE4, *2 92.969 1821 ips, dps, CA125, , EGF, IL1RA 96.662

1784 ips, dps, CA125, EMIUN, MDK, 97.621 1822 ips, dps, CA125, , EGF, HE4 96.129

1785 ips, dps, CA125, EMIUN, MDK, 97.301 1823 ips, dps, CA125,*1,EGF,*2 96.52 EGF 1824 ips, dps, CA125,*1, GMCSF, 96.023

1786 ips, dps, CA125, EMIUN, MDK, 97.124 IL1RA

GMCSF 1825 ips, dps, CA125, , GMCSF, HE4 95.526

1787 ips, dps, CA125, EMIUN, MDK, 97.656 1826 ips, dps, CA125,*1, GMCSF, *2 96.058 IL1RA 1827 ips, dps, CA125, , IL1RA, HE4 95.597

1788 ips, dps, CA125, EMIUN, MDK, 97.372 1828 ips, dps, CA125, *1, IL1RA, *2 95.668 HE4 1829 ips, dps, CA125,*1,HE4,*2 95.881

1789 ips, dps, CA125, EMIUN, MDK, *2 97.727 1830 ips, dps, CA125, EGF, GMCSF, 96.236

1790 ips, dps, CA125, EMIUN, Ί, EGF 96.555 IL1RA

1791 ips, dps, CA125, EMIUN, Ί, 96.484 1831 ips, dps, CA125, EGF, GMCSF, 96.52 GMCSF HE4

1792 ips, dps, CA125, EMIUN, Ί, IL1RA 96.804 1832 ips, dps, CA125, EGF, GMCSF, *2 96.307

1793 ips, dps, CA125, EMIUN, Ί.ΗΕ4 96.768 1833 ips, dps, CA125, EGF, IL1RA, HE4 96.023

1794 ips, dps, CA125, EMIUN, Ί,*2 97.017 1834 ips, dps, CA125, EGF, IL1RA, *2 96.236

1795 ips, dps, CA125, EMIUN, EGF, 96.378 1835 ips, dps, CA125, EGF, HE4, *2 95.881 GMCSF 1836 ips, dps, CA125, GMCSF, IL1RA, 95.277

1796 ips, dps, CA125, EMIUN, EGF, 97.159 HE4

IL1RA 1837 ips, dps, CA125, GMCSF, IL1RA, 95.668

1797 ips, dps, CA125, EMIUN, EGF, 96.875 *2

HE4 1838 ips, dps, CA125, GMCSF, HE4, *2 95.703

1798 ips, dps, CA125, EMIUN, EGF, *2 96.768 1839 ips, dps, CA125, IL1RA, HE4, *2 95.455

1799 ips, dps, CA125, EMIUN, GMCSF, 96.555 1840 ips, dps, EMIUN, MDK, Ί, EGF 93.963 IL1RA 1841 ips, dps, EMIUN, MDK, Ί, GMCSF 94.07

1800 ips, dps, CA125, EMIUN, GMCSF, 96.733 1842 ips, dps, EMIUN, MDK, *1,IL1RA 94.318 HE4 1843 ips, dps, EMIUN, MDK, Ί.ΗΕ4 93.839

1801 ips, dps, CA125, EMIUN, GMCSF, 96.52 1844 ips, dps, EMIUN, MDK, Ί,*2 94.425

*2

1845 ips, dps, EMIUN, MDK, EGF, 92.72

1802 ips, dps, CA125, EMIUN, IL1RA, 97.23 GMCSF

HE4 1846 ips, dps, EMIUN, MDK, EGF, 93.111

1803 ips, dps, CA125, EMIUN, IL1RA, *2 97.124 IL1RA

1804 ips, dps, CA125, EMIUN, HE4, *2 96.946 1847 ips, dps, EMIUN, MDK, EGF, HE4 92.738

1805 ips, dps, CA125, MDK, , EGF 97.23 1848 ips, dps, EMIUN, MDK, EGF, *2 93.466

1806 ips, dps, CA125, MDK, Ί, GMCSF 97.266 1849 ips, dps, EMIUN, MDK, GMCSF, 93.253

1807 ips, dps, CA125, MDK, *1, IL1RA 97.159 IL1RA

1808 ips, dps, CA125, MDK,*1,HE4 97.088 1850 ips, dps, EMIUN, MDK, GMCSF, 93.146

1809 ips, dps, CA125, MDK,*1,*2 96.946 HE4

1810 ips, dps, CA125, MDK, EGF, 97.159 1851 ips, dps, EMIUN, MDK, GMCSF, *2 93.75 GMCSF 1852 ips, dps, EMIUN, MDK, IL1RA, HE4 93.288

1811 ips, dps, CA125, MDK, EGF, IL1RA 97.053 1853 ips, dps, EMIUN, MDK, IL1RA, *2 94.034

1812 ips, dps, CA125, MDK, EGF, HE4 96.804 1854 ips, dps, EMIUN, MDK, HE4, *2 93.395

1813 ips, dps, CA125, MDK, EGF, *2 97.053 1855 ips, dps, EMIUN, Ί, EGF, GMCSF 92.045

1814 ips, dps, CA125, MDK, GMCSF, 97.053 1856 ips, dps, EMIUN, Ί, EGF, IL1RA 93.253 IL1RA 1857 ips, dps, EMIUN, Ί, EGF, HE4 92.578

1815 ips, dps, CA125, MDK, GMCSF, 96.875 1858 ips, dps, EMIUN, Ί, EGF, *2 93.075 HE4 1859 ips, dps, EMIUN, Ί, GMCSF, 93.217

1816 ips, dps, CA125, MDK, GMCSF, *2 97.159 IL1RA

1817 ips, dps, CA125, MDK, IL1RA, HE4 96.662 1860 ips, dps, EMIUN, Ί, GMCSF, HE4 92.827

1818 ips, dps, CA125, MDK, IL1RA, *2 96.875 1861 ips, dps, EMIUN, Ί, GMCSF, *2 93.04

1819 ips, dps, CA125, MDK, HE4, *2 96.626 1862 ips, dps, EMILIN, *1, IL1RA, HE4 93.43 1863 ips, dps, EMILIN, *1, IL1RA, *2 93.572 1909 ips, dps, GMCSF, IL1RA, HE4,*2 88.92

1864 ips, dps, EMILIN, Ί,ΗΕ4,*2 93.182 1910 ips, CA125, EMILIN, MDK, Ί, EGF 97.088

1865 ips, dps, EMILIN, EGF.GMCSF, 91.477 1911 ips, CA125, EMILIN, MDK, Ί, 97.053 IL1RA GMCSF

1866 ips, dps, EMILIN, EGF.GMCSF, 91.122 1912 ips, CA125, EMILIN, MDK, Ί, 97.23 HE4 IL1RA

1867 ips, dps, EMILIN, EGF, GMCSF, *2 91.016 1913 ips, CA125, EMILIN, MDK, Ί. ΗΕ4 96.911

1868 ips, dps, EMILIN, EGF, IL1RA, HE4 91.477 1914 ips, CA125, EMILIN, MDK, Ί,*2 97.159

1869 ips, dps, EMILIN, EGF, IL1RA, *2 92.223 1915 ips, CA125, EMILIN, MDK, EGF, 96.697

1870 ips, dps, EMILIN, EGF, HE4,*2 91.797 GMCSF

1871 ips, dps, EMILIN, GMCSF, IL1RA, 92.614 1916 ips, CA125, EMILIN, MDK, EGF, 96.982 HE4 IL1RA

1872 ips, dps, EMILIN, GMCSF, IL1RA, 92.791 1917 ips, CA125, EMILIN, MDK, EGF, 96.768

*2 HE4

1873 ips, dps, EMILIN, GMCSF, HE4, *2 92.188 1918 ips, CA125, EMILIN, MDK, EGF, *2 96.768

1874 ips, dps, EMILIN, IL1RA, HE4, *2 92.631 1919 ips, CA125, EMILIN, MDK, 96.999

1875 ips, dps, MDK,*1, EGF, GMCSF 94.034 GMCSF, IL1RA

1876 ips, dps, MDK, , EGF, IL1RA 93.999 1920 ips, CA125, EMILIN, MDK, 96.982

1877 ips, dps, MDK, , EGF, HE4 93.501 GMCSF, HE4

1878 ips, dps, MDK,*1,EGF,*2 94.034 1921 ips, CA125, EMILIN, MDK, 96.946

1879 ips, dps, MDK, Ί, GMCSF, IL1RA 94.318 GMCSF, *2

1880 ips, dps, MDK, Ί, GMCSF, HE4 94.141 1922 ips, CA125, EMILIN, MDK, IL1RA, 97.053

1881 ips, dps, MDK, Ί, GMCSF, *2 94.531 HE4

1882 ips, dps, MDK, , IL1RA, HE4 93.395 1923 ips, CA125, EMILIN, MDK, IL1RA, 97.195

*2

1883 ips, dps, MDK, *1, IL1RA, *2 94.141

1884 ips, dps, MDK,*1,HE4,*2 93.643 1924 ips, CA125, EMILIN, MDK, HE4, *2 96.875

1885 ips, dps, MDK, EGF, GMCSF, 92.56 1925 ips, CA125, EMILIN, Ί, EGF, 95.419 IL1RA GMCSF

1886 ips, dps, MDK, EGF, GMCSF, HE4 91.797 1926 ips, CA125, EMILIN, Ί, EGF, 95.579

1887 ips, dps, MDK, EGF, GMCSF, *2 92.365 IL1RA

1888 ips, dps, MDK, EGF, IL1RA, HE4 91.335 1927 ips, CA125, EMILIN, Ί, EGF, HE4 95.455

1889 ips, dps, MDK, EGF, IL1RA, *2 92.844 1928 ips, CA125, EMILIN, Ί, EGF, *2 95.739

1890 ips, dps, MDK, EGF, HE4, *2 92.116 1929 ips, CA125, EMILIN, Ί, GMCSF, 95.703

GMCSF, IL1RA, IL1RA

1891 ips, dps, MDK, 92.365

HE4 1930 ips, CA125, EMILIN, Ί, GMCSF, 95.774

1892 ips, dps, MDK, GMCSF, IL1RA, *2 92.88 HE4

1893 ips, dps, MDK, GMCSF, HE4, *2 92.507 1931 ips, CA125, EMILIN, Ί, GMCSF, *2 95.597

1894 ips, dps, MDK, IL1RA, HE4, *2 91.726 1932 ips, CA125, EMILIN, *1,IL1RA, 96.005

HE4

1895 ips, dps, , EGF, GMCSF, IL1RA 91.797

1933 ips, CA125, EMILIN, *1,IL1RA, *2 96.005

1896 ips, dps, , EGF, GMCSF, HE4 91.655

1934 ips, CA125, EMILIN, Ί,ΗΕ4,*2 96.023

1897 ips, dps, , EGF, GMCSF, *2 91.371

1935 ips, CA125, EMILIN, EGF.GMCSF, 95.206

1898 ips, dps, , EGF, IL1RA, HE4 91.335

IL1RA

1899 ips, dps, , EGF, IL1RA, *2 91.726

1936 ips, CA125, EMILIN, EGF.GMCSF, 95.597

1900 ips, dps, *1, EGF, HE4,*2 91.513

HE4

1901 ips, dps, , GMCSF, IL1RA, HE4 90.98

1937 ips, CA125, EMILIN, EGF.GMCSF, 95.277

1902 ips, dps, , GMCSF, IL1RA, *2 91.442 *2

1903 ips, dps, , GMCSF, HE4,*2 91.122

1938 ips, CA125, EMILIN, EGF, IL1RA, 95.668

1904 ips, dps, *1, IL1RA, HE4, *2 90.376

HE4

1905 ips, dps, EGF.GMCSF, IL1RA, 88.778

1939 ips, CA125, EMILIN, EGF, IL1RA, 95.845 HE4 *2

1906 ips, dps, EGF.GMCSF, IL1RA, *2 90.021

1940 ips, CA125, EMILIN, EGF,HE4,*2 95.49

1907 ips, dps, EGF, GMCSF, HE4, *2 89.897

1941 ips, CA125, EMILIN, GMCSF, 95.952

1908 ips, dps, EGF, IL1RA, HE4, *2 89.453 IL1RA, HE4 1980 ips, EMIUN, MDK, Ί, EGF, 91.797

1942 ips, CA125, EMIUN, GMCSF, 95.632 GMCSF

IL1RA, *2 1981 ips, EMIUN, MDK, Ί, EGF, IL1RA 92.152

1943 ips, CA125, EMIUN, GMCSF, HE4, 96.058 1982 ips, EMIUN, MDK, Ί, EGF, HE4 92.081

*2 1983 ips, EMIUN, MDK, Ί, EGF, *2 92.116

1944 ips, CA125, EMIUN, IL1RA, HE4, 96.147 1984 ips, EMIUN, MDK, Ί, GMCSF, 91.957

IL1RA

1945 ips, CA125, MDK, Ί, EGF.GMCSF 96.839 1985 ips, EMIUN, MDK, Ί, GMCSF, 91.992

1946 ips, CA125, MDK, , EGF, IL1RA 96.662 HE4

1947 ips, CA125, MDK, , EGF, HE4 96.52 1986 ips, EMIUN, MDK, Ί, GMCSF, *2 92.259

1948 ips, CA125, MDK,*1,EGF,*2 96.484 1987 ips, EMIUN, MDK, *1,IL1RA, HE4 92.223

1949 ips, CA125, MDK, Ί, GMCSF, 97.053 1988 ips, EMIUN, MDK, *1,IL1RA, *2 91.868 IL1RA 1989 ips, EMIUN, MDK, Ί,ΗΕ4,*2 92.33

1950 ips, CA125, MDK, Ί, GMCSF, HE4 97.053 1990 ips, EMIUN, MDK, EGF.GMCSF, 90.945

1951 ips, CA125, MDK, Ί, GMCSF, *2 97.017 IL1RA

1952 ips, CA125, MDK, , IL1RA, HE4 96.555 1991 ips, EMIUN, MDK, EGF.GMCSF, 90.518

1953 ips, CA125, MDK, *1, IL1RA, *2 96.662 HE4

1954 ips, CA125, MDK,*1,HE4,*2 96.804 1992 ips, EMIUN, MDK, EGF.GMCSF, 90.625

*2

1955 ips, CA125, MDK, EGF, GMCSF, 96.768

IL1RA 1993 ips, EMIUN, MDK, EGF, IL1RA, 90.998

1956 ips, CA125, MDK, EGF, GMCSF, 96.626 HE4

HE4 1994 ips, EMIUN, MDK, EGF, IL1RA, *2 91.122

1957 ips, CA125, MDK, EGF, GMCSF, *2 96.662 1995 ips, EMIUN, MDK, EGF, HE4, *2 90.217

1958 ips, CA125, MDK, EGF, IL1RA, 96.413 1996 ips, EMIUN, MDK, GMCSF, IL1RA, 91.051 HE4 HE4

1959 ips, CA125, MDK, EGF, IL1RA, *2 96.342 1997 ips, EMIUN, MDK, GMCSF, IL1RA, 91.246

*2

1960 ips, CA125, MDK, EGF, HE4,*2 96.165

1961 ips, CA125, MDK, GMCSF, IL1RA, 96.715 1998 ips, EMIUN, MDK, GMCSF, HE4, 90.98

*2

HE4

1962 ips, CA125, MDK, GMCSF, IL1RA, 96.555 1999 ips, EMIUN, MDK, IL1RA, HE4, *2 91.158

*2 2000 ips, EMIUN, Ί, EGF, GMCSF, 88.388

1963 ips, CA125, MDK, GMCSF, HE4,*2 96.449 IL1RA

1964 ips, CA125, MDK, IL1RA, HE4, *2 96.165 2001 ips, EMIUN, Ί, EGF, GMCSF, HE4 88.281

1965 ips, CA125, *1, EGF, GMCSF, 94.709 2002 ips, EMIUN, Ί, EGF, GMCSF, *2 88.388 IL1RA 2003 ips, EMIUN, Ί, EGF, IL1RA, HE4 88.974

1966 ips, CA125, , EGF, GMCSF, HE4 94.815 2004 ips, EMIUN, Ί, EGF, IL1RA, *2 88.388

1967 ips, CA125, *1, EGF, GMCSF, *2 94.851 2005 ips, EMIUN, Ί, EGF, HE4, *2 88.565

1968 ips, CA125, , EGF, IL1RA, HE4 94.265 2006 ips, EMIUN, Ί, GMCSF, IL1RA, 90.128

1969 ips, CA125, , EGF, IL1RA, *2 94.744 HE4

1970 ips, CA125,*1,EGF, HE4, *2 94.496 2007 ips, EMIUN, Ί, GMCSF, IL1RA, *2 89.293

1971 ips, CA125, , GMCSF, IL1RA, 94.602 2008 ips, EMIUN, Ί, GMCSF, HE4, *2 89.489 HE4 2009 ips, EMILIN, *1, IL1RA, HE4, *2 89.595

1972 ips, CA125, , GMCSF, IL1RA, *2 94.851 2010 ips, EMILIN, EGF.GMCSF, IL1RA, 87.784

1973 ips, CA125, , GMCSF, HE4,*2 94.744 HE4

1974 ips, CA125, *1, IL1RA, HE4, *2 94.123 2011 ips, EMILIN, EGF.GMCSF, IL1RA, 87.5

*2

1975 ips, CA125, EGF.GMCSF, IL1RA, 94.744

HE4 2012 ips, EMILIN, EGF.GMCSF, HE4, *2 86.186

1976 ips, CA125, EGF.GMCSF, IL1RA, 94.105 2013 ips, EMILIN, EGF, IL1RA.HE4, *2 86.648

*2 2014 ips, EMILIN, GMCSF, IL1RA, HE4, 88.725

*2

1977 ips, CA125, EGF, GMCSF, HE4, *2 94.496

1978 ips, CA125, EGF, IL1RA, HE4,*2 94.212 2015 ips, MDK, Ί, EGF, GMCSF, IL1RA 91.797

1979 ips, CA125, GMCSF, IL1RA, HE4, 94.354 2016 ips, MDK, Ί, EGF, GMCSF, HE4 91.548

*2 2017 ips, MDK, Ί, EGF, GMCSF, *2 91.673 2018 ips, MDK, , EGF, IL1RA, HE4 90.767 2056 mps, dps, CA125, EMIUN, HE4, *2 97.656

2019 ips, MDK, , EGF, IL1RA, *2 90.874 2057 mps, dps, CA125, MDK, , EGF 97.017

2020 ips, MDK, , EGF, HE4, *2 90.589 2058 mps, dps, CA125, MDK, Ί, 96.946

2021 ips, MDK, , GMCSF, IL1RA, HE4 91.584 GMCSF

2022 ips, MDK, , GMCSF, IL1RA, *2 92.045 2059 mps, dps, CA125, MDK, *1, IL1RA 96.911

2023 ips, MDK, Ί, GMCSF, HE4, *2 91.868 2060 mps, dps, CA125, MDK,*1,HE4 96.911

2024 ips, MDK, *1, IL1RA, HE4, *2 90.661 2061 mps, dps, CA125, MDK,*1,*2 97.017

2025 ips, MDK, EGF, GMCSF, IL1RA, 88.672 2062 mps, dps, CA125, MDK, EGF, 96.733 HE4 GMCSF

2026 ips, MDK, EGF, GMCSF, IL1RA, *2 89.24 2063 mps, dps, CA125, MDK, EGF, 96.946

2027 ips, MDK, EGF, GMCSF, HE4, *2 88.92 IL1RA

2028 ips, MDK, EGF, IL1RA, HE4,*2 88.21 2064 mps, dps, CA125, MDK, EGF, HE4 96.875

2029 ips, MDK, GMCSF, IL1RA, HE4,*2 88.619 2065 mps, dps, CA125, MDK, EGF,*2 96.911

2030 ips, , EGF, GMCSF, IL1RA, HE4 85.618 2066 mps, dps, CA125, MDK, GMCSF, 96.804

2031 ips, , EGF, GMCSF, IL1RA, *2 86.222 IL1RA

2032 ips, *1 , EGF, GMCSF, HE4, *2 86.044 2067 mps, dps, CA125, MDK, GMCSF, 96.626

2033 ips, *1, EGF, IL1RA, HE4, *2 84.872 HE4

2034 ips, , GMCSF, IL1RA, HE4,*2 85.724 2068 mps, dps, CA125, MDK, GMCSF, 96.697

*2

2035 ips, EGF, GMCSF, IL1RA, HE4,*2 82.386

2036 mps, dps,CA125, EMIUN, MDK, Ί 97.869 2069 mps, dps, CA125, MDK, IL1RA, 96.946

2037 mps, dps,CA125, EMIUN, MDK, 97.798 HE4

EGF 2070 mps, dps, CA125, MDK, IL1RA, *2 96.946

2038 mps, dps,CA125, EMIUN, MDK, 97.834 2071 mps, dps, CA125, MDK, HE4, *2 96.751 GMCSF 2072 mps, dps, CA125, *1, EGF, GMCSF 95.384

2039 mps, dps,CA125, EMIUN, MDK, 98.118 2073 mps, dps, CA125, , EGF, IL1RA 95.881 IL1RA 2074 mps, dps, CA125, , EGF, HE4 95.632

2040 mps, dps,CA125, EMIUN, MDK, 98.082 2075 mps, dps, CA125,*1,EGF,*2 95.81 HE4 2076 mps, dps, CA125, , GMCSF, 95.668

2041 mps, dps, CA125, EMIUN, MDK, *2 97.976 IL1RA

2042 mps, dps,CA125, EMIUN, Ί, EGF 97.337 2077 mps, dps, CA125, , GMCSF, HE4 95.135

2043 mps, dps,CA125, EMIUN, Ί, 97.266 2078 mps, dps, CA125, *1, GMCSF, *2 95.348 GMCSF 2079 mps, dps, CA125, , IL1RA, HE4 95.739

2044 mps, dps,CA125, EMIUN, Ί, 97.514 2080 mps, dps, CA125, *1, IL1RA, *2 95.881 IL1RA 2081 mps, dps, CA125,*1,HE4,*2 95.703

2045 mps, dps,CA125, EMIUN, Ί.ΗΕ4 97.301 2082 mps, dps, CA125, EGF, GMCSF, 95.526

2046 mps, dps,CA125, EMIUN, *1,*2 97.443 IL1RA

2047 mps, dps,CA125, EMIUN, EGF, 97.354 2083 mps, dps, CA125, EGF, GMCSF, 95.561 GMCSF HE4

2048 mps, dps,CA125, EMIUN, EGF, 97.408 2084 mps, dps, CA125, EGF, GMCSF, *2 95.419 IL1RA 2085 mps, dps, CA125, EGF, IL1RA, 95.881

2049 mps, dps,CA125, EMIUN, EGF, 97.372 HE4

HE4 2086 mps, dps, CA125, EGF, IL1RA, *2 95.81

2050 mps, dps,CA125, EMIUN, EGF, *2 97.55 2087 mps, dps, CA125, EGF,HE4,*2 95.774

2051 mps, dps,CA125, EMIUN, 97.372 2088 mps, dps, CA125, GMCSF, IL1RA, 95.49 GMCSF, IL1RA HE4

2052 mps, dps,CA125, EMIUN, 97.301 2089 mps, dps, CA125, GMCSF, IL1RA, 95.455 GMCSF, HE4 *2

2053 mps, dps,CA125, EMIUN, 97.514 2090 mps, dps, CA125, GMCSF, HE4,*2 95.135 GMCSF, *2 2091 mps, dps, CA125, 1 LIRA, HE4, *2 95.561

2054 mps, dps,CA125, EMIUN, IL1RA, 97.656 2092 mps, dps, EMIUN, MDK, Ί, EGF 95.668 HE4 2093 mps, dps, EMIUN, MDK, Ί, 95.455

2055 mps, dps,CA125, EMIUN, IL1RA, 97.585 GMCSF

*2 2094 mps, dps, EMIUN, MDK, *1,IL1RA 96.342 2095 mps, dps, EMIUN, MDK, Ί.ΗΕ4 95.987 2132 mps, dps, MDK, Ί, GMCSF, HE4 94.07

2096 mps, dps, EMIUN, MDK, Ί,*2 96.289 2133 mps, dps, MDK, Ί, GMCSF, *2 94.815

2097 mps, dps, EMIUN, MDK, EGF, 94.531 2134 mps, dps, MDK, , IL1RA, HE4 95.099 GMCSF 2135 mps, dps, MDK, *1, IL1RA, *2 95.455

2098 mps, dps, EMIUN, MDK, EGF, 95.49 2136 mps, dps, MDK,*1,HE4,*2 94.709 IL1RA 2137 mps, dps, MDK, EGF, GMCSF, 93.324

2099 mps, dps, EMIUN, MDK, EGF, HE4 94.886 IL1RA

2100 mps, dps, EMIUN, MDK, EGF,*2 95.206 2138 mps, dps, MDK, EGF, GMCSF, 92.614

2101 mps, dps, EMIUN, MDK.GMCSF, 95.384 HE4

IL1RA 2139 mps, dps, MDK, EGF, GMCSF, *2 92.898

2102 mps, dps, EMIUN, MDK.GMCSF, 94.922 2140 mps, dps, MDK, EGF, IL1RA, HE4 93.359 HE4 2141 mps, dps, MDK, EGF, IL1RA, *2 94.336

2103 mps, dps, EMIUN, MDK.GMCSF, 95.241 2142 mps, dps, MDK, EGF, HE4, *2 93.04

*2

2143 mps, dps, MDK.GMCSF, IL1RA, 93.501

2104 mps, dps, EMIUN, MDK, IL1RA, 95.987 HE4

HE4 2144 mps, dps, MDK.GMCSF, IL1RA, *2 93.928

2105 mps, dps, EMIUN, MDK, IL1RA, *2 96.236 2145 mps, dps, MDK, GMCSF, HE4, *2 92.898

2106 mps, dps, EMIUN, MDK, HE4,*2 95.348 2146 mps, dps, MDK, IL1RA, HE4, *2 94.673

2107 mps, dps, EMIUN, Ί, EGF, 93.999 2147 mps, dps, , EGF, GMCSF, IL1RA 91.442 GMCSF 2148 mps, dps, , EGF, GMCSF, HE4 90.27

2108 mps, dps, EMIUN, Ί, EGF, IL1RA 95.561 2149 mps, dps, , EGF, GMCSF, *2 90.98

2109 mps, dps, EMIUN, Ί, EGF, HE4 94.07 2150 mps, dps, , EGF, IL1RA, HE4 92.116

2110 mps, dps, EMIUN, Ί, EGF, *2 95.135 2151 mps, dps, *1, EGF, IL1RA, *2 92.525

2111 mps, dps, EMIUN, Ί, GMCSF, 95.739 2152 mps, dps,*1,EGF,HE4, *2 91.406 IL1RA 2153 mps, dps, , GMCSF, IL1RA, HE4 90.927

2112 mps, dps, EMIUN, Ί, GMCSF, 94.105 2154 mps, dps, , GMCSF, IL1RA, *2 91.335 HE4 2155 mps, dps, , GMCSF, HE4,*2 90.536

2113 mps, dps, EMIUN, Ί, GMCSF, *2 95.011 2156 mps, dps, *1, IL1RA, HE4, *2 91.761

2114 mps, dps, EMILIN, *1, IL1RA, HE4 96.076 2157 mps, dps, EGF, GMCSF, IL1RA, 90.057

2115 mps, dps, EMILIN, *1,IL1RA, *2 96.058 HE4

2116 mps, dps, EMILIN, Ί,ΗΕ4,*2 95.348 2158 mps, dps, EGF, GMCSF, IL1RA, *2 90.305

2117 mps, dps, EMILIN, EGF, GMCSF, 94.78 2159 mps, dps, EGF, GMCSF, HE4, *2 89.134 IL1RA 2160 mps, dps, EGF, IL1RA, HE4,*2 90.874

2118 mps, dps, EMILIN, EGF, GMCSF, 92.969 2161 mps, dps, GMCSF, IL1RA, HE4,*2 89.773 HE4 2162 mps, CA125, EMILIN, MDK, Ί, 97.763

2119 mps, dps, EMILIN, EGF, GMCSF, 93.04 EGF

*2

2163 mps, CA125, EMILIN, MDK, Ί, 97.834

2120 mps, dps, EMILIN, EGF, IL1RA, 95.49 GMCSF

HE4 2164 mps, CA125, EMILIN, MDK, Ί, 98.082

2121 mps, dps, EMILIN, EGF, IL1RA, *2 95.526 IL1RA

2122 mps, dps, EMILIN, EGF, HE4,*2 93.643 2165 mps, CA125, EMILIN, MDK, Ί, 97.905

2123 mps, dps, EMILIN, GMCSF, IL1RA, 95.135 HE4

HE4 2166 mps, CA125, EMILIN, MDK, Ί, *2 97.905

2124 mps, dps, EMILIN, GMCSF, IL1RA, 95.632 2167 mps, CA125, EMILIN, MDK, EGF, 97.585

*2

GMCSF

2125 mps, dps, EMILIN, GMCSF, HE4, 93.555 2168 mps, CA125, EMILIN, MDK, EGF, 97.55

IL1RA

2126 mps, dps, EMILIN, IL1RA, HE4, *2 95.774 2169 mps, CA125, EMILIN, MDK, EGF, 97.798

2127 mps, dps, MDK, Ί, EGF, GMCSF 94.176 HE4

2128 mps, dps, MDK, , EGF, IL1RA 94.851 2170 mps, CA125, EMILIN, MDK, EGF, 97.656

2129 mps, dps, MDK, , EGF, HE4 94.034 *2

2130 mps, dps, MDK,*1,EGF,*2 94.762 2171 mps, CA125, EMILIN, MDK, 97.55

2131 mps, dps, MDK, Ί, GMCSF, IL1RA 94.886 GMCSF, IL1RA 2172 mps, CA125, EMIUN, MDK, 97.905 IL1RA

GMCSF, HE4 2202 mps, CA125, MDK, Ί, GMCSF, 96.52

2173 mps, CA125, EMIUN, MDK, 97.798 HE4

GMCSF, *2 2203 mps, CA125, MDK, Ί, GMCSF, *2 96.484

2174 mps, CA125, EMIUN, MDK, IL1RA, 97.94 2204 mps, CA125, MDK, , IL1RA, HE4 96.733 HE4 2205 mps, CA125, MDK, *1, IL1RA, *2 96.946

2175 mps, CA125, EMIUN, MDK, IL1RA, 97.905 2206 mps, CA125, MDK,*1, HE4, *2 96.555

*2

2207 mps, CA125, MDK, EGF, GMCSF, 96.378

2176 mps, CA125, EMIUN, MDK, HE4, 98.011 IL1RA

2208 mps, CA125, MDK, EGF, GMCSF, 96.271

2177 mps, CA125, EMIUN, Ί, EGF, 96.768 HE4

GMCSF 2209 mps, CA125, MDK, EGF, GMCSF, 95.952

2178 mps, CA125, EMIUN, Ί, EGF, 97.088 *2

IL1RA 2210 mps, CA125, MDK, EGF, IL1RA, 96.342

2179 mps, CA125, EMIUN, Ί, EGF, 96.946 HE4

HE4 2211 mps, CA125, MDK, EGF, IL1RA, *2 96.52

2180 mps, CA125, EMIUN, Ί, EGF, *2 97.088 2212 mps, CA125, MDK, EGF, HE4, *2 96.36

2181 mps, CA125, EMIUN, Ί, GMCSF, 97.337 2213 mps, CA125, MDK, GMCSF, 96.555 IL1RA IL1RA, HE4

2182 mps, CA125, EMIUN, Ί, GMCSF, 96.982 2214 mps, CA125, MDK, GMCSF, 96.449 HE4 IL1RA, *2

2183 mps, CA125, EMIUN, Ί, GMCSF, 97.159 2215 mps, CA125, MDK, GMCSF, HE4, 96.484

*2 *2

2184 mps, CA125, EMIUN, Ί, IL1RA, 97.337 2216 mps, CA125, MDK, IL1RA, HE4, *2 96.768 HE4 2217 mps, CA125, *1, EGF, GMCSF, 94.673

2185 mps, CA125, EMIUN, Ί, IL1RA, *2 97.443 IL1RA

2186 mps, CA125, EMIUN, Ί, HE4, *2 97.053 2218 mps, CA125, *1, EGF, GMCSF, 94.247

2187 mps, CA125, EMIUN, EGF, 96.839 HE4

GMCSF, IL1RA 2219 mps, CA125, *1, EGF, GMCSF, *2 94.851

2188 mps, CA125, EMIUN, EGF, 96.946 2220 mps, CA125, , EGF, IL1RA, HE4 94.602 GMCSF, HE4 2221 mps, CA125, *1, EGF, IL1RA, *2 94.993

2189 mps, CA125, EMIUN, EGF, 96.804 2222 mps, CA125,*1,EGF,HE4,*2 94.425 GMCSF, *2 2223 mps, CA125, , GMCSF, IL1RA, 94.798

2190 mps, CA125, EMIUN, EGF, IL1RA, 97.053 HE4

HE4 2224 mps, CA125, , GMCSF, IL1RA, 94.886

2191 mps, CA125, EMIUN, EGF, IL1RA, 97.195 *2

*2

2225 mps, CA125, *1, GMCSF, HE4, *2 94.496

2192 mps, CA125, EMIUN, EGF, HE4, 96.911 2226 mps, CA125, *1, IL1RA, HE4, *2 95.241

*2

2227 mps, CA125, EGF, GMCSF, IL1RA, 94.638

2193 mps, CA125, EMIUN, GMCSF, 97.266 HE4

IL1RA, HE4 2228 mps, CA125, EGF, GMCSF, IL1RA, 94.602

2194 mps, CA125, EMIUN, GMCSF, 97.195 *2

IL1RA, *2 2229 mps, CA125, EGF, GMCSF, HE4, 94.425

2195 mps, CA125, EMIUN, GMCSF, 97.088 *2

HE4, *2 2230 mps, CA125, EGF, IL1RA, HE4, *2 94.531

2196 mps, CA125, EMIUN, IL1RA, HE4, 97.55 2231 mps, CA125, GMCSF, IL1RA, HE4, 94.851

*2 *2

2197 mps, CA125, MDK, Ί, EGF, 96.378 2232 mps, EMIUN, MDK, , EGF, 95.526 GMCSF GMCSF

2198 mps, CA125, MDK, Ί, EGF, IL1RA 96.413 2233 mps, EMIUN, MDK, , EGF, 95.597

2199 mps, CA125, MDK, Ί, EGF, HE4 96.555 IL1RA

2200 mps, CA125, MDK,*1, EGF, *2 96.378 2234 mps, EMIUN, MDK, , EGF, HE4 95.49

2201 mps, CA125, MDK, Ί, GMCSF, 96.591 2235 mps, EMIUN, MDK, , EGF, *2 95.916 2236 mps, EMIUN, MDK,*1, GMCSF, 95.543 2270 mps, MDK, , EGF, IL1RA, HE4 93.608 IL1RA 2271 mps, MDK, , EGF, IL1RA, *2 94.247

2237 mps, EMIUN, MDK,*1, GMCSF, 95.313 2272 mps, MDK, , EGF, HE4, *2 93.714 HE4 2273 mps, MDK, Ί, GMCSF, IL1RA, 93.821

2238 mps, EMIUN, MDK,*1, GMCSF, *2 95.916 HE4

2239 mps, EMIUN, MDK, Ί, IL1RA, HE4 95.969 2274 mps, MDK, Ί, GMCSF, IL1RA, *2 94.389

2240 mps, EMIUN, MDK, *1,IL1RA, *2 96.165 2275 mps, MDK, Ί, GMCSF, HE4, *2 94.212

2241 mps, EMIUN, MDK, Ί, ΗΕ4,*2 96.094 2276 mps, MDK, *1, IL1RA, HE4, *2 94.212

2242 mps, EMIUN, MDK, EGF, GMCSF, 94.247 2277 mps, MDK, EGF, GMCSF, IL1RA, 91.903 IL1RA HE4

2243 mps, EMIUN, MDK, EGF, GMCSF, 93.821 2278 mps, MDK, EGF, GMCSF, IL1RA, 91.726 HE4 *2

2244 mps, EMIUN, MDK, EGF, GMCSF, 94.105 2279 mps, MDK, EGF, GMCSF, HE4, *2 91.868

*2

2280 mps, MDK, EGF, IL1RA, HE4, *2 92.578

2245 mps, EMIUN, MDK, EGF, IL1RA, 94.212 2281 mps, MDK, GMCSF, IL1RA, HE4, 93.04 HE4 *2

2246 mps, EMIUN, MDK, EGF, IL1RA, 94.46 2282 mps, , EGF, GMCSF, IL1RA, 90.128

*2

HE4

2247 mps, EMIUN, MDK, EGF, HE4, *2 94.354 2283 mps, , EGF, GMCSF, IL1RA, *2 90.092

2248 mps, EMIUN, MDK, GMCSF, 94.283 2284 mps, , EGF, GMCSF, HE4,*2 89.382 IL1RA, HE4 2285 mps, , EGF, IL1RA, HE4, *2 90.518

2249 mps, EMIUN, MDK, GMCSF, 94.691 2286 mps, , GMCSF, IL1RA, HE4,*2 89.205 IL1RA, *2 2287 mps, EGF, GMCSF, IL1RA, HE4, 88.672

2250 mps, EMIUN, MDK, GMCSF, HE4, 94.531 *2

*2

2288 dps,CA125, EMILIN, MDK, , 94.78

2251 mps, EMIUN, MDK, IL1RA, HE4,*2 95.277 EGF

2252 mps, EMIUN, Ί, EGF, GMCSF, 94.247 2289 dps,CA125, EMILIN, MDK, Ί, 94.993 IL1RA GMCSF

2253 mps, EMIUN, Ί, EGF, GMCSF, 92.72 2290 dps,CA125, EMILIN, MDK, Ί, 94.957 HE4 IL1RA

2254 mps, EMIUN, Ί, EGF, GMCSF, *2 94.034 2291 dps,CA125, EMILIN, MDK, Ί. ΗΕ4 95.028

2255 mps, EMIUN, Ί, EGF, IL1RA, HE4 94.283 2292 dps,CA125, EMILIN, MDK, *1,*2 95.366

2256 mps, EMIUN, Ί, EGF, IL1RA, *2 94.815 2293 dps, CA125, EMILIN, MDK, EGF, 93.963

2257 mps, EMIUN, Ί, EGF, HE4, *2 93.466 GMCSF

2258 mps, EMIUN, Ί, GMCSF, IL1RA, 94.531 2294 dps, CA125, EMILIN, MDK, EGF, 94.46 HE4 IL1RA

2259 mps, EMIUN, Ί, GMCSF, IL1RA, 94.851 2295 dps, CA125, EMILIN, MDK, EGF, 94.105

*2

HE4

2260 mps, EMIUN, Ί, GMCSF, HE4, *2 93.714 2296 dps, CA125, EMILIN, MDK, EGF, 94.673

2261 mps, EMILIN, *1, IL1RA, HE4, *2 94.78 *2

2262 mps, EMILIN, EGF, GMCSF, 92.898 2297 dps, CA125, EMILIN, MDK, 94.105 IL1RA, HE4 GMCSF, IL1RA

2263 mps, EMILIN, EGF, GMCSF, 92.969 2298 dps, CA125, EMILIN, MDK, 94.141 IL1RA, *2 GMCSF, HE4

2264 mps, EMILIN, EGF, GMCSF, HE4, 90.82 2299 dps, CA125, EMILIN, MDK, 94.922

*2 GMCSF, *2

2265 mps, EMILIN, EGF, IL1RA, HE4, *2 93.537 2300 dps,CA125, EMILIN, MDK, IL1RA, 94.141

2266 mps, EMILIN, GMCSF, IL1RA, 94.212 HE4

HE4, *2 2301 dps,CA125, EMILIN, MDK, IL1RA, 95.099

2267 mps, MDK, Ί, EGF, GMCSF, 93.714 *2

IL1RA 2302 dps,CA125, EMILIN, MDK, HE4,*2 94.922

2268 mps, MDK, Ί, EGF, GMCSF, HE4 93.661 2303 dps,CA125, EMILIN, Ί, EGF, 93.395

2269 mps, MDK, Ί, EGF, GMCSF, *2 94.105 GMCSF 2304 dps, CA125, EMILIN, , EGF, 93.91 HE4

IL1RA 2337 dps,CA125, MDK, EGF, IL1RA, *2 94.886

2305 dps, CA125, EMILIN, Ί, EGF, HE4 93.395 2338 dps,CA125, MDK, EGF, HE4,*2 94.212

2306 dps, CA125, EMILIN, Ί, EGF, *2 93.963 2339 dps,CA125, MDK.GMCSF, IL1RA, 93.572

2307 dps, CA125, EMILIN, *1, GMCSF, 93.768 HE4

IL1RA 2340 dps,CA125, MDK.GMCSF, IL1RA, 94.567

2308 dps, CA125, EMILIN, Ί, GMCSF, 93.608 *2

HE4 2341 dps, CA125, MDK, GMCSF, HE4, 93.999

2309 dps, CA125, EMILIN, Ί, GMCSF, 93.75 *2

*2 2342 dps,CA125, MDK, IL1RA, HE4,*2 94.141

2310 dps, CA125, EMILIN, *1,IL1RA, 93.999 2343 dps, CA125,*1, EGF, GMCSF, 92.614 HE4 IL1RA

2311 dps, CA125, EMILIN, *1,IL1RA, *2 94.407 2344 dps, CA125,*1, EGF, GMCSF, 91.726

2312 dps, CA125, EMILIN, Ί,ΗΕ4,*2 94.052 HE4

2313 dps, CA125, EMILIN, EGF, 93.43 2345 dps, CA125,*1, EGF, GMCSF, *2 92.294 GMCSF, IL1RA 2346 dps, CA125, , EGF, IL1RA, HE4 92.596

2314 dps, CA125, EMILIN, EGF, 92.933 2347 dps, CA125, , EGF, IL1RA, *2 93.359 GMCSF, HE4 2348 dps,CA125,*1,EGF, HE4, *2 92.614

2315 dps, CA125, EMILIN, EGF, 93.288 2349 dps, CA125,*1, GMCSF, IL1RA, 91.513 GMCSF, *2 HE4

2316 dps, CA125, EMILIN, EGF, IL1RA, 93.714 2350 dps, CA125,*1, GMCSF, IL1RA, *2 92.294 HE4 2351 dps, CA125,*1, GMCSF, HE4, *2 91.406

2317 dps, CA125, EMILIN, EGF, IL1RA, 94.425 2352 dps, CA125, *1, IL1RA, HE4, *2 92.152

*2

2353 dps,CA125, EGF, GMCSF, IL1RA, 92.01

2318 dps, CA125, EMILIN, EGF, HE4, *2 93.679 HE4

2319 dps, CA125, EMILIN, GMCSF, 93.679 2354 dps,CA125, EGF, GMCSF, IL1RA, 92.401 IL1RA, HE4 *2

2320 dps, CA125, EMILIN, GMCSF, 94.141 2355 dps, CA125, EGF, GMCSF, HE4, 91.3 IL1RA, *2 *2

2321 dps, CA125, EMILIN, GMCSF, 93.608 2356 dps,CA125, EGF, IL1RA, HE4, *2 92.294 HE4, *2 2357 dps, CA125, GMCSF, IL1RA, HE4, 91.317

2322 dps, CA125, EMILIN, IL1RA, HE4, 94.105 *2

*2

2358 dps, EMILIN, MDK, Ί, EGF, 90.483

2323 dps, CA125, MDK, , EGF, 94.638 GMCSF

GMCSF 2359 dps, EMILIN, MDK, Ί, EGF, IL1RA 91.087

2324 dps, CA125, MDK, , EGF, IL1RA 95.046 2360 dps, EMILIN, MDK, Ί, EGF, HE4 90.589

2325 dps, CA125, MDK, , EGF, HE4 94.407 2361 dps, EMILIN, MDK, Ί, EGF, *2 92.045

2326 dps, CA125, MDK,*1,EGF,*2 94.851 2362 dps, EMILIN, MDK, Ί, GMCSF, 91.016

2327 dps, CA125, MDK, Ί, GMCSF, 94.709 IL1RA

IL1RA 2363 dps, EMILIN, MDK, Ί, GMCSF, 90.874

2328 dps, CA125, MDK, Ί, GMCSF, 94.389 HE4

HE4 2364 dps, EMILIN, MDK, Ί, GMCSF, *2 91.832

2329 dps, CA125, MDK, Ί, GMCSF, *2 94.922 2365 dps, EMILIN, MDK, *1 JURA, HE4 91.229

2330 dps, CA125, MDK, *1, IL1RA, HE4 94.709 2366 dps, EMILIN, MDK, *1, IL1RA, *2 92.401

2331 dps, CA125, MDK, *1, IL1RA, *2 94.957 2367 dps, EMILIN, MDK, Ί. ΗΕ4, *2 92.152

2332 dps, CA125, MDK,*1,HE4,*2 94.709 2368 dps, EMILIN, MDK, EGF, GMCSF, 87.5

2333 dps, CA125, MDK, EGF, GMCSF, 94.105 IL1RA

IL1RA 2369 dps, EMILIN, MDK, EGF, GMCSF, 87.251

2334 dps, CA125, MDK, EGF, GMCSF, 93.714 HE4

HE4 2370 dps, EMILIN, MDK, EGF, GMCSF, 88.707

2335 dps, CA125, MDK, EGF, GMCSF, 94.531 *2

*2

2371 dps, EMILIN, MDK, EGF, IL1RA, 88.388

2336 dps, CA125, MDK, EGF, IL1RA, 94.141 HE4 2372 dps, EMIUN, MDK, EGF, IL1RA, *2 89.879 2411 dps, , EGF, IL1RA, HE4, *2 86.275

2373 dps, EMIUN, MDK, EGF, HE4, *2 89.631 2412 dps, , GMCSF, IL1RA, HE4,*2 84.375

2374 dps, EMIUN, MDK, GMCSF, 88.636 2413 dps, EGF, GMCSF, IL1RA, HE4, *2 81.445 IL1RA, HE4 2414 CA125, EMILIN, MDK, , EGF, 91.371

2375 dps, EMIUN, MDK, GMCSF, 90.217 GMCSF

IL1RA, *2 2415 CA125, EMILIN, MDK, , EGF, 91.797

2376 dps, EMIUN, MDK, GMCSF, HE4, 89.631 IL1RA

*2 2416 CA125, EMILIN, MDK, , EGF, 91.619

2377 dps, EMIUN, MDK, IL1RA, HE4,*2 90.376 HE4

2378 dps, EMIUN, Ί, EGF, GMCSF, 86.896 2417 CA125, EMILIN, MDK, , EGF, *2 91.868 IL1RA 2418 CA125, EMILIN, MDK, , GMCSF, 92.045

2379 dps, EMIUN, Ί, EGF, GMCSF, 86.523 IL1RA

HE4 2419 CA125, EMILIN, MDK, , GMCSF, 92.081

2380 dps, EMIUN, Ί, EGF, GMCSF, *2 87.216 HE4

2381 dps, EMIUN, Ί, EGF, IL1RA, HE4 88.565 2420 CA125, EMILIN, MDK, , GMCSF, 92.045

2382 dps, EMIUN, Ί, EGF, IL1RA, *2 89.063 *2

2383 dps, EMIUN, Ί, EGF, HE4,*2 88.317 2421 CA125, EMILIN, MDK, *1, IL1RA, 92.259

2384 dps, EMIUN, Ί, GMCSF, IL1RA, 88.636 HE4

HE4 2422 CA125, EMILIN, MDK, *1, IL1RA, 92.543

*2

2385 dps, EMIUN, Ί, GMCSF, IL1RA, 88.814

*2 2423 CA125, EMILIN, MDK, , ΗΕ4,*2 92.294

2386 dps, EMIUN, Ί, GMCSF, HE4, *2 88.53 2424 CA125, EMILIN, MDK, EGF, 91.051

2387 dps, EMILIN, *1, IL1RA, HE4, *2 90.305 GMCSF, IL1RA

2388 dps, EMIUN, EGF, GMCSF, IL1RA, 84.428 2425 CA125, EMILIN, MDK, EGF, 90.199 HE4 GMCSF, HE4

2389 dps, EMILIN, EGF, GMCSF, IL1RA, 85.369 2426 CA125, EMILIN, MDK, EGF, 90.625

*2 GMCSF, *2

2390 dps, EMIUN, EGF, GMCSF, HE4, 84.499 2427 CA125, EMILIN, MDK, EGF, IL1RA, 90.909

HE4

2391 dps, EMILIN, EGF, IL1RA, HE4,*2 87.678 2428 CA125, EMILIN, MDK, EGF, IL1RA, 91.477

*2

2392 dps, EMILIN, GMCSF, IL1RA, HE4, 88.406

*2 2429 CA125, EMILIN, MDK, EGF, HE4, 90.661

*2

2393 dps, MDK, Ί, EGF, GMCSF, 90.554

IL1RA 2430 CA125, EMILIN, MDK, GMCSF, 91.193

2394 dps, MDK, Ί, EGF, GMCSF, HE4 89.311 IL1RA, HE4

2395 dps, MDK, Ί, EGF, GMCSF, *2 91.406 2431 CA125, EMILIN, MDK, GMCSF, 91.406

2396 dps, MDK, , EGF, IL1RA, HE4 90.288 IL1RA, *2

2397 dps, MDK, , EGF, IL1RA, *2 91.619 2432 CA125, EMILIN, MDK, GMCSF, 90.945

2398 dps, MDK, Ί, EGF, HE4,*2 90.732 HE4, *2

2399 dps, MDK, Ί, GMCSF, IL1RA, HE4 90.376 2433 CA125, EMILIN, MDK, IL1RA, HE4, 91.69

*2

2400 dps, MDK, Ί, GMCSF, IL1RA, *2 91.442

2401 dps, MDK, Ί, GMCSF, HE4, *2 91.477 2434 CA125, EMILIN, Ί, EGF, GMCSF, 88.938

2402 dps,MDK,*1,IL1RA, HE4, *2 91.282 IL1RA

2403 dps, MDK, EGF, GMCSF, IL1RA, 84.961 2435 CA125, EMILIN, Ί, EGF, GMCSF, 88.885 HE4 HE4

2404 dps, MDK, EGF, GMCSF, IL1RA, 88.246 2436 CA125, EMILIN, Ί, EGF, GMCSF, 88.903

*2 *2

2405 dps, MDK, EGF, GMCSF, HE4, *2 87.393 2437 CA125, EMILIN, Ί, EGF, IL1RA, 88.707 dps, MDK, EGF, IL1RA, HE4, *2 HE4

2406 87.926

2407 dps, MDK, GMCSF, IL1RA, HE4,*2 CA125, EMILIN, Ί,

88.175 2438 EGF, IL1RA, *2 89.116

2408 dps, , EGF, GMCSF, IL1RA, HE4 CA125, EMILIN, Ί, EGF, HE4, *2 88.4

85.245 2439 94

2409 dps, , EGF, GMCSF, IL1RA, *2 125, EMILIN, Ί, GM

86.506 2440 CA CSF, 89.595

IL1RA, HE4

2410 dps, , EGF, GMCSF, HE4, *2 84.197 2441 CA125, EMIUN, Ί, GMCSF, 90.199 2473 EMILIN, MDK, Ί, EGF, IL1RA, 83.665 IL1RA, *2 HE4

2442 CA125, EMIUN, , GMCSF, HE4, 89.879 2474 EMILIN, MDK, Ί, EGF, IL1RA, *2 84.588

*2 2475 EMILIN, MDK, Ί, EGF, HE4,*2 84.091

2443 CA125, EMILIN, *1, IL1RA, HE4, *2 90.021 2476 EMILIN, MDK, Ί, GMCSF, IL1RA, 84.162

2444 CA125, EMILIN, EGF, GMCSF, 87.979 HE4

IL1RA, HE4 2477 EMILIN, MDK, Ί, GMCSF, IL1RA, 84.411

2445 CA125, EMILIN, EGF, GMCSF, 88.033 *2

IL1RA, *2 2478 EMIUN, MDK, Ί, GMCSF, HE4,*2 84.783

2446 CA125, EMILIN, EGF, GMCSF, 87.607 2479 EMILIN, MDK, *1, IL1RA, HE4, *2 84.482 HE4, *2 2480 EMILIN, MDK, EGF.GMCSF, 79.048

2447 CA125, EMIUN.EGF, IL1RA, HE4, 87.997 IL1RA, HE4

*2

2481 EMILIN, MDK, EGF.GMCSF, 80.842

2448 CA125, EMILIN, GMCSF, IL1RA, 89.205 IL1RA, *2

HE4, *2 2482 EMILIN, MDK, EGF, GMCSF, HE4, 80.114

2449 CA125, MDK,*1, EGF.GMCSF, 90.341 *2

IL1RA 2483 EMIUN, MDK, EGF, IL1RA, HE4, 79.936

2450 CA125, MDK,*1, EGF.GMCSF, 90.27 *2

HE4 2484 EMIUN, MDK, GMCSF, IL1RA, 81.499

2451 CA125, MDK,*1, EGF, GMCSF, *2 90.341 HE4, *2

2452 CA125, MDK, , EGF, IL1RA, HE4 90.376 2485 EMILIN, Ί, EGF, GMCSF, IL1RA, 76.349

2453 CA125, MDK, , EGF, IL1RA, *2 90.767 HE4

2454 CA125, MDK, *1, EGF, HE4, *2 89.702 2486 EMILIN, Ί, EGF, GMCSF, IL1RA, 76.864

2455 CA125, MDK, Ί, GMCSF, IL1RA, 90.732 *2

HE4 2487 EMIUN, Ί, EGF, GMCSF, HE4, *2 75.888

2456 CA125, MDK, Ί, GMCSF, IL1RA, 90.696 2488 EMILIN, *1, EGF, IL1RA, HE4, *2 76.598

*2 2489 EMILIN, Ί, GMCSF, IL1RA, HE4, 79.084

2457 CA125, MDK, Ί, GMCSF, HE4, *2 90.856 *2

2458 CA125, MDK, Ί, I LIRA, HE4, *2 90.518 2490 EMIUN, EGF, GMCSF, IL1RA, 71.982

2459 CA125, MDK, EGF, GMCSF, 88.459 HE4, *2

IL1RA, HE4 2491 MDK, Ί, EGF, GMCSF, IL1RA, 78.8

2460 CA125, MDK, EGF, GMCSF, 89.063 HE4

IL1RA, *2 2492 MDK, Ί, EGF, GMCSF, IL1RA, *2 79.936

2461 CA125, MDK, EGF, GMCSF, HE4, 87.926 2493 MDK, Ί, EGF, GMCSF, HE4,*2 80.398

*2 2494 MDK, , EGF, IL1RA, HE4, *2 78.871

2462 CA125, MDK, EGF, IL1RA, HE4, *2 89.116 2495 MDK, Ί, GMCSF, IL1RA, HE4,*2 79.599

2463 CA125, MDK, GMCSF, IL1RA, 88.459 2496 MDK, EGF.GMCSF, IL1RA, HE4, 72.55 HE4, *2 *2

2464 CA125, , EGF, GMCSF, IL1RA, 84.197 2497 , EGF, GMCSF, IL1RA, HE4,*2 62.979 HE4 2498 ips, mps, dps, CA125, EMILIN, 98.58

2465 CA125, , EGF, GMCSF, IL1RA, 84.766 MDK,

*2

2499 ips, mps, dps, CA125, EMILIN, 98.544

2466 CA125, , EGF, GMCSF, HE4,*2 83.487 MDK, EGF

2467 CA125, *1, EGF, IL1RA, HE4, *2 84.357 2500 ips, mps, dps, CA125, EMILIN, 98.544

2468 CA125, , GMCSF, IL1RA, HE4, 84.73 MDK, GMCSF

*2 2501 ips, mps, dps, CA125, EMILIN, 98.686

2469 CA125, EGF.GMCSF, IL1RA, HE4, 82.138 MDK, IL1RA

*2 2502 ips, mps, dps, CA125, EMILIN, 98.615

2470 EMIUN, MDK, Ί, EGF.GMCSF, 83.629 MDK, HE4

IL1RA 2503 ips, mps, dps, CA125, EMILIN, 98.544

2471 EMILIN, MDK, Ί, EGF, GMCSF, 83.594 MDK, *2

HE4 2504 ips, mps, dps, CA125, EMILIN, Ί, 98.295

2472 EMILIN, MDK, Ί, EGF, GMCSF, *2 84.233 EGF 2505 ips, mps, dps, CA125, EMILIN, , 98.295 2532 ips, mps, dps, CA125, MDK, I LI RA, 97.905 GMCSF *2

2506 ips, mps, dps, CA125, EMILIN, Ί , 98.438 2533 ips, mps, dps, CA125, MDK, HE4, 97.976 IL1 RA

2507 ips, mps, dps, CA125, EMILIN, Ί , 98.402 2534 ips, mps, dps, CA125, *1 , EGF, 97.053 HE4 GMCSF

2508 ips, mps, dps, CA125, EMILIN, Ί , 98.544 2535 ips, mps, dps, CA125, *1 , EGF, 97.301

*2 IL1 RA

2509 ips, mps, dps, CA125, EMILIN, 98.153 2536 ips, mps, dps, CA125, *1 , EGF, 97.479 EGF, GMCSF HE4

2510 ips, mps, dps, CA125, EMILIN, 98.242 2537 ips, mps, dps, CA125, *1 , EGF, *2 97.408 EGF, IL1 RA 2538 ips, mps, dps, CA125, , GMCSF, 97.23

2511 ips, mps, dps, CA125, EMILIN, 98.438 IL1 RA

EGF, HE4 2539 ips, mps, dps, CA125, , GMCSF, 96.982

2512 ips, mps, dps, CA125, EMILIN, 98.295 HE4

EGF, *2 2540 ips, mps, dps, CA125, , GMCSF, 96.982

2513 ips, mps, dps, CA125, EMILIN, 98.26 *2

GMCSF, IL1 RA 2541 ips, mps, dps, CA125, , IL1 RA, 97.372

2514 ips, mps, dps, CA125, EMILIN, 98.26 HE4

GMCSF, HE4 2542 ips, mps, dps, CA125, , IL1 RA, *2 97.372

2515 ips, mps, dps, CA125, EMILIN, 98.295 2543 ips, mps, dps, CA125, *1 , HE4, *2 97.159 GMCSF, *2 2544 ips, mps, dps, CA125, EGF, 97.159

2516 ips, mps, dps, CA125, EMILIN, 98.509 GMCSF, IL1 RA

IL1 RA, HE4 2545 ips, mps, dps, CA125, EGF, 97.159

2517 ips, mps, dps, CA125, EMILIN, 98.438 GMCSF, HE4

IL1 RA, *2 2546 ips, mps, dps, CA125, EGF, 96.839

2518 ips, mps, dps, CA125, EMILIN, 98.509 GMCSF, *2

HE4, *2 2547 ips, mps, dps, CA125, EGF, IL1 RA, 97.337

2519 ips, mps, dps, CA125, MDK, Ί , 98.047 HE4

EGF 2548 ips, mps, dps, CA125, EGF, I LI RA, 97.124

2520 ips, mps, dps, CA125, MDK, Ί , 97.976 *2

GMCSF 2549 ips, mps, dps, CA125, EGF, HE4, 97.55

2521 ips, mps, dps, CA125, MDK, Ί , 98.118 *2

IL1 RA 2550 ips, mps, dps, CA125, GMCSF, 97.195

2522 ips, mps, dps, CA125, MDK, Ί , 98.082 IL1 RA, HE4

HE4 2551 ips, mps, dps, CA125, GMCSF, 96.911

2523 ips, mps, dps, CA125, MDK, Ί , *2 98.082 IL1 RA, *2

2524 ips, mps, dps, CA125, MDK, EGF, 97.976 2552 ips, mps, dps, CA125, GMCSF, 97.07 GMCSF HE4, *2

2525 ips, mps, dps, CA125, MDK, EGF, 98.047 2553 ips, mps, dps, CA125, IL1 RA, HE4, 97.23 IL1 RA *2

2526 ips, mps, dps, CA125, MDK, EGF, 98.295 2554 ips, mps, dps, EMILIN, MDK, Ί, 96.36 HE4 EGF

2527 ips, mps, dps, CA125, MDK, EGF, 98.011 2555 ips, mps, dps, EMILIN, MDK, Ί, 96.378

*2 GMCSF

2528 ips, mps, dps, CA125, MDK, 97.869 2556 ips, mps, dps, EMILIN, MDK, Ί, 97.195 GMCSF, IL1 RA IL1 RA

2529 ips, mps, dps, CA125, MDK, 98.047 2557 ips, mps, dps, EMILIN, MDK, Ί, 96.484 GMCSF, HE4 HE4

2530 ips, mps, dps, CA125, MDK, 98.011 2558 ips, mps, dps, EMILIN, MDK, Ί , *2 96.626 GMCSF, *2 2559 ips, mps, dps, EMILIN, MDK, EGF, 96.413

2531 ips, mps, dps, CA125, MDK, I LI RA, 97.976 GMCSF

HE4 2560 ips, mps, dps, EMILIN, MDK, EGF, 97.159 IL1RA 2588 ips.mps, dps, EMILIN, IL1RA, HE4, 96.484

2561 ips.mps, dps, EMIUN, MDK, EGF, 96.271 *2

HE4 2589 ips.mps, dps, MDK, , EGF, 95.739

2562 ips.mps, dps, EMIUN, MDK, EGF, 96.342 GMCSF

*2 2590 ips.mps, dps, MDK, , EGF, 96.129

2563 ips.mps, dps, EMIUN, MDK, 97.23 IL1RA

GMCSF, IL1RA 2591 ips.mps, dps, MDK, *1, EGF, HE4 95.419

2564 ips.mps, dps, EMIUN, MDK, 96.147 2592 ips.mps, dps, MDK, *1, EGF, *2 95.668 GMCSF, HE4 2593 ips.mps, dps, MDK, , GMCSF, 96.183

2565 ips.mps, dps, EMIUN, MDK, 96.165 IL1RA

GMCSF, *2 2594 ips.mps, dps, MDK, , GMCSF, 95.49

2566 ips.mps, dps, EMIUN, MDK, 97.266 HE4

IL1RA, HE4 2595 ips.mps, dps, MDK, , GMCSF, *2 95.916

2567 ips.mps, dps, EMIUN, MDK, 97.124 2596 ips.mps, dps, MDK, *1, IL1RA, 96.094 IL1RA, *2 HE4

2568 ips.mps, dps, EMIUN, MDK, HE4, 96.254 2597 ips.mps, dps, MDK, *1, IL1RA, *2 96.271

*2

2598 ips.mps, dps, MDK,*1,HE4, *2 95.774

2569 ips.mps, dps, EMIUN, Ί, EGF, 95.313 2599 ips, mps, dps, MDK, EGF, GMCSF, 95.561 GMCSF IL1RA

2570 ips.mps, dps, EMIUN, Ί, EGF, 96.449 2600 ips, mps, dps, MDK, EGF, GMCSF, 94.922 IL1RA HE4

2571 ips.mps, dps, EMIUN, Ί, EGF, 95.561 2601 ips, mps, dps, MDK, EGF, GMCSF, 95.064 HE4 *2

2572 ips.mps, dps, EMIUN, Ί, EGF, *2 95.916 2602 ips.mps, dps, MDK, EGF, IL1RA, 95.632

2573 ips.mps, dps, EMIUN, Ί, GMCSF, 96.626 HE4

IL1RA 2603 ips.mps, dps, MDK, EGF, IL1RA, 95.774

2574 ips.mps, dps, EMIUN, Ί, GMCSF, 95.455 *2

HE4 2604 ips, mps, dps, MDK, EGF, HE4, *2 95.241

2575 ips.mps, dps, EMIUN, Ί, GMCSF, 95.703 2605 ips, mps, dps, MDK, GMCSF, 95.668

*2

IL1RA, HE4

2576 ips.mps, dps, EMILIN, *1, IL1RA, 96.804 2606 ips, mps, dps, MDK, GMCSF, 95.703 HE4 IL1RA, *2

2577 ips.mps, dps, EMILIN, *1, IL1RA, 96.768 2607 ips, mps, dps, MDK, GMCSF, HE4, 94.957

*2 *2

2578 ips.mps, dps, EMILIN, Ί, HE4, *2 95.721 2608 ips.mps, dps, MDK, IL1RA, HE4, 95.987

2579 ips.mps, dps, EMILIN, EGF, 96.662 *2

GMCSF, IL1RA 2609 ips.mps, dps, , EGF, GMCSF, 94.034

2580 ips.mps, dps, EMILIN, EGF, 95.384 IL1RA

GMCSF, HE4 2610 ips.mps, dps, , EGF, GMCSF, 93.146

2581 ips.mps, dps, EMILIN, EGF, 95.028 HE4

GMCSF, *2 2611 ips, mps, dps, , EGF, GMCSF, *2 93.608

2582 ips.mps, dps, EMILIN, EGF, 96.839 2612 ips.mps, dps, , EGF, IL1RA, HE4 94.034 IL1RA, HE4 2613 ips.mps, dps, , EGF, IL1RA, *2 94.638

2583 ips.mps, dps, EMILIN, EGF, 96.449 2614 ips.mps, dps, , EGF, HE4, *2 93.501 IL1RA, *2 2615 ips.mps, dps, , GMCSF, IL1RA, 93.786

2584 ips.mps, dps, EMILIN, EGF, HE4, 95.277 HE4

*2

2616 ips.mps, dps, , GMCSF, IL1RA, 94.07

2585 ips.mps, dps, EMILIN, GMCSF, 96.626 *2

IL1RA, HE4 2617 ips.mps, dps, , GMCSF, HE4, *2 93.892

2586 ips.mps, dps, EMILIN, GMCSF, 96.52 2618 ips.mps, dps, , IL1RA, HE4, *2 94.247 IL1RA, *2 2619 ips, mps, dps, EGF, GMCSF, 93.928

2587 ips.mps, dps, EMILIN, GMCSF, 95.224 IL1RA, HE4

HE4, *2 2620 ips, mps, dps, EGF, GMCSF, 93.786 IL1RA, *2 IL1RA, *2

2621 ips, mps, dps, EGF, GMCSF, HE4, 92.72 2648 ips, mps, CA125, EMIUN, Ί, HE4, 98.757

*2 *2

2622 ips, mps, dps, EGF, IL1RA, HE4,*2 93.608 2649 ips, mps, CA125, EMIUN, EGF, 98.544

2623 ips, mps, dps, GMCSF, IL1RA, 93.608 GMCSF, IL1RA

HE4, *2 2650 ips, mps, CA125, EMIUN, EGF, 98.473

2624 ips, mps, CA125, EMIUN, MDK, Ί, 98.757 GMCSF, HE4

EGF 2651 ips, mps, CA125, EMIUN, EGF, 98.295

2625 ips, mps, CA125, EMIUN, MDK, Ί, 98.651 GMCSF, *2

GMCSF 2652 ips, mps, CA125, EMIUN, EGF, 98.757

2626 ips, mps, CA125, EMIUN, MDK, Ί, 98.935 IL1RA, HE4

IL1RA 2653 ips, mps, CA125, EMIUN, EGF, 98.615

2627 ips, mps, CA125, EMIUN, MDK, Ί, 98.828 IL1RA, *2

HE4 2654 ips, mps, CA125, EMIUN, EGF, 98.544

2628 ips, mps, CA125, EMIUN, MDK, Ί, 98.828 HE4, *2

*2 2655 ips, mps, CA125, EMIUN, GMCSF, 98.81

2629 ips, mps, CA125, EMIUN, MDK, 98.793 IL1RA, HE4

EGF, GMCSF 2656 ips, mps, CA125, EMIUN, GMCSF, 98.473

2630 ips, mps, CA125, EMIUN, MDK, 98.864 IL1RA, *2

EGF, IL1RA 2657 ips, mps, CA125, EMIUN, GMCSF, 98.473

2631 ips, mps, CA125, EMIUN, MDK, 98.828 HE4, *2

EGF, HE4 2658 ips, mps, CA125, EMIUN, IL1RA, 98.722

2632 ips, mps, CA125, EMIUN, MDK, 98.864 HE4, *2

EGF,*2 2659 ips, mps, CA125, MDK, , EGF, 98.438

2633 ips, mps, CA125, EMIUN, MDK, 99.006 GMCSF

GMCSF, IL1RA 2660 ips, mps, CA125, MDK, , EGF, 98.509

2634 ips, mps, CA125, EMIUN, MDK, 98.828 IL1RA

GMCSF, HE4 2661 ips, mps, CA125, MDK, , EGF, 98.295

2635 ips, mps, CA125, EMIUN, MDK, 98.828 HE4

GMCSF, *2 2662 ips, mps, CA125, MDK,*1, EGF,*2 98.366

2636 ips, mps, CA125, EMIUN, MDK, 98.97 2663 ips, mps, CA125, ΜϋΚ,Ί, 98.331 IL1RA, HE4 GMCSF, IL1RA

2637 ips, mps, CA125, EMIUN, MDK, 98.97 2664 ips, mps, CA125, ΜϋΚ,Ί, 98.473 IL1RA, *2 GMCSF, HE4

2638 ips, mps, CA125, EMIUN, MDK, 98.935 2665 ips, mps, CA125, ΜϋΚ,Ί, 98.366 HE4, *2 GMCSF, *2

2639 ips, mps, CA125, EMIUN, Ί, EGF, 98.224 2666 ips, mps, CA125, MDK, *1, IL1RA, 98.473 GMCSF HE4

2640 ips, mps, CA125, EMIUN, Ί, EGF, 98.651 2667 ips, mps, CA125, MDK, *1, IL1RA, 98.331 IL1RA *2

2641 ips, mps, CA125, EMIUN, Ί, EGF, 98.473 2668 ips, mps, CA125, MDK,*1, HE4, *2 98.26 HE4 2669 ips, mps, CA125, MDK, EGF, 98.26

2642 ips, mps, CA125, EMIUN, Ί, EGF, 98.509 GMCSF, IL1RA

*2 2670 ips, mps, CA125, MDK, EGF, 98.438

2643 ips, mps, CA125, EMIUN, Ί, 98.615 GMCSF, HE4

GMCSF, IL1RA 2671 ips, mps, CA125, MDK, EGF, 98.331

2644 ips, mps, CA125, EMIUN, Ί, 98.366 GMCSF, *2

GMCSF, HE4 2672 ips, mps, CA125, MDK, EGF, 98.544

2645 ips, mps, CA125, EMIUN, Ί, 98.402 IL1RA, HE4

GMCSF, *2 2673 ips, mps, CA125, MDK, EGF, 98.295

2646 ips, mps, CA125, EMIUN, Ί, 98.757 IL1RA, *2

IL1RA, HE4 2674 ips, mps, CA125, MDK, EGF, HE4, 98.331

2647 ips, mps, CA125, EMIUN, Ί, 98.651 *2 2675 ips, mps, CA125, MDK, GMCSF, 98.295 2702 ips.mps, EMILIN, MDK, *1, IL1RA, 97.195 IL1RA, HE4 *2

2676 ips, mps, CA125, MDK, GMCSF, 98.153 2703 ips.mps, EMILIN, MDK, Ί, ΗΕ4,*2 96.786 IL1RA, *2 2704 ips, mps, EMILIN, MDK, EGF, 97.017

2677 ips, mps, CA125, MDK, GMCSF, 98.295 GMCSF, IL1RA

HE4, *2 2705 ips, mps, EMILIN, MDK, EGF, 96.555

2678 ips.mps, CA125, MDK, IL1RA, 98.224 GMCSF, HE4

HE4, *2 2706 ips, mps, EMILIN, MDK, EGF, 96.591

2679 ips.mps, CA125, *1, EGF, GMCSF, 97.372 GMCSF, *2

IL1RA 2707 ips, mps, EMILIN, MDK, EGF, 97.337

2680 ips.mps, CA125, *1, EGF, GMCSF, 97.23 IL1RA, HE4

HE4 2708 ips, mps, EMILIN, MDK, EGF, 97.159

2681 ips.mps, CA125, *1, EGF, GMCSF, 97.124 IL1RA, *2

*2 2709 ips, mps, EMILIN, MDK, EGF, HE4, 96.342

2682 ips.mps, CA125, , EGF, IL1RA, 97.479 *2

HE4 2710 ips, mps, EMILIN, MDK, GMCSF, 97.017

2683 ips.mps, CA125, , EGF, IL1RA, 97.55 IL1RA, HE4

*2 2711 ips, mps, EMILIN, MDK, GMCSF, 96.875

2684 ips.mps, CA125,*1,EGF, HE4,*2 97.443 IL1RA, *2

2685 ips.mps, CA125, , GMCSF, 97.372 2712 ips, mps, EMILIN, MDK, GMCSF, 95.916 IL1RA, HE4 HE4, *2

2686 ips.mps, CA125, , GMCSF, 97.053 2713 ips.mps, EMILIN, MDK, IL1RA, 97.017 IL1RA, *2 HE4, *2

2687 ips.mps, CA125, , GMCSF, HE4, 97.301 2714 ips.mps, EMILIN, Ί, EGF, 96.076

*2 GMCSF, IL1RA

2688 ips.mps, CA125, , IL1RA, HE4, 97.55 2715 ips.mps, EMILIN, Ί, EGF, 95.028

GMCSF, HE4

2689 ips, mps, CA125, EGF, GMCSF, 97.372 2716 ips.mps, EMILIN, Ί, EGF, 95.419 IL1RA, HE4 GMCSF, *2

2690 ips, mps, CA125, EGF, GMCSF, 96.946 2717 ips.mps, EMILIN, Ί, EGF, IL1RA, 96.928 IL1RA, *2 HE4

2691 ips, mps, CA125, EGF, GMCSF, 97.088 2718 ips.mps, EMILIN, Ί, EGF, IL1RA, 96.911 HE4, *2 *2

2692 ips.mps, CA125, EGF, IL1RA, 97.301 2719 ips.mps, EMILIN, Ί, EGF, HE4, *2 95.49 HE4, *2 2720 ips.mps, EMILIN, Ί, GMCSF, 96.626

2693 ips.mps, CA125, GMCSF, IL1RA, 97.283 IL1RA, HE4

HE4, *2 2721 ips.mps, EMILIN, Ί, GMCSF, 96.378

2694 ips.mps, EMILIN, MDK, , EGF, 96.768 IL1RA, *2

GMCSF 2722 ips.mps, EMILIN, Ί, GMCSF, 95.348

2695 ips.mps, EMILIN, MDK, Ί, EGF, 97.23 HE4, *2

IL1RA 2723 ips.mps, EMILIN, *1, IL1RA, HE4, 96.768

2696 ips.mps, EMILIN, MDK, Ί, EGF, 96.555 *2

HE4 2724 ips.mps, EMILIN, EGF, GMCSF, 96.662

2697 ips.mps, EMILIN, MDK, Ί, EGF, 97.053 IL1RA, HE4

*2 2725 ips.mps, EMILIN, EGF, GMCSF, 96.52

2698 ips.mps, EMILIN, MDK, Ί, 97.159 IL1RA, *2

GMCSF, IL1RA 2726 ips.mps, EMILIN, EGF, GMCSF, 94.531

2699 ips.mps, EMILIN, MDK, Ί, 96.236 HE4, *2

GMCSF, HE4 2727 ips.mps, EMILIN, EGF, IL1RA, 96.697

2700 ips.mps, EMILIN, MDK, Ί, 96.591 HE4, *2

GMCSF, *2 2728 ips.mps, EMILIN, GMCSF, IL1RA, 96.271

2701 ips.mps, EMILIN, MDK, *1 JURA, 97.212 HE4, *2

HE4 2729 ips.mps, MDK, Ί, EGF, GMCSF, 95.774 IL1RA 2758 ips, dps, CA125, EMILIN, MDK, 97.479

2730 ips.mps, MDK, Ί, EGF.GMCSF, 95.313 EGF, *2

HE4 2759 ips, dps, CA125, EMILIN, MDK, 97.195

2731 ips.mps, MDK, Ί, EGF.GMCSF, 95.81 GMCSF, IL1RA

*2 2760 ips, dps, CA125, EMILIN, MDK, 97.266

2732 ips.mps, MDK,*1, EGF, IL1RA, 95.81 GMCSF, HE4

HE4 2761 ips, dps, CA125, EMILIN, MDK, 97.337

2733 ips.mps, MDK,*1, EGF, IL1RA, *2 96.058 GMCSF, *2

2734 ips.mps, MDK,*1, EGF, HE4,*2 95.561 2762 ips, dps, CA125, EMILIN, MDK, 97.443

2735 ips.mps, MDK,*1,GMCSF, IL1RA, 95.455 IL1RA, HE4

HE4 2763 ips, dps, CA125, EMILIN, MDK, 97.621

2736 ips.mps, MDK,*1,GMCSF, IL1RA, 95.668 IL1RA, *2

*2 2764 ips, dps, CA125, EMILIN, MDK, 97.514

2737 ips.mps, MDK,*1,GMCSF, HE4, 95.206 HE4, *2

2765 ips, dps, CA125, EMILIN, Ί, EGF, 96.129

2738 ips.mps, MDK, *1,IL1RA,HE4,*2 95.703 GMCSF

2739 ips, mps, MDK, EGF, GMCSF, 95.632 2766 ips, dps, CA125, EMILIN, , EGF, 96.839 IL1RA, HE4 IL1RA

2740 ips, mps, MDK, EGF.GMCSF, 95.241 2767 ips, dps, CA125, EMILIN, , EGF, 96.342 IL1RA, *2 HE4

2741 ips, mps, MDK, EGF, GMCSF, 94.549 2768 ips, dps, CA125, EMILIN, , EGF, 96.413

*2

HE4, *2

2742 ips.mps, MDK, EGF, IL1RA, HE4, 95.561 2769 ips, dps, CA125, EMILIN, , 96.555

*2 GMCSF, IL1RA

2743 ips.mps, MDK, GMCSF, IL1RA, 94.851 2770 ips, dps, CA125, EMILIN, Ί, 96.555 HE4, *2 GMCSF, HE4

2744 ips, mps, , EGF, GMCSF, IL1RA, 93.04 2771 ips, dps, CA125, EMILIN, , 96.52 HE4 GMCSF, *2

2745 ips, mps, , EGF.GMCSF, IL1RA, 93.821 2772 ips, dps, CA125, EMILIN, , 96.946

*2 IL1RA, HE4

2746 ips, mps, , EGF, GMCSF, HE4, 92.507 2773 ips, dps, CA125, EMILIN, , 96.839

*2 IL1RA, *2

2747 ips, mps, , EGF, IL1RA, HE4, *2 93.679 2774 ips, dps, CA125, EMILIN, , HE4, 96.768

*2

2748 ips, mps, , GMCSF, IL1RA, HE4, 93.288

*2 2775 ips, dps, CA125, EMILIN, EGF, 96.413

2749 ips.mps, EGF.GMCSF, IL1RA, 93.04 GMCSF, IL1RA

HE4, *2 2776 ips, dps, CA125, EMILIN, EGF, 96.555

2750 ips, dps, CA125, EMILIN, MDK, , 97.567 GMCSF, HE4

EGF 2777 ips, dps, CA125, EMILIN, EGF, 96.094

2751 ips, dps, CA125, EMILIN, MDK, , 97.372 GMCSF, *2

GMCSF 2778 ips, dps, CA125, EMILIN, EGF, 97.159

2752 ips, dps, CA125, EMILIN, MDK, , 97.798 IL1RA, HE4

IL1RA 2779 ips, dps, CA125, EMILIN, EGF, 97.124

2753 ips, dps, CA125, EMILIN, MDK, , 97.337 IL1RA, *2

HE4 2780 ips, dps, CA125, EMILIN, EGF, 96.697

2754 ips, dps, CA125, EMILIN, MDK, , 97.621 HE4, *2

*2 2781 ips, dps, CA125, EMILIN, GMCSF, 96.768

2755 ips, dps, CA125, EMILIN, MDK, 97.088 IL1RA, HE4

EGF, GMCSF 2782 ips, dps, CA125, EMILIN, GMCSF, 96.591

2756 ips, dps, CA125, EMILIN, MDK, 97.372 IL1RA, *2

EGF, IL1RA 2783 ips, dps, CA125, EMILIN, GMCSF, 96.733

2757 ips, dps, CA125, EMILIN, MDK, 97.266 HE4, *2

EGF, HE4 2784 ips, dps, CA125, EMILIN, IL1RA, 97.195 HE4, *2 IL1RA, *2

2785 ips, dps, CA125, MDK, , EGF, 97.337 2813 ips, dps, CA125, , GMCSF, HE4, 95.81 GMCSF *2

2786 ips, dps, CA125, MDK, , EGF, 97.124 2814 ips, dps, CA125, *1, IL1RA, HE4, *2 95.384 IL1RA 2815 ips, dps, CA125, EGF, GMCSF, 96.2

2787 ips, dps, CA125, MDK, , EGF, 96.982 IL1RA, HE4

HE4 2816 ips, dps, CA125, EGF, GMCSF, 95.987

2788 ips, dps, CA125, MDK,*1, EGF,*2 97.159 IL1RA, *2

2789 ips, dps, CA125, MDK, Ί, GMCSF, 97.408 2817 ips, dps, CA125, EGF, GMCSF, 95.916 IL1RA HE4, *2

2790 ips, dps, CA125, MDK, Ί, GMCSF, 97.195 2818 ips, dps, CA125, EGF, IL1RA, HE4, 95.952 HE4 *2

2791 ips, dps, CA125, MDK, Ί, GMCSF, 97.354 2819 ips, dps, CA125, GMCSF, IL1RA, 95.597

*2 HE4, *2

2792 ips, dps, CA125, MDK, *1, IL1RA, 96.982 2820 ips, dps, EMILIN, MDK, , EGF, 93.999 HE4 GMCSF

2793 ips, dps, CA125, MDK, *1, IL1RA, 97.212 2821 ips, dps, EMILIN, MDK, Ί, EGF, 93.999

*2 IL1RA

2794 ips, dps, CA125, MDK,*1,HE4,*2 96.875 2822 ips, dps, EMILIN, MDK, Ί, EGF, 93.697

2795 ips, dps, CA125, MDK, EGF, 97.159 HE4

GMCSF, IL1RA 2823 ips, dps, EMILIN, MDK, Ί, EGF, *2 94.034

2796 ips, dps, CA125, MDK, EGF, 96.946 2824 ips, dps, EMILIN, MDK, Ί, 94.283 GMCSF, HE4 GMCSF, IL1RA

2797 ips, dps, CA125, MDK, EGF, 97.195 2825 ips, dps, EMILIN, MDK, Ί, 94.212 GMCSF, *2 GMCSF, HE4

2798 ips, dps, CA125, MDK, EGF, 96.768 2826 ips, dps, EMILIN, MDK, Ί, 94.141 IL1RA, HE4 GMCSF, *2

2799 ips, dps, CA125, MDK, EGF, 96.946 2827 ips, dps, EMILIN, MDK, *1 JURA, 94.389 IL1RA, *2 HE4

2800 ips, dps, CA125, MDK, EGF, HE4, 96.804 2828 ips, dps, EMILIN, MDK, *1,IL1RA, 94.567

*2 *2

2801 ips, dps, CA125, MDK, GMCSF, 96.662 2829 ips, dps, EMILIN, MDK, Ί,ΗΕ4,*2 94.389 IL1RA, HE4 2830 ips, dps, EMILIN, MDK, EGF, 92.862

2802 ips, dps, CA125, MDK, GMCSF, 96.911 GMCSF, IL1RA

IL1RA, *2 2831 ips, dps, EMILIN, MDK, EGF, 92.56

2803 ips, dps, CA125, MDK, GMCSF, 96.697 GMCSF, HE4

HE4, *2 2832 ips, dps, EMILIN, MDK, EGF, 93.146

2804 ips, dps, CA125, MDK, IL1RA, HE4, 96.626 GMCSF, *2

*2

2833 ips, dps, EMILIN, MDK, EGF, 92.862

2805 ips, dps, CA125,*1, EGF, GMCSF, 96.058 IL1RA, HE4

IL1RA 2834 ips, dps, EMILIN, MDK, EGF, 93.572

2806 ips, dps, CA125,*1, EGF, GMCSF, 96.094 IL1RA, *2

HE4 2835 ips, dps, EMILIN, MDK, EGF, HE4, 93.04

2807 ips, dps, CA125,*1, EGF, GMCSF, 96.342 *2

*2 2836 ips, dps, EMILIN, MDK, GMCSF, 93.466

2808 ips, dps, CA125, , EGF, IL1RA, 96.378 IL1RA, HE4

HE4 2837 ips, dps, EMILIN, MDK, GMCSF, 94.141

2809 ips, dps, CA125, , EGF, IL1RA, 96.378 IL1RA, *2

*2 2838 ips, dps, EMILIN, MDK, GMCSF, 93.271

2810 ips, dps, CA125,*1, EGF, HE4,*2 95.881 HE4, *2

2811 ips, dps, CA125,*1, GMCSF, 95.739 2839 ips, dps, EMILIN, MDK, IL1RA, 93.679 IL1RA, HE4 HE4, *2

2812 ips, dps, CA125,*1, GMCSF, 95.916 2840 ips, dps, EMILIN, Ί, EGF, GMCSF, 92.738 IL1RA HE4, *2

2841 ips, dps, EMILIN, , EGF, GMCSF, 92.33 2870 ips, dps, , EGF, GMCSF, IL1RA, 91.761 HE4 HE4

2842 ips, dps, EMILIN, Ί, EGF, GMCSF, 92.543 2871 ips, dps, , EGF, GMCSF, IL1RA, 91.619

*2 *2

2843 ips, dps, EMILIN, Ί, EGF, IL1RA, 93.324 2872 ips, dps, , EGF, GMCSF, HE4, *2 91.442 HE4 2873 ips, dps, *1, EGF, IL1RA, HE4, *2 91.158

2844 ips, dps, EMILIN, Ί, EGF, IL1RA, 93.501 2874 ips, dps, , GMCSF, IL1RA, HE4, 90.909

*2 *2

2845 ips, dps, EMILIN, Ί, EGF, HE4, *2 92.969 2875 ips, dps, EGF, GMCSF, IL1RA, 90.021

2846 ips, dps, EMILIN, Ί, GMCSF, 93.271 HE4, *2

IL1RA, HE4 2876 ips, CA125, EMILIN, MDK, Ί, EGF, 96.697

2847 ips, dps, EMILIN, Ί, GMCSF, 93.466 GMCSF

IL1RA, *2 2877 ips, CA125, EMILIN, MDK, Ί, EGF, 97.124

2848 ips, dps, EMILIN, Ί, GMCSF, HE4, 93.075 IL1RA

*2

2878 ips, CA125, EMILIN, MDK, Ί, EGF, 96.946

2849 ips, dps, EMILIN, *1, IL1RA, HE4, 93.608 HE4

2879 ips, CA125, EMILIN, MDK, Ί, EGF, 97.124

2850 ips, dps, EMILIN, EGF, GMCSF, 91.442 *2

IL1RA, HE4 2880 ips, CA125, EMILIN, MDK, Ί, 96.733

2851 ips, dps, EMILIN, EGF, GMCSF, 91.69 GMCSF, IL1RA

IL1RA, *2 2881 ips, CA125, EMILIN, MDK, Ί, 96.928

2852 ips, dps, EMILIN, EGF, GMCSF, 91.211 GMCSF, HE4

HE4, *2 2882 ips, CA125, EMILIN, MDK, Ί, 96.982

2853 ips, dps, EMILIN, EGF, IL1RA, 91.832 GMCSF, *2

HE4, *2 2883 ips, CA125, EMILIN, MDK, Ί, 97.053

2854 ips, dps, EMILIN, GMCSF, IL1RA, 92.756 IL1RA, HE4

HE4, *2 2884 ips, CA125, EMILIN, MDK, Ί, 97.266

2855 ips, dps, MDK,*1, EGF, GMCSF, 94.567 IL1RA, *2

IL1RA 2885 ips, CA125, EMILIN, MDK, Ί.ΗΕ4, 97.088

2856 ips, dps, MDK,*1, EGF, GMCSF, 93.963 *2

HE4 2886 ips, CA125, EMILIN, MDK, EGF, 96.662

2857 ips, dps, MDK,*1, EGF, GMCSF, 94.176 GMCSF, IL1RA

*2 2887 ips, CA125, EMILIN, MDK, EGF, 96.626

2858 ips, dps, MDK, , EGF, IL1RA, 93.608 GMCSF, HE4

HE4 2888 ips, CA125, EMILIN, MDK, EGF, 96.413

2859 ips, dps, MDK, , EGF, IL1RA, *2 94.034 GMCSF, *2

2860 ips, dps, MDK, , EGF, HE4, *2 93.501 2889 ips, CA125, EMILIN, MDK, EGF, 96.697

2861 ips, dps, MDK, Ί, GMCSF, IL1RA, 94.318 IL1RA, HE4

HE4 2890 ips, CA125, EMILIN, MDK, EGF, 96.839

2862 ips, dps, MDK, Ί, GMCSF, IL1RA, 94.531 IL1RA, *2

*2 2891 ips, CA125, EMILIN, MDK, EGF, 96.662

2863 ips, dps, MDK, Ί, GMCSF, HE4,*2 93.963 HE4, *2

2864 ips, dps, MDK, *1, IL1RA, HE4,*2 93.359 2892 ips, CA125, EMILIN, MDK, 96.697

2865 ips, dps, MDK, EGF, GMCSF, 92.01 GMCSF, IL1RA, HE4

IL1RA, HE4 2893 ips, CA125, EMILIN, MDK, 96.733

2866 ips, dps, MDK, EGF, GMCSF, 93.04 GMCSF, IL1RA, *2

IL1RA, *2 2894 ips, CA125, EMILIN, MDK, 96.804

2867 ips, dps, MDK, EGF, GMCSF, HE4, 92.507 GMCSF, HE4, *2

*2 2895 ips, CA125, EMILIN, MDK, IL1RA, 96.875

2868 ips, dps, MDK, EGF, IL1RA, HE4, 92.028 HE4, *2

*2 2896 ips, CA125, EMILIN, Ί, EGF, 95.17

2869 ips, dps, MDK, GMCSF, IL1RA, 92.543 GMCSF, IL1RA 2897 ips, CA125, EMIUN, Ί, EGF, 94.957 2924 ips, CA125, MDK, EGF, IL1RA, 96.2 GMCSF, HE4 HE4, *2

2898 ips, CA125, EMIUN, Ί, EGF, 95.241 2925 ips, CA125, MDK, GMCSF, IL1RA, 96.307 GMCSF, *2 HE4, *2

2899 ips, CA125, EMIUN, Ί, EGF, 95.277 2926 ips, CA125, *1, EGF, GMCSF, 94.389 IL1RA, HE4 IL1RA, HE4

2900 ips, CA125, EMIUN, Ί, EGF, 95.721 2927 ips, CA125, *1, EGF, GMCSF, 94.247 IL1RA, *2 IL1RA, *2

2901 ips, CA125, EMIUN, Ί, EGF, HE4, 95.384 2928 ips, CA125, , EGF, GMCSF, HE4, 94.425

*2 *2

2902 ips, CA125, EMIUN, Ί, GMCSF, 95.721 2929 ips, CA125, , EGF, IL1RA, HE4, 93.981 IL1RA, HE4 *2

2903 ips, CA125, EMIUN, Ί, GMCSF, 95.739 2930 ips, CA125, , GMCSF, IL1RA, 94.46 IL1RA, *2 HE4, *2

2904 ips, CA125, EMIUN, Ί, GMCSF, 95.632 2931 ips, CA125, EGF, GMCSF, IL1RA, 94.034 HE4, *2 HE4, *2

2905 ips, CA125, EMILIN, *1, IL1RA, 95.916 2932 ips, EMILIN, MDK, Ί, EGF, 91.903 HE4, *2 GMCSF, IL1RA

2906 ips, CA125, EMILIN, EGF, GMCSF, 95.206 2933 ips, EMILIN, MDK, Ί, EGF, 91.868 IL1RA, HE4 GMCSF, HE4

2907 ips, CA125, EMILIN, EGF, GMCSF, 95.17 2934 ips, EMILIN, MDK, Ί, EGF, 91.761 IL1RA, *2 GMCSF, *2

2908 ips, CA125, EMILIN, EGF, GMCSF, 95.455 2935 ips, EMILIN, MDK, Ί, EGF, IL1RA, 91.797 HE4, *2 HE4

2909 ips, CA125, EMILIN, EGF, IL1RA, 95.348 2936 ips, EMILIN, MDK, Ί, EGF, IL1RA, 91.797 HE4, *2 *2

2910 ips, CA125, EMILIN, GMCSF, 95.703 2937 ips, EMILIN, MDK, Ί, EGF, HE4, 92.01 IL1RA, HE4, *2 *2

2911 ips, CA125, MDK, , EGF, 96.911 2938 ips, EMILIN, MDK, Ί, GMCSF, 92.436 GMCSF, IL1RA IL1RA, HE4

2912 ips, CA125, MDK, , EGF, 96.804 2939 ips, EMILIN, MDK, Ί, GMCSF, 91.903 GMCSF, HE4 IL1RA, *2

2913 ips, CA125, MDK, , EGF, 96.804 2940 ips, EMILIN, MDK, Ί, GMCSF, 92.116 GMCSF, *2 HE4, *2

2914 ips, CA125, MDK, , EGF, IL1RA, 96.591 2941 ips, EMILIN, MDK, *1, IL1RA, HE4, 92.276 HE4 *2

2915 ips, CA125, MDK, , EGF, IL1RA, 96.733 2942 ips, EMILIN, MDK, EGF, GMCSF, 90.927

*2 IL1RA, HE4

2916 ips, CA125, MDK, , EGF, HE4, *2 96.307 2943 ips, EMILIN, MDK, EGF, GMCSF, 90.625

2917 ips, CA125, MDK, Ί, GMCSF, 96.911 IL1RA, *2

IL1RA, HE4 2944 ips, EMILIN, MDK, EGF, GMCSF, 90.057

2918 ips, CA125, MDK, Ί, GMCSF, 96.768 HE4, *2

IL1RA, *2 2945 ips, EMILIN, MDK, EGF, IL1RA, 90.554

2919 ips, CA125, MDK, Ί, GMCSF, 96.768 HE4, *2

HE4, *2 2946 ips, EMILIN, MDK, GMCSF, IL1RA, 91.193

2920 ips, CA125, MDK, , IL1RA, HE4, 96.555 HE4, *2

*2 2947 ips, EMILIN, Ί, EGF, GMCSF, 88.849

2921 ips, CA125, MDK, EGF, GMCSF, 96.555 IL1RA, HE4

IL1RA, HE4 2948 ips, EMILIN, Ί, EGF, GMCSF, 88.228

2922 ips, CA125, MDK, EGF, GMCSF, 96.449 IL1RA, *2

IL1RA, *2 2949 ips, EMILIN, Ί, EGF, GMCSF, 88.033

2923 ips, CA125, MDK, EGF, GMCSF, 96.094 HE4, *2

HE4, *2 2950 ips, EMILIN, Ί, EGF, IL1RA, HE4, 88.317 *2 HE4

2951 ips, EMILIN, , GMCSF, IL1RA, 89.808 2978 mps, dps, CA125, EMILIN, Ί, EGF, 97.479 HE4, *2 *2

2952 ips, EMILIN, EGF, GMCSF, IL1RA, 86.47 2979 mps, dps, CA125, EMILIN, Ί, 97.479 HE4, *2 GMCSF, IL1RA

2953 ips, MDK,*1, EGF, GMCSF, IL1RA, 91.158 2980 mps, dps, CA125, EMILIN, Ί, 97.195 HE4 GMCSF, HE4

2954 ips, MDK,*1, EGF, GMCSF, IL1RA, 91.264 2981 mps, dps, CA125, EMILIN, Ί, 97.301

*2 GMCSF, *2

2955 ips, MDK, , EGF, GMCSF, HE4, 91.229 2982 mps, dps, CA125, EMILIN, Ί, 97.408

IL1RA, HE4

2956 ips, MDK, *1, EGF, IL1RA, HE4, *2 90.447 2983 mps, dps, CA125, EMILIN, Ί, 97.621

2957 ips, MDK, Ί, GMCSF, IL1RA, HE4, 91.442 IL1RA, *2

*2 2984 mps, dps, CA125, EMILIN, Ί, HE4, 97.408

2958 ips, MDK, EGF, GMCSF, IL1RA, 88.388 *2

HE4, *2 2985 mps, dps, CA125, EMILIN, EGF, 97.23

2959 ips, , EGF, GMCSF, IL1RA, HE4, 85.387 GMCSF, IL1RA

*2 2986 mps, dps, CA125, EMILIN, EGF, 97.195

2960 mps, dps,CA125, EMILIN, MDK, 97.869 GMCSF, HE4

Ί, EGF 2987 mps, dps, CA125, EMILIN, EGF, 97.212

2961 mps, dps,CA125, EMILIN, MDK, 97.834 GMCSF, *2

Ί, GMCSF 2988 mps, dps, CA125, EMILIN, EGF, 97.55

2962 mps, dps,CA125, EMILIN, MDK, 98.118 IL1RA, HE4

Ί, IL1RA 2989 mps, dps, CA125, EMILIN, EGF, 97.656

2963 mps, dps,CA125, EMILIN, MDK, 98.118 IL1RA, *2

Ί, HE4 2990 mps, dps, CA125, EMILIN, EGF, 97.408

2964 mps, dps, CA125, EMILIN, MDK, 98.153 HE4, *2

*-| *2 2991 mps, dps, CA125, EMILIN, 97.514

2965 mps, dps,CA125, EMILIN, MDK, 97.656 GMCSF, IL1RA, HE4

EGF, GMCSF 2992 mps, dps, CA125, EMILIN, 97.55

2966 mps, dps,CA125, EMILIN, MDK, 98.153 GMCSF, IL1RA, *2

EGF, IL1RA 2993 mps, dps, CA125, EMILIN, 97.337

2967 mps, dps,CA125, EMILIN, MDK, 97.798 GMCSF, HE4, *2

EGF, HE4 2994 mps, dps, CA125, EMILIN, IL1RA, 97.727

2968 mps, dps,CA125, EMILIN, MDK, 97.798 HE4, *2

EGF,*2 2995 mps, dps, CA125, MDK, , EGF, 96.946

2969 mps, dps,CA125, EMILIN, MDK, 97.869 GMCSF

GMCSF, IL1RA 2996 mps, dps, CA125, MDK, , EGF, 97.159

2970 mps, dps,CA125, EMILIN, MDK, 97.834 IL1RA

GMCSF, HE4 2997 mps, dps, CA125, MDK, , EGF, 97.159

2971 mps, dps,CA125, EMILIN, MDK, 97.798 HE4

GMCSF, *2 2998 mps, dps, CA125, MDK, , EGF, 97.053

2972 mps, dps,CA125, EMILIN, MDK, 98.118 *2

IL1RA, HE4 2999 mps, dps, CA125, MDK, Ί, 96.946

2973 mps, dps,CA125, EMILIN, MDK, 98.082 GMCSF, IL1RA

IL1RA, *2 3000 mps, dps, CA125, MDK, Ί, 96.911

2974 mps, dps,CA125, EMILIN, MDK, 97.976 GMCSF, HE4

HE4, *2 3001 mps, dps, CA125, MDK, Ί, 97.053

2975 mps, dps,CA125, EMILIN, Ί, EGF, 97.23 GMCSF, *2

GMCSF 3002 mps, dps, CA125, MDK, *1, IL1RA, 97.266

2976 mps, dps,CA125, EMILIN, Ί, EGF, 97.585 HE4

IL1RA 3003 mps, dps, CA125, MDK, *1, IL1RA, 97.23

2977 mps, dps,CA125, EMILIN, Ί, EGF, 97.301 *2 3004 mps, dps,CA125, MDK,*1,HE4,*2 97.017 IL1RA

3005 mps, dps, CA125, MDK, EGF, 96.982 3032 mps, dps, EMILIN, MDK, Ί, EGF, 95.703 GMCSF, IL1RA HE4

3006 mps, dps, CA125, MDK, EGF, 96.804 3033 mps, dps, EMILIN, MDK, Ί, EGF, 95.952 GMCSF, HE4 *2

3007 mps, dps, CA125, MDK, EGF, 96.662 3034 mps, dps, EMILIN, MDK, Ί, 96.307 GMCSF, *2 GMCSF, IL1RA

3008 mps, dps, CA125, MDK, EGF, 97.195 3035 mps, dps, EMILIN, MDK, Ί, 95.49 IL1RA, HE4 GMCSF, HE4

3009 mps, dps, CA125, MDK, EGF, 97.053 3036 mps, dps, EMILIN, MDK, Ί, 95.916 IL1RA, *2 GMCSF, *2

3010 mps, dps, CA125, MDK, EGF, HE4, 96.768 3037 mps, dps, EMILIN, MDK, *1 JURA, 96.307

*2 HE4

3011 mps, dps, CA125, MDK, GMCSF, 96.911 3038 mps, dps, EMILIN, MDK, *1,IL1RA, 96.591 IL1RA, HE4 *2

3012 mps, dps, CA125, MDK, GMCSF, 96.875 3039 mps, dps, EMILIN, MDK, Ί.ΗΕ4, 96.236 IL1RA, *2 *2

3013 mps, dps, CA125, MDK, GMCSF, 96.733 3040 mps, dps, EMILIN, MDK, EGF, 95.419 HE4, *2 GMCSF, IL1RA

3014 mps, dps, CA125, MDK, IL1RA, 97.195 3041 mps, dps, EMILIN, MDK, EGF, 94.638 HE4, *2 GMCSF, HE4

3015 mps, dps, CA125,*1,EGF, 95.49 3042 mps, dps, EMILIN, MDK, EGF, 94.851 GMCSF, IL1RA GMCSF, *2

3016 mps, dps, CA125,*1,EGF, 95.526 3043 mps, dps, EMILIN, MDK, EGF, 95.597 GMCSF, HE4 IL1RA, HE4

3017 mps, dps, CA125,*1,EGF, 95.348 3044 mps, dps, EMILIN, MDK, EGF, 95.739 GMCSF, *2 IL1RA, *2

3018 mps, dps, CA125, , EGF, IL1RA, 95.881 3045 mps, dps, EMILIN, MDK, EGF, 94.975 HE4 HE4, *2

3019 mps, dps, CA125, , EGF, IL1RA, 95.987 3046 mps, dps, EMILIN, MDK, GMCSF, 95.739

*2 IL1RA, HE4

3020 mps, dps,CA125,*1,EGF, HE4,*2 95.881 3047 mps, dps, EMILIN, MDK, GMCSF, 96.058

3021 mps, dps, CA125, *1, GMCSF, 95.526 IL1RA, *2

IL1RA, HE4 3048 mps, dps, EMILIN, MDK, GMCSF, 95.099

3022 mps, dps, CA125, *1, GMCSF, 95.81 HE4, *2

IL1RA, *2 3049 mps, dps, EMILIN, MDK, IL1RA, 96.449

3023 mps, dps, CA125, *1, GMCSF, 95.313 HE4, *2

HE4, *2 3050 mps, dps, EMILIN, Ί, EGF, 95.028

3024 mps, dps, CA125, , IL1RA, HE4, 95.774 GMCSF, IL1RA

*2 3051 mps, dps, EMILIN, Ί, EGF, 93.679

3025 mps, dps, CA125, EGF, GMCSF, 95.703 GMCSF, HE4

IL1RA, HE4 3052 mps, dps, EMILIN, Ί, EGF, 94.709

3026 mps, dps, CA125, EGF, GMCSF, 95.668 GMCSF, *2

IL1RA, *2 3053 mps, dps, EMILIN, Ί, EGF, IL1RA, 95.597

3027 mps, dps, CA125, EGF, GMCSF, 95.455 HE4

HE4, *2 3054 mps, dps, EMILIN, Ί, EGF, IL1RA, 95.739

3028 mps, dps,CA125, EGF, IL1RA, 96.023 *2

HE4, *2 3055 mps, dps, EMILIN, Ί, EGF, HE4, 94.602

3029 mps, dps, CA125, GMCSF, IL1RA, 95.419 *2

HE4, *2 3056 mps, dps, EMILIN, Ί, GMCSF, 95.597

3030 mps, dps, EMILIN, MDK, *1, EGF, 95.614 IL1RA, HE4

GMCSF 3057 mps, dps, EMILIN, Ί, GMCSF, 95.685

3031 mps, dps, EMILIN, MDK, Ί, EGF, 96.342 IL1RA, *2 3058 mps, dps, EMILIN, *1, GMCSF, 94.638 EGF, GMCSF

HE4, *2 3087 mps, CA125, EMILIN, MDK, Ί, 97.976

3059 mps, dps, EMILIN, *1, IL1RA, HE4, 96.023 EGF, IL1RA

*2 3088 mps, CA125, EMILIN, MDK, Ί, 97.674

3060 mps, dps, EMILIN, EGF, GMCSF, 94.709 EGF, HE4

IL1RA, HE4 3089 mps, CA125, EMILIN, MDK, Ί, 97.798

3061 mps, dps, EMILIN, EGF, GMCSF, 94.744 EGF, *2

IL1RA, *2 3090 mps, CA125, EMILIN, MDK, Ί, 97.94

3062 mps, dps, EMILIN, EGF, GMCSF, 93.253 GMCSF, IL1RA

HE4, *2 3091 mps, CA125, EMILIN, MDK, Ί, 97.905

3063 mps, dps, EMILIN, EGF, IL1RA, 95.277 GMCSF, HE4

HE4, *2 3092 mps, CA125, EMILIN, MDK, Ί, 97.834

3064 mps, dps, EMILIN, GMCSF, IL1RA, 95.277 GMCSF, *2

HE4, *2 3093 mps, CA125, EMILIN, MDK, Ί, 98.047

3065 mps, dps, MDK,*1, EGF, GMCSF, 94.567 IL1RA, HE4

IL1RA 3094 mps, CA125, EMILIN, MDK, Ί, 98.082

3066 mps, dps, MDK,*1, EGF, GMCSF, 93.714 IL1RA, *2

HE4 3095 mps, CA125, EMILIN, MDK, Ί, 98.082

3067 mps, dps, MDK,*1, EGF, GMCSF, 94.638 HE4, *2

*2 3096 mps, CA125, EMILIN, MDK, EGF, 97.301

3068 mps, dps, MDK, , EGF, IL1RA, 94.673 GMCSF, IL1RA

HE4 3097 mps, CA125, EMILIN, MDK, EGF, 97.638

3069 mps, dps, MDK, , EGF, IL1RA, *2 95.064 GMCSF, HE4

3070 mps, dps, MDK, , EGF, HE4, *2 94.46 3098 mps, CA125, EMILIN, MDK, EGF, 97.621

3071 mps, dps, MDK, Ί, GMCSF, 94.744 GMCSF, *2

IL1RA, HE4 3099 mps, CA125, EMILIN, MDK, EGF, 97.763

3072 mps, dps, MDK, Ί, GMCSF, 95.17 IL1RA, HE4

IL1RA, *2 3100 mps, CA125, EMILIN, MDK, EGF, 97.55

3073 mps, dps, MDK, Ί, GMCSF, HE4, 94.371 IL1RA, *2

*2 3101 mps, CA125, EMILIN, MDK, EGF, 97.816

3074 mps, dps, MDK, *1, IL1RA, HE4, *2 95.099 HE4, *2

3075 mps, dps, MDK, EGF, GMCSF, 93.182 3102 mps, CA125, EMILIN, MDK, 97.798 IL1RA, HE4 GMCSF, IL1RA, HE4

3076 mps, dps, MDK, EGF, GMCSF, 93.555 3103 mps, CA125, EMILIN, MDK, 97.727 IL1RA, *2 GMCSF, IL1RA, *2

3077 mps, dps, MDK, EGF, GMCSF, 92.489 3104 mps, CA125, EMILIN, MDK, 97.834 HE4, *2 GMCSF, HE4, *2

3078 mps, dps, MDK, EGF, IL1RA, HE4, 94.212 3105 mps, CA125, EMILIN, MDK, IL1RA, 98.082

*2 HE4, *2

3079 mps, dps, MDK, GMCSF, IL1RA, 93.999 3106 mps, CA125, EMILIN, Ί, EGF, 97.088 HE4, *2 GMCSF, IL1RA

3080 mps, dps, , EGF, GMCSF, IL1RA, 91.193 3107 mps, CA125, EMILIN, Ί, EGF, 96.733 HE4 GMCSF, HE4

3081 mps, dps, , EGF, GMCSF, IL1RA, 91.69 3108 mps, CA125, EMILIN, Ί, EGF, 96.982

*2 GMCSF, *2

3082 mps, dps, , EGF, GMCSF, HE4, 90.661 3109 mps, CA125, EMILIN, Ί, EGF, 97.124

*2 IL1RA, HE4

3083 mps, dps, , EGF, IL1RA, HE4, *2 92.045 3110 mps, CA125, EMILIN, Ί, EGF, 97.23

3084 mps, dps, , GMCSF, IL1RA, HE4, 90.856 IL1RA, *2

*2 3111 mps, CA125, EMILIN, Ί, EGF, 97.017

3085 mps, dps, EGF, GMCSF, IL1RA, 90.181 HE4, *2

HE4, *2 3112 mps, CA125, EMILIN, Ί, GMCSF, 97.283

3086 mps, CA125, EMILIN, MDK, Ί, 97.727 IL1RA, HE4 3113 mps, CA125, EMILIN, Ί, GMCSF, 97.514 *2

IL1RA, *2 3140 mps, CA125, , GMCSF, IL1RA, 94.638

3114 mps, CA125, EMILIN, Ί, GMCSF, 97.07 HE4, *2

HE4, *2 3141 mps, CA125, EGF, GMCSF, IL1RA, 94.531

3115 mps, CA125, EMILIN, Ί, IL1RA, 97.372 HE4, *2

HE4, *2 3142 mps, EMILIN, MDK, , EGF, 95.277

3116 mps, CA125, EMILIN, EGF, 96.768 GMCSF, IL1RA

GMCSF, IL1RA, HE4 3143 mps, EMILIN, MDK, Ί, EGF, 94.78

3117 mps, CA125, EMILIN, EGF, 97.017 GMCSF, HE4

GMCSF, IL1RA, *2 3144 mps, EMILIN, MDK, , EGF, 95.384

3118 mps, CA125, EMILIN, EGF, 96.626 GMCSF, *2

GMCSF, HE4, *2 3145 mps, EMILIN, MDK, , EGF, 95.703

3119 mps, CA125, EMILIN, EGF, IL1RA, 97.017 IL1RA, HE4

HE4, *2 3146 mps, EMILIN, MDK, , EGF, 95.561

3120 mps, CA125, EMILIN, GMCSF, 97.195 IL1RA, *2

IL1RA, HE4, *2 3147 mps, EMILIN, MDK, , EGF, HE4, 95.614

3121 mps, CA125, MDK, Ί, EGF, 96.697 *2

GMCSF, IL1RA 3148 mps, EMILIN, MDK, , GMCSF, 95.241

3122 mps, CA125, MDK, Ί, EGF, 96.52 IL1RA, HE4

GMCSF, HE4 3149 mps, EMILIN, MDK, , GMCSF, 95.561

3123 mps, CA125, MDK, , EGF, 96.449 IL1RA, *2

GMCSF, *2 3150 mps, EMILIN, MDK, , GMCSF, 95.668

3124 mps, CA125, MDK, Ί, EGF, 96.662 HE4, *2

IL1RA, HE4 3151 mps, EMILIN, MDK, *1, IL1RA, 95.916

3125 mps, CA125, MDK, Ί, EGF, 96.591 HE4, *2

IL1RA, *2 3152 mps, EMILIN, MDK, EGF, GMCSF, 94.034

3126 mps, CA125, MDK, Ί, EGF, HE4, 96.555 IL1RA, HE4

*2 3153 mps, EMILIN, MDK, EGF, GMCSF, 94.318

3127 mps, CA125, MDK, Ί, GMCSF, 96.911 IL1RA, *2

IL1RA, HE4 3154 mps, EMILIN, MDK, EGF, GMCSF, 93.839

3128 mps, CA125, MDK, Ί, GMCSF, 96.768 HE4, *2

IL1RA, *2 3155 mps, EMILIN, MDK, EGF, IL1RA, 94.567

3129 mps, CA125, MDK, Ί, GMCSF, 96.733 HE4, *2

HE4, *2 3156 mps, EMILIN, MDK, GMCSF, 94.531

3130 mps, CA125, MDK, Ί, IL1RA, HE4, 97.017 IL1RA, HE4, *2

*2 3157 mps, EMILIN, Ί, EGF, GMCSF, 93.697

3131 mps, CA125, MDK, EGF, GMCSF, 96.431 IL1RA, HE4

IL1RA, HE4 3158 mps, EMILIN, Ί, EGF, GMCSF, 94.212

3132 mps, CA125, MDK, EGF, GMCSF, 96.165 IL1RA, *2

IL1RA, *2 3159 mps, EMILIN, Ί, EGF, GMCSF, 93.111

3133 mps, CA125, MDK, EGF, GMCSF, 96.2 HE4, *2

HE4, *2 3160 mps, EMILIN, Ί, EGF, IL1RA, 94.389

3134 mps, CA125, MDK, EGF, IL1RA, 96.538 HE4, *2

HE4, *2 3161 mps, EMILIN, Ί, GMCSF, IL1RA, 94.567

3135 mps, CA125, MDK, GMCSF, 96.484 HE4, *2

IL1RA, HE4, *2 3162 mps, EMILIN, EGF, GMCSF, 92.862

3136 mps, CA125,*1, EGF, GMCSF, 94.602 IL1RA, HE4, *2

IL1RA, HE4 3163 mps, MDK, Ί, EGF, GMCSF, 93.572

3137 mps, CA125,*1, EGF, GMCSF, 94.744 IL1RA, HE4

IL1RA, *2 3164 mps, MDK, Ί, EGF, GMCSF, 93.963

3138 mps, CA125,*1, EGF, GMCSF, 94.531 IL1RA, *2

HE4, *2 3165 mps, MDK, Ί, EGF, GMCSF, HE4, 93.537

3139 mps, CA125, , EGF, IL1RA, HE4, 94.709 *2 3166 mps, MDK, , EGF, IL1RA, HE4, 94.034 GMCSF, *2

*2 3193 dps,CA125, EMIUN, Ί, EGF, 93.501

3167 mps, MDK, , GMCSF, IL1RA, 93.999 IL1RA, HE4

HE4, *2 3194 dps,CA125, EMIUN, Ί, EGF, 93.821

3168 mps, MDK, EGF, GMCSF, IL1RA, 92.365 IL1RA, *2

HE4, *2 3195 dps,CA125, EMIUN, Ί, EGF, 93.537

3169 mps, , EGF, GMCSF, IL1RA, 89.862 HE4, *2

HE4, *2 3196 dps,CA125, EMIUN, Ί, GMCSF, 93.608

3170 dps, CA125, EMIUN, MDK, Ί, 94.141 IL1RA, HE4

EGF, GMCSF 3197 dps,CA125, EMIUN, Ί, GMCSF, 94.105

3171 dps, CA125, EMIUN, MDK, Ί, 94.638 IL1RA, *2

EGF, IL1RA 3198 dps,CA125, EMIUN, Ί, GMCSF, 93.501

3172 dps, CA125, EMIUN, MDK, Ί, 94.744 HE4, *2

EGF, HE4 3199 dps,CA125, EMILIN, *1, IL1RA, 94.212

3173 dps, CA125, EMIUN, ΜϋΚ,Ί, 94.78 HE4, *2

EGF,*2 3200 dps, CA125, EMILIN, EGF, 92.951

3174 dps, CA125, EMIUN, MDK, Ί, 94.691 GMCSF, IL1RA, HE4

GMCSF, IL1RA 3201 dps, CA125, EMILIN, EGF, 93.395

3175 dps, CA125, EMIUN, MDK, Ί, 94.709 GMCSF, IL1RA, *2

GMCSF, HE4 3202 dps, CA125, EMILIN, EGF, 92.791

3176 dps, CA125, EMIUN, MDK, Ί, 94.957 GMCSF, HE4, *2

GMCSF, *2 3203 dps,CA125, EMILIN, EGF, IL1RA, 93.608

3177 dps, CA125, EMIUN, MDK, Ί, 94.815 HE4, *2

IL1RA, HE4 3204 dps, CA125, EMILIN, GMCSF, 93.59

3178 dps, CA125, EMIUN, MDK, Ί, 95.099 IL1RA, HE4, *2

IL1RA, *2 3205 dps,CA125, MDK, Ί, EGF, 94.744

3179 dps, CA125, EMIUN, MDK, Ί, 95.206 GMCSF, IL1RA

HE4, *2 3206 dps,CA125, MDK, Ί, EGF, 94.318

3180 dps, CA125, EMIUN, MDK, EGF, 93.857 GMCSF, HE4

GMCSF, IL1RA 3207 dps,CA125, MDK, Ί, EGF, 94.957

3181 dps, CA125, EMIUN, MDK, EGF, 93.892 GMCSF, *2

GMCSF, HE4 3208 dps,CA125, MDK, , EGF, IL1RA, 94.602

3182 dps, CA125, EMIUN, MDK, EGF, 94.389 HE4

GMCSF, *2 3209 dps,CA125, MDK, , EGF, IL1RA, 95.028

3183 dps, CA125, EMIUN, MDK, EGF, 94.07 *2

IL1RA, HE4 3210 dps,CA125, MDK, , EGF, HE4, 94.638

3184 dps, CA125, EMIUN, MDK, EGF, 94.638

IL1RA, *2 3211 dps,CA125, MDK, Ί, GMCSF, 94.425

3185 dps, CA125, EMIUN, MDK, EGF, 94.567 IL1RA, HE4

HE4, *2 3212 dps,CA125, MDK, Ί, GMCSF, 94.815

3186 dps, CA125, EMIUN, MDK, 94.247 IL1RA, *2

GMCSF, IL1RA, HE4 3213 dps,CA125, MDK, Ί, GMCSF, 94.709

3187 dps, CA125, EMIUN, MDK, 94.531 HE4, *2

GMCSF, IL1RA, *2 3214 dps,CA125, MDK, *1, IL1RA, HE4, 94.78

3188 dps, CA125, EMIUN, MDK, 94.407 *2

GMCSF, HE4, *2 3215 dps, CA125, MDK, EGF, GMCSF, 93.75

3189 dps, CA125, EMIUN, MDK, IL1RA, 94.709 IL1RA, HE4

HE4, *2 3216 dps, CA125, MDK, EGF, GMCSF, 94.496

3190 dps, CA125, EMIUN, Ί, EGF, 93.395 IL1RA, *2

GMCSF, IL1RA 3217 dps, CA125, MDK, EGF, GMCSF, 93.75

3191 dps, CA125, EMIUN, Ί, EGF, 92.756 HE4, *2

GMCSF, HE4 3218 dps,CA125, MDK, EGF, IL1RA, 94.496

3192 dps, CA125, EMIUN, Ί, EGF, 93.466 HE4, *2 3219 dps, CA125, MDK, GMCSF, IL1RA, 93.768 HE4, *2

HE4, *2 3246 dps, EMIUN, EGF, GMCSF, IL1RA, 85.636

3220 dps, CA125,*1,EGF, GMCSF, 92.045 HE4, *2

IL1RA, HE4 3247 dps, MDK, Ί, EGF, GMCSF, 89.915

3221 dps, CA125,*1,EGF, GMCSF, 92.294 IL1RA, HE4

IL1RA, *2 3248 dps, MDK, Ί, EGF, GMCSF, 90.909

3222 dps, CA125,*1,EGF, GMCSF, 91.584 IL1RA, *2

HE4, *2 3249 dps, MDK, Ί, EGF, GMCSF, HE4, 90.092

3223 dps, CA125, , EGF, IL1RA, HE4, 92.401 *2

*2 3250 dps, MDK, , EGF, IL1RA, HE4, *2 90.483

3224 dps, CA125, , GMCSF, IL1RA, 91.335 3251 dps, MDK, Ί, GMCSF, IL1RA, 90.767 HE4, *2 HE4, *2

3225 dps, CA125, EGF, GMCSF, IL1RA, 91.797 3252 dps, MDK, EGF, GMCSF, IL1RA, 87.251 HE4, *2 HE4, *2

3226 dps, EMIUN, MDK, Ί, EGF, 90.572 3253 dps, , EGF, GMCSF, IL1RA, 84.677 GMCSF, IL1RA HE4, *2

3227 dps, EMIUN, MDK, Ί, EGF, 90.199 3254 CA125, EMIUN, MDK, , EGF, 91.442 GMCSF, HE4 GMCSF, IL1RA

3228 dps, EMIUN, MDK, Ί, EGF, 91.335 3255 CA125, EMIUN, MDK, , EGF, 91.158 GMCSF, *2 GMCSF, HE4

3229 dps, EMIUN, MDK, Ί, EGF, 90.643 3256 CA125, EMIUN, MDK, , EGF, 91.317 IL1RA, HE4 GMCSF, *2

3230 dps, EMIUN, MDK, Ί, EGF, 91.797 3257 CA125, EMIUN, MDK, , EGF, 91.548 IL1RA, *2 IL1RA, HE4

3231 dps, EMIUN, MDK, Ί, EGF, HE4, 91.655 3258 CA125, EMIUN, MDK, , EGF, 91.903

*2 IL1RA, *2

3232 dps, EMIUN, MDK, Ί, GMCSF, 91.016 3259 CA125, EMIUN, MDK, , EGF, 91.548 IL1RA, HE4 HE4, *2

3233 dps, EMIUN, MDK, Ί, GMCSF, 91.726 3260 CA125, EMIUN, MDK, , GMCSF, 91.726 IL1RA, *2 IL1RA, HE4

3234 dps, EMIUN, MDK, Ί, GMCSF, 92.081 3261 CA125, EMIUN, MDK, , GMCSF, 91.903 HE4, *2 IL1RA, *2

3235 dps, EMIUN, MDK, *1, IL1 A, HE4, 92.223 3262 CA125, EMIUN, MDK, , GMCSF, 91.974

*2 HE4, *2

3236 dps, EMIUN, MDK, EGF, GMCSF, 87.145 3263 CA125, EMIUN, MDK, *1, IL1RA, 92.081 IL1RA, HE4 HE4, *2

3237 dps, EMIUN, MDK, EGF, GMCSF, 89.276 3264 CA125, EMIUN, MDK, EGF, 90.554 IL1RA, *2 GMCSF, IL1RA, HE4

3238 dps, EMIUN, MDK, EGF, GMCSF, 88.228 3265 CA125, EMIUN, MDK, EGF, 90.447 HE4, *2 GMCSF, IL1RA, *2

3239 dps, EMIUN, MDK, EGF, IL1RA, 89.222 3266 CA125, EMIUN, MDK, EGF, 90.128 HE4, *2 GMCSF, HE4, *2

3240 dps, EMIUN, MDK, GMCSF, 89.915 3267 CA125, EMIUN, MDK, EGF, IL1RA, 91.193 IL1RA, HE4, *2 HE4, *2

3241 dps, EMIUN, Ί, EGF, GMCSF, 87.109 3268 CA125, EMIUN, MDK, GMCSF, 91.264 IL1RA, HE4 IL1RA, HE4, *2

3242 dps, EMIUN, Ί, EGF, GMCSF, 88.068 3269 CA125, EMIUN, Ί, EGF, GMCSF, 88.53 IL1RA, *2 IL1RA, HE4

3243 dps, EMIUN, Ί, EGF, GMCSF, 86.506 3270 CA125, EMIUN, Ί, EGF, GMCSF, 89.24 HE4, *2 IL1RA, *2

3244 dps, EMIUN, Ί, EGF, IL1RA, HE4, 88.849 3271 CA125, EMIUN, Ί, EGF, GMCSF, 88.548

*2 HE4, *2

3245 dps, EMIUN, Ί, GMCSF, IL1RA, 89.205 3272 CA125, EMIUN, Ί, EGF, IL1RA, 88.672 HE4, *2 3299 ips, mps, dps, CA125, EMIUN, 98.331

3273 CA125, EMIUN, Ί, GMCSF, 89.702 MDK, GMCSF, IL1RA

IL1RA, HE4, *2 3300 ips, mps, dps, CA125, EMIUN, 98.082

3274 CA125, EMIUN, EGF, GMCSF, 87.536 MDK, GMCSF, HE4

IL1RA, HE4, *2 3301 ips, mps, dps, CA125, EMIUN, 97.976

3275 CA125, MDK,*1, EGF, GMCSF, 90.092 MDK, GMCSF, *2

IL1RA, HE4 3302 ips, mps, dps, CA125, EMIUN, 98.295

3276 CA125, MDK,*1, EGF, GMCSF, 89.95 MDK, IL1RA, HE4

IL1RA, *2 3303 ips, mps, dps, CA125, EMIUN, 98.295

3277 CA125, MDK,*1, EGF, GMCSF, 89.968 MDK, I LIRA, *2

HE4, *2 3304 ips, mps, dps, CA125, EMIUN, 98.047

3278 CA125, MDK, , EGF, IL1RA, 90.27 MDK, HE4, *2

HE4, *2 3305 ips, mps, dps, CA125, EMIUN, Ί, 97.905

3279 CA125, MDK, Ί, GMCSF, IL1RA, 90.447 EGF, GMCSF

HE4, *2 3306 ips, mps, dps, CA125, EMIUN, Ί, 98.153

3280 CA125, MDK, EGF, GMCSF, 87.962 EGF, IL1RA

IL1RA, HE4, *2 3307 ips, mps, dps, CA125, EMIUN, Ί, 98.047

3281 CA125, , EGF, GMCSF, IL1RA, 83.097 EGF, HE4

HE4, *2 3308 ips, mps, dps, CA125, EMIUN, Ί, 98.118

3282 EMIUN, MDK, Ί, EGF, GMCSF, 83.203 EGF, *2

IL1RA, HE4 3309 ips, mps, dps, CA125, EMIUN, Ί, 98.082

3283 EMIUN, MDK, Ί, EGF, GMCSF, 83.736 GMCSF, IL1RA

IL1RA, *2 3310 ips, mps, dps, CA125, EMIUN, Ί, 98.082

3284 EMIUN, MDK, Ί, EGF, GMCSF, 83.896 GMCSF, HE4

HE4, *2 3311 ips, mps, dps, CA125, EMIUN, Ί, 98.082

3285 EMIUN, MDK, *1, EGF, IL1RA, 83.736 GMCSF, *2

HE4, *2 3312 ips, mps, dps, CA125, EMIUN, Ί, 98.26

3286 EMIUN, MDK, Ί, GMCSF, IL1RA, 84.268 IL1RA, HE4

HE4, *2 3313 ips, mps, dps, CA125, EMIUN, Ί, 98.189

3287 EMIUN, MDK, EGF, GMCSF, 79.936 IL1RA, *2

IL1RA, HE4, *2 3314 ips, mps, dps, CA125, EMIUN, Ί, 98.224

3288 EMIUN, Ί, EGF, GMCSF, IL1RA, 76.385 HE4, *2

HE4, *2 3315 ips, mps, dps, CA125, EMIUN, 98.082

3289 MDK, Ί, EGF, GMCSF, IL1RA, 79.048 EGF, GMCSF, IL1RA

HE4, *2 3316 ips, mps, dps, CA125, EMIUN, 97.905

3290 ips, mps, dps, CA125, EMIUN, 98.011 EGF, GMCSF, HE4

ΜϋΚ,Ί, EGF 3317 ips, mps, dps, CA125, EMIUN, 97.976

3291 ips, mps, dps, CA125, EMIUN, 98.082 EGF, GMCSF, *2

MDK, Ί, GMCSF 3318 ips, mps, dps, CA125, EMIUN, 98.26

3292 ips, mps, dps, CA125, EMIUN, 98.153 EGF, IL1RA, HE4

MDK, *1, IL1RA 3319 ips, mps, dps, CA125, EMIUN, 98.224

3293 ips, mps, dps, CA125, EMIUN, 98.047 EGF, IL1RA, *2

ΜϋΚ,Ί, HE4 3320 ips, mps, dps, CA125, EMIUN, 98.082

3294 ips, mps, dps, CA125, EMIUN, 98.047 EGF, HE4, *2

MDK,*1,*2 3321 ips, mps, dps, CA125, EMIUN, 98.224

3295 ips, mps, dps, CA125, EMIUN, 98.153 GMCSF, IL1RA, HE4

MDK, EGF, GMCSF 3322 ips, mps, dps, CA125, EMIUN, 98.082

3296 ips, mps, dps, CA125, EMIUN, 98.295 GMCSF, IL1RA, *2

MDK, EGF, IL1RA 3323 ips, mps, dps, CA125, EMIUN, 98.118

3297 ips, mps, dps, CA125, EMIUN, 98.082 GMCSF, HE4, *2

MDK, EGF, HE4 3324 ips, mps, dps, CA125, EMIUN, 98.295

3298 ips, mps, dps, CA125, EMIUN, 98.082 IL1RA, HE4, *2

MDK, EGF, *2 3325 ips, mps, dps, CA125, MDK, Ί, 97.763 EGF, GMCSF 3352 ips, mps, dps, CA125, , GMCSF, 96.733

3326 ips, mps, dps, CA125, MDK, Ί , 97.834 IL1 RA, *2

EGF, IL1 RA 3353 ips, mps, dps, CA125, , GMCSF, 96.946

3327 ips, mps, dps, CA125, MDK, Ί , 98.047 HE4, *2

EGF, HE4 3354 ips, mps, dps, CA125, , IL1 RA, 96.911

3328 ips, mps, dps, CA125, MDK, Ί , 97.905 HE4, *2

EGF, *2 3355 ips, mps, dps, CA125, EGF, 97.088

3329 ips, mps, dps, CA125, MDK, Ί , 97.869 GMCSF, IL1 RA, HE4

GMCSF, IL1 RA 3356 ips, mps, dps, CA125, EGF, 96.946

3330 ips, mps, dps, CA125, MDK, Ί , 97.798 GMCSF, IL1 RA, *2

GMCSF, HE4 3357 ips, mps, dps, CA125, EGF, 97.088

3331 ips, mps, dps, CA125, MDK, Ί , 97.674 GMCSF, HE4, *2

GMCSF, *2 3358 ips, mps, dps, CA125, EGF, I LI RA, 97.23

3332 ips, mps, dps, CA125, MDK, Ί , 97.905 HE4, *2

IL1 RA, HE4 3359 ips, mps, dps, CA125, GMCSF, 96.911

3333 ips, mps, dps, CA125, MDK, Ί , 97.869 IL1 RA, HE4, *2

IL1 RA, *2 3360 ips, mps, dps, EMILIN, MDK, , 95.881

3334 ips, mps, dps, CA125, MDK, Ί , 97.798 EGF, GMCSF

HE4, *2 3361 ips, mps, dps, EMILIN, MDK, Ί, 96.697

3335 ips, mps, dps, CA125, MDK, EGF, 97.692 EGF, IL1 RA

GMCSF, IL1 RA 3362 ips, mps, dps, EMILIN, MDK, Ί, 95.81

3336 ips, mps, dps, CA125, MDK, EGF, 97.798 EGF, HE4

GMCSF, HE4 3363 ips, mps, dps, EMILIN, MDK, Ί, 95.916

3337 ips, mps, dps, CA125, MDK, EGF, 97.692 EGF, *2

GMCSF, *2 3364 ips, mps, dps, EMILIN, MDK, Ί, 96.413

3338 ips, mps, dps, CA125, MDK, EGF, 97.834 GMCSF, IL1 RA

IL1 RA, HE4 3365 ips, mps, dps, EMILIN, MDK, Ί, 95.774

3339 ips, mps, dps, CA125, MDK, EGF, 97.727 GMCSF, HE4

IL1 RA, *2 3366 ips, mps, dps, EMILIN, MDK, Ί, 95.987

3340 ips, mps, dps, CA125, MDK, EGF, 97.834 GMCSF, *2

HE4, *2 3367 ips, mps, dps, EMILIN, MDK, Ί, 96.768

3341 ips, mps, dps, CA125, MDK, 97.656 IL1 RA, HE4

GMCSF, IL1 RA, HE4 3368 ips, mps, dps, EMILIN, MDK, Ί, 96.431

3342 ips, mps, dps, CA125, MDK, 97.656 IL1 RA, *2

GMCSF, IL1 RA, *2 3369 ips, mps, dps, EMILIN, MDK, Ί, 95.703

3343 ips, mps, dps, CA125, MDK, 97.692 HE4, *2

GMCSF, HE4, *2 3370 ips, mps, dps, EMILIN, MDK, EGF, 96.449

3344 ips, mps, dps, CA125, MDK, I LI RA, 97.798 GMCSF, IL1 RA

HE4, *2 3371 ips, mps, dps, EMILIN, MDK, EGF, 95.632

3345 ips, mps, dps, CA125, *1 , EGF, 96.911 GMCSF, HE4

GMCSF, IL1 RA 3372 ips, mps, dps, EMILIN, MDK, EGF, 95.668

3346 ips, mps, dps, CA125, *1 , EGF, 97.124 GMCSF, *2

GMCSF, HE4 3373 ips, mps, dps, EMILIN, MDK, EGF, 96.342

3347 ips, mps, dps, CA125, *1 , EGF, 96.822 IL1 RA, HE4

GMCSF, *2 3374 ips, mps, dps, EMILIN, MDK, EGF, 96.52

3348 ips, mps, dps, CA125, *1 , EGF, 97.195 IL1 RA, *2

IL1 RA, HE4 3375 ips, mps, dps, EMILIN, MDK, EGF, 95.526

3349 ips, mps, dps, CA125, *1 , EGF, 97.017 HE4, *2

IL1 RA, *2 3376 ips, mps, dps, EMILIN, MDK, 96.697

3350 ips, mps, dps, CA125, *1 , EGF, 97.23 GMCSF, IL1 RA, HE4

HE4, *2 3377 ips, mps, dps, EMILIN, MDK, 96.342

3351 ips, mps, dps, CA125, , GMCSF, 96.875 GMCSF, IL1 RA, *2

IL1 RA, HE4 3378 ips, mps, dps, EMILIN, MDK, 95.526 GMCSF, HE4, *2 3405 ips, mps, dps, MDK, EGF, GMCSF, 95.277

3379 ips, mps, dps, EMILIN, MDK, 96.449 IL1RA, HE4

IL1RA, HE4, *2 3406 ips, mps, dps, MDK, EGF, GMCSF, 94.886

3380 ips, mps, dps, EMILIN, Ί, EGF, 95.969 IL1RA, *2

GMCSF, IL1RA 3407 ips, mps, dps, MDK, EGF, GMCSF, 94.638

3381 ips, mps, dps, EMILIN, Ί, EGF, 94.886 HE4, *2

GMCSF, HE4 3408 ips, mps, dps, MDK, EGF, IL1RA, 94.922

3382 ips, mps, dps, EMILIN, Ί, EGF, 94.993 HE4, *2

GMCSF, *2 3409 ips, mps, dps, MDK, GMCSF, 95.011

3383 ips, mps, dps, EMILIN, Ί, EGF, 96.271 IL1RA, HE4, *2

IL1RA, HE4 3410 ips, mps, dps, , EGF, GMCSF, 93.288

3384 ips, mps, dps, EMILIN, Ί, EGF, 96.165 IL1RA, HE4

IL1RA, *2 3411 ips, mps, dps, , EGF, GMCSF, 93.537

3385 ips, mps, dps, EMILIN, Ί, EGF, 95.099 IL1RA, *2

HE4, *2 3412 ips, mps, dps, , EGF, GMCSF, 92.898

3386 ips, mps, dps, EMILIN, Ί, GMCSF, 96.165 HE4, *2

IL1RA, HE4 3413 ips, mps, dps, , EGF, IL1RA, 93.466

3387 ips, mps, dps, EMILIN, Ί, GMCSF, 96.342 HE4, *2

IL1RA, *2 3414 ips, mps, dps, , GMCSF, IL1RA, 93.359

3388 ips, mps, dps, EMILIN, Ί, GMCSF, 95.153 HE4, *2

HE4, *2 3415 ips, mps, dps, EGF, GMCSF, 93.288

3389 ips, mps, dps, EMILIN, *1, IL1RA, 96.2 IL1RA, HE4, *2

HE4, *2 3416 ips, mps, CA125, EMILIN, MDK, Ί, 98.26

3390 ips, mps, dps, EMILIN, EGF, 96.307 EGF, GMCSF

GMCSF, IL1RA, HE4 3417 ips, mps, CA125, EMILIN, MDK, Ί, 98.438

3391 ips, mps, dps, EMILIN, EGF, 95.756 EGF, IL1RA

GMCSF, IL1RA, *2 3418 ips, mps, CA125, EMILIN, MDK, , 98.26

3392 ips, mps, dps, EMILIN, EGF, 94.886 EGF, HE4

GMCSF, HE4, *2 3419 ips, mps, CA125, EMILIN, MDK, Ί, 98.295

3393 ips, mps, dps, EMILIN, EGF, 96.2 EGF, *2

IL1RA, HE4, *2 3420 ips, mps, CA125, EMILIN, MDK, Ί, 98.58

3394 ips, mps, dps, EMILIN, GMCSF, 96.129 GMCSF, IL1RA

IL1RA, HE4, *2 3421 ips, mps, CA125, EMILIN, MDK, Ί, 98.26

3395 ips, mps, dps, MDK, Ί, EGF, 95.135 GMCSF, HE4

GMCSF, IL1RA 3422 ips, mps, CA125, EMILIN, MDK, Ί, 98.366

3396 ips, mps, dps, MDK, Ί, EGF, 94.957 GMCSF, *2

GMCSF, HE4 3423 ips, mps, CA125, EMILIN, MDK, Ί, 98.544

3397 ips, mps, dps, MDK, Ί, EGF, 95.028 IL1RA, HE4

GMCSF, *2 3424 ips, mps, CA125, EMILIN, MDK, Ί, 98.58

3398 ips, mps, dps, MDK, Ί, EGF, 95.295 IL1RA, *2

IL1RA, HE4 3425 ips, mps, CA125, EMILIN, MDK, Ί, 98.295

3399 ips, mps, dps, MDK, Ί, EGF, 95.437 HE4, *2

IL1RA, *2 3426 ips, mps, CA125, EMILIN, MDK, 98.651

3400 ips, mps, dps, MDK, , EGF, HE4, 94.869 EGF, GMCSF, IL1RA

*2 3427 ips, mps, CA125, EMILIN, MDK, 98.473

3401 ips, mps, dps, MDK, Ί, GMCSF, 95.348 EGF, GMCSF, HE4

IL1RA, HE4 3428 ips, mps, CA125, EMILIN, MDK, 98.509

3402 ips, mps, dps, MDK, Ί, GMCSF, 95.206 EGF, GMCSF, *2

IL1RA, *2 3429 ips, mps, CA125, EMILIN, MDK, 98.651

3403 ips, mps, dps, MDK, Ί, GMCSF, 95.028 EGF, IL1RA, HE4

HE4, *2 3430 ips, mps, CA125, EMILIN, MDK, 98.615

3404 ips, mps, dps, MDK, Ί, IL1RA, 95.241 EGF, IL1RA, *2

HE4, *2 3431 ips, mps, CA125, EMILIN, MDK, 98.402 EGF, HE4, *2 3458 ips, mps, CA125, ΜϋΚ,Ί, 97.976

3432 ips, mps, CA125, EMILIN, MDK, 98.615 GMCSF, IL1RA, *2

GMCSF, IL1RA, HE4 3459 ips, mps, CA125, ΜϋΚ,Ί, 97.976

3433 ips, mps, CA125, EMILIN, MDK, 98.651 GMCSF, HE4, *2

GMCSF, IL1RA, *2 3460 ips, mps, CA125, MDK, *1, IL1RA, 98.047

3434 ips, mps, CA125, EMILIN, MDK, 98.491 HE4, *2

GMCSF, HE4, *2 3461 ips, mps, CA125, MDK, EGF, 98.082

3435 ips, mps, CA125, EMILIN, MDK, 98.651 GMCSF, IL1RA, HE4

IL1RA, HE4, *2 3462 ips, mps, CA125, MDK, EGF, 97.834

3436 ips, mps, CA125, EMILIN, Ί, EGF, 98.295 GMCSF, IL1RA, *2

GMCSF, IL1RA 3463 ips, mps, CA125, MDK, EGF, 98.011

3437 ips, mps, CA125, EMILIN, Ί, EGF, 98.136 GMCSF, HE4, *2

GMCSF, HE4 3464 ips, mps, CA125, MDK, EGF, 97.905

3438 ips, mps, CA125, EMILIN, Ί, EGF, 98.153 IL1RA, HE4, *2

GMCSF, *2 3465 ips, mps, CA125, MDK, GMCSF, 98.047

3439 ips, mps, CA125, EMILIN, Ί, EGF, 98.402 IL1RA, HE4, *2

IL1RA, HE4 3466 ips,mps,CA125,*1, EGF.GMCSF, 97.124

3440 ips, mps, CA125, EMILIN, Ί, EGF, 98.331 IL1RA, HE4

IL1RA, *2 3467 ips,mps,CA125,*1, EGF.GMCSF, 97.017

3441 ips, mps, CA125, EMILIN, Ί, EGF, 98.224 IL1RA, *2

HE4, *2 3468 ips,mps,CA125,*1, EGF.GMCSF, 96.946

3442 ips, mps, CA125, EMILIN, Ί, 98.331 HE4, *2

GMCSF, IL1RA, HE4 3469 ips,mps,CA125,*1, EGF, IL1RA, 97.159

3443 ips, mps, CA125, EMILIN, Ί, 98.295 HE4, *2

GMCSF, IL1RA, *2 3470 ips, mps, CA125, *1, GMCSF, 96.839

3444 ips, mps, CA125, EMILIN, Ί, 98.26 IL1RA, HE4, *2

GMCSF, HE4, *2 3471 ips, mps, CA125, EGF, GMCSF, 97.017

3445 ips, mps, CA125, EMILIN, Ί, 98.473 IL1RA, HE4, *2

IL1RA, HE4, *2 3472 ips, mps, EMILIN, MDK, Ί, EGF, 96.342

3446 ips, mps, CA125, EMILIN, EGF, 98.438 GMCSF, IL1RA

GMCSF, IL1RA, HE4 3473 ips, mps, EMILIN, MDK, Ί, EGF, 95.916

3447 ips, mps, CA125, EMILIN, EGF, 98.366 GMCSF, HE4

GMCSF, IL1RA, *2 3474 ips, mps, EMILIN, MDK, Ί, EGF, 96.094

3448 ips, mps, CA125, EMILIN, EGF, 98.1 GMCSF, *2

GMCSF, HE4, *2 3475 ips, mps, EMILIN, MDK, Ί, EGF, 96.662

3449 ips, mps, CA125, EMILIN, EGF, 98.366 IL1RA, HE4

IL1RA, HE4, *2 3476 ips, mps, EMILIN, MDK, Ί, EGF, 96.733

3450 ips, mps, CA125, EMILIN, GMCSF, 98.438 IL1RA, *2

IL1RA, HE4, *2 3477 ips, mps, EMILIN, MDK, Ί, EGF, 96.165

3451 ips, mps, CA125, MDK, , EGF, 98.011 HE4, *2

GMCSF, IL1RA 3478 ips, mps, EMILIN, MDK, Ί, 96.555

3452 ips, mps, CA125, MDK, , EGF, 98.047 GMCSF, IL1RA, HE4

GMCSF, HE4 3479 ips, mps, EMILIN, MDK, Ί, 96.449

3453 ips, mps, CA125, MDK, , EGF, 97.905 GMCSF, IL1RA, *2

GMCSF, *2 3480 ips, mps, EMILIN, MDK, Ί, 95.774

3454 ips, mps, CA125, MDK, , EGF, 98.118 GMCSF, HE4, *2

IL1RA, HE4 3481 ips, mps, EMILIN, MDK, *1 JURA, 96.733

3455 ips, mps, CA125, MDK, , EGF, 97.976 HE4, *2

IL1RA, *2 3482 ips, mps, EMILIN, MDK, EGF, 96.662

3456 ips, mps, CA125, MDK, , EGF, 97.976 GMCSF, IL1RA, HE4

HE4, *2 3483 ips, mps, EMILIN, MDK, EGF, 96.52

3457 ips, mps, CA125, MDK, Ί, 98.047 GMCSF, IL1RA, *2

GMCSF, IL1RA, HE4 3484 ips, mps, EMILIN, MDK, EGF, 95.668 GMCSF, HE4, *2 3511 ips, dps, CA125, EMIUN, MDK, 96.804

3485 ips, mps, EMIUN, MDK, EGF, 96.697 EGF, GMCSF, HE4

IL1RA, HE4, *2 3512 ips, dps, CA125, EMIUN, MDK, 97.195

3486 ips, mps, EMIUN, MDK, GMCSF, 96.626 EGF, GMCSF, *2

IL1RA, HE4, *2 3513 ips, dps, CA125, EMIUN, MDK, 97.088

3487 ips, mps, EMIUN, Ί, EGF, 95.916 EGF, IL1RA, HE4

GMCSF, IL1RA, HE4 3514 ips, dps, CA125, EMIUN, MDK, 97.443

3488 ips, mps, EMIUN, Ί, EGF, 95.739 EGF, IL1RA, *2

GMCSF, IL1RA, *2 3515 ips, dps, CA125, EMIUN, MDK, 96.804

3489 ips, mps, EMIUN, Ί, EGF, 94.851 EGF, HE4, *2

GMCSF, HE4, *2 3516 ips, dps, CA125, EMIUN, MDK, 97.088

3490 ips, mps, EMIUN, Ί, EGF, IL1RA, 96.165 GMCSF, IL1RA, HE4

HE4, *2 3517 ips, dps, CA125, EMIUN, MDK, 97.301

3491 ips, mps, EMIUN, Ί, GMCSF, 96.058 GMCSF, IL1RA, *2

IL1RA, HE4, *2 3518 ips, dps, CA125, EMIUN, MDK, 97.124

3492 ips, mps, EMIUN, EGF, GMCSF, 96.023 GMCSF, HE4, *2

IL1RA, HE4, *2 3519 ips, dps, CA125, EMIUN, MDK, 97.443

3493 ips, mps, MDK, Ί, EGF, GMCSF, 94.957 IL1RA, HE4, *2

IL1RA, HE4 3520 ips, dps, CA125, EMIUN, , EGF, 96.413

3494 ips, mps, MDK, Ί, EGF, GMCSF, 95.099 GMCSF, IL1RA

IL1RA, *2 3521 ips, dps, CA125, EMIUN, Ί, EGF, 96.165

3495 ips, mps, MDK, Ί, EGF, GMCSF, 94.833 GMCSF, HE4

HE4, *2 3522 ips, dps, CA125, EMIUN, , EGF, 96.2

3496 ips, mps, MDK, , EGF, IL1RA, 95.206 GMCSF, *2

HE4, *2 3523 ips, dps, CA125, EMIUN, , EGF, 96.484

3497 ips, mps, MDK, Ί, GMCSF, IL1RA, 95.135 IL1RA, HE4

HE4, *2 3524 ips, dps, CA125, EMIUN, , EGF, 96.52

3498 ips, mps, MDK, EGF, GMCSF, 94.851 IL1RA, *2

IL1RA, HE4, *2 3525 ips, dps, CA125, EMIUN, , EGF, 96.413

3499 ips, mps, , EGF.GMCSF, IL1RA, 92.862 HE4, *2

HE4, *2 3526 ips, dps, CA125, EMIUN, , 96.378

3500 ips, dps, CA125, EMIUN, MDK, , 97.124 GMCSF, IL1RA, HE4

EGF.GMCSF 3527 ips, dps, CA125, EMIUN, , 96.342

3501 ips, dps, CA125, EMIUN, MDK, , 97.461 GMCSF, IL1RA, *2

EGF, IL1RA 3528 ips, dps, CA125, EMIUN, , 96.129

3502 ips, dps, CA125, EMIUN, MDK, , 97.159 GMCSF, HE4, *2

EGF, HE4 3529 ips, dps, CA125, EMIUN, , 96.591

3503 ips, dps, CA125, EMIUN, MDK, , 97.514 IL1RA, HE4, *2

EGF,*2 3530 ips, dps, CA125, EMIUN, EGF, 96.307

3504 ips, dps, CA125, EMIUN, MDK, , 97.195 GMCSF, IL1RA, HE4

GMCSF, IL1RA 3531 ips, dps, CA125, EMIUN, EGF, 96.378

3505 ips, dps, CA125, EMIUN, MDK, , 97.088 GMCSF, IL1RA, *2

GMCSF, HE4 3532 ips, dps, CA125, EMIUN, EGF, 96.342

3506 ips, dps, CA125, EMIUN, MDK, , 97.088 GMCSF, HE4, *2

GMCSF, *2 3533 ips, dps, CA125, EMIUN, EGF, 96.804

3507 ips, dps, CA125, EMIUN, MDK, , 97.408 IL1RA, HE4, *2

IL1RA, HE4 3534 ips, dps, CA125, EMIUN, GMCSF, 96.484

3508 ips, dps, CA125, EMIUN, MDK, Ί, 97.479 IL1RA, HE4, *2

IL1RA, *2 3535 ips, dps, CA125, MDK, Ί, EGF, 97.337

3509 ips, dps, CA125, EMIUN, MDK, , 97.248 GMCSF, IL1RA

HE4, *2 3536 ips, dps, CA125, MDK, Ί, EGF, 97.088

3510 ips, dps, CA125, EMIUN, MDK, 97.053 GMCSF, HE4

EGF.GMCSF, IL1RA 3537 ips, dps, CA125, MDK, Ί, EGF, 97.159 GMCSF,*2 3564 ips, dps, EMILIN, MDK, Ί, 93.768

3538 ips, dps, CA125, MDK, , EGF, 96.911 GMCSF, HE4, *2

IL1RA, HE4 3565 ips, dps, EMILIN, MDK, *1 JURA, 93.643

3539 ips, dps, CA125, MDK, , EGF, 96.982 HE4, *2

IL1RA, *2 3566 ips, dps, EMILIN, MDK, EGF, 92.259

3540 ips, dps, CA125, MDK, , EGF, 96.733 GMCSF, IL1RA, HE4

HE4, *2 3567 ips, dps, EMILIN, MDK, EGF, 93.004

3541 ips, dps, CA125, MDK,*1,GMCSF, 97.053 GMCSF, IL1RA, *2

IL1RA, HE4 3568 ips, dps, EMILIN, MDK, EGF, 92.152

3542 ips, dps, CA125, MDK,*1,GMCSF, 97.017 GMCSF, HE4, *2

IL1RA, *2 3569 ips, dps, EMILIN, MDK, EGF, 92.756

3543 ips, dps, CA125, MDK,*1,GMCSF, 96.804 IL1RA, HE4, *2

HE4, *2 3570 ips, dps, EMILIN, MDK, GMCSF, 92.951

3544 ips, dps, CA125, MDK, *1, IL1RA, 96.573 IL1RA, HE4, *2

HE4, *2 3571 ips, dps, EMILIN, Ί, EGF.GMCSF, 92.116

3545 ips, dps, CA125, MDK, EGF, 96.839 IL1RA, HE4

GMCSF, IL1RA, HE4 3572 ips, dps, EMILIN, Ί, EGF.GMCSF, 92.134

3546 ips, dps, CA125, MDK, EGF, 96.911 IL1RA, *2

GMCSF, IL1RA, *2 3573 ips, dps, EMILIN, Ί, EGF.GMCSF, 91.903

3547 ips, dps, CA125, MDK, EGF, 96.911 HE4, *2

GMCSF, HE4, *2 3574 ips, dps, EMILIN, Ί, EGF, IL1RA, 92.436

3548 ips, dps, CA125, MDK, EGF, 96.52 HE4, *2

IL1RA, HE4, *2 3575 ips, dps, EMILIN, Ί, GMCSF, 92.631

3549 ips, dps, CA125, MDK, GMCSF, 96.591 IL1RA, HE4, *2

IL1RA, HE4, *2 3576 ips, dps, EMILIN, EGF.GMCSF, 91.016

3550 ips, dps, CA125,*1, EGF.GMCSF, 95.987 IL1RA, HE4, *2

IL1RA, HE4 3577 ips, dps, MDK, Ί, EGF, GMCSF, 93.892

3551 ips, dps, CA125,*1, EGF.GMCSF, 95.703 IL1RA, HE4

IL1RA, *2 3578 ips, dps, MDK, Ί, EGF, GMCSF, 94.141

3552 ips, dps, CA125,*1, EGF.GMCSF, 95.987 IL1RA, *2

HE4, *2 3579 ips, dps, MDK, Ί, EGF, GMCSF, 93.572

3553 ips, dps, CA125, , EGF, IL1RA, 95.987 HE4, *2

HE4, *2 3580 ips, dps, MDK, , EGF, IL1RA, 93.04

3554 ips, dps, CA125,*1, GMCSF, 95.348 HE4, *2

IL1RA, HE4, *2 3581 ips, dps, MDK, Ί, GMCSF, IL1RA, 93.892

3555 ips, dps, CA125, EGF.GMCSF, 95.81 HE4, *2

IL1RA, HE4, *2 3582 ips, dps, MDK, EGF, GMCSF, 92.347

3556 ips, dps, EMILIN, MDK, , EGF, 93.413 IL1RA, HE4, *2

GMCSF, IL1RA 3583 ips, dps, , EGF, GMCSF, IL1RA, 91.122

3557 ips, dps, EMILIN, MDK, Ί, EGF, 92.862 HE4, *2

GMCSF, HE4 3584 ips, CA125, EMILIN, MDK, Ί, EGF, 96.52

3558 ips, dps, EMILIN, MDK, Ί, EGF, 93.324 GMCSF, IL1RA

GMCSF, *2 3585 ips, CA125, EMILIN, MDK, Ί, EGF, 96.449

3559 ips, dps, EMILIN, MDK, Ί, EGF, 93.004 GMCSF, HE4

IL1RA, HE4 3586 ips, CA125, EMILIN, MDK, Ί, EGF, 96.413

3560 ips, dps, EMILIN, MDK, Ί, EGF, 93.928 GMCSF, *2

IL1RA, *2 3587 ips, CA125, EMILIN, MDK, Ί, EGF, 96.555

3561 ips, dps, EMILIN, MDK, Ί, EGF, 93.501 IL1RA, HE4

HE4, *2 3588 ips, CA125, EMILIN, MDK, Ί, EGF, 96.768

3562 ips, dps, EMILIN, MDK, Ί, 93.377 IL1RA, *2

GMCSF, IL1RA, HE4 3589 ips, CA125, EMILIN, MDK, Ί, EGF, 96.484

3563 ips, dps, EMILIN, MDK, Ί, 94.016 HE4, *2

GMCSF, IL1RA, *2 3590 ips, CA125, EMILIN, MDK, Ί, 96.449 GMCSF, IL1RA, HE4 3617 ips, EMILIN, MDK, EGF, GMCSF, 90.341

3591 ips, CA125, EMILIN, MDK, *1, 96.555 IL1RA, HE4, *2

GMCSF, IL1RA, *2 3618 ips, EMILIN, Ί, EGF, GMCSF, 88.281

3592 ips, CA125, EMILIN, MDK, Ί, 96.591 IL1RA, HE4, *2

GMCSF, HE4, *2 3619 ips, MDK, Ί, EGF, GMCSF, IL1RA, 90.856

3593 ips, CA125, EMILIN, MDK, Ί, 96.697 HE4, *2

IL1RA, HE4, *2 3620 mps, dps, CA125, EMILIN, MDK, 97.443

3594 ips, CA125, EMILIN, MDK, EGF, 96.236 , EGF, GMCSF

GMCSF, IL1RA, HE4 3621 mps, dps, CA125, EMILIN, MDK, 97.674

3595 ips, CA125, EMILIN, MDK, EGF, 96.662 , EGF, IL1RA

GMCSF, IL1RA, *2 3622 mps, dps, CA125, EMILIN, MDK, 97.479

3596 ips, CA125, EMILIN, MDK, EGF, 96.289 , EGF, HE4

GMCSF, HE4, *2 3623 mps, dps, CA125, EMILIN, MDK, 97.55

3597 ips, CA125, EMILIN, MDK, EGF, 96.591 *1, EGF, *2

IL1RA, HE4, *2 3624 mps, dps, CA125, EMILIN, MDK, 97.656

3598 ips, CA125, EMILIN, MDK, 96.697 , GMCSF, IL1RA

GMCSF, IL1RA, HE4,*2 3625 mps, dps, CA125, EMILIN, MDK, 97.55

3599 ips, CA125, EMILIN, Ί, EGF, 95.028 Ί, GMCSF, HE4

GMCSF, IL1RA, HE4 3626 mps, dps, CA125, EMILIN, MDK, 97.585

3600 ips, CA125, EMILIN, Ί, EGF, 95.419 , GMCSF, *2

GMCSF, IL1RA, *2 3627 mps, dps, CA125, EMILIN, MDK, 97.656

3601 ips, CA125, EMILIN, Ί, EGF, 95.064 *1,IL1RA, HE4

GMCSF, HE4, *2 3628 mps, dps, CA125, EMILIN, MDK, 97.656

3602 ips, CA125, EMILIN, Ί, EGF, 95.455 *1,IL1RA, *2

IL1RA, HE4, *2 3629 mps, dps, CA125, EMILIN, MDK, 97.621

3603 ips, CA125, EMILIN, Ί, GMCSF, 95.561 Ί,ΗΕ4,*2

IL1RA, HE4, *2 3630 mps, dps, CA125, EMILIN, MDK, 97.55

3604 ips, CA125, EMILIN, EGF, GMCSF, 95.295 EGF, GMCSF, IL1RA

IL1RA, HE4, *2 3631 mps, dps, CA125, EMILIN, MDK, 97.39

3605 ips, CA125, MDK, , EGF, 96.768 EGF, GMCSF, HE4

GMCSF, IL1RA, HE4 3632 mps, dps, CA125, EMILIN, MDK, 97.514

3606 ips, CA125, MDK, , EGF, 96.555 EGF, GMCSF, *2

GMCSF, IL1RA, *2 3633 mps, dps, CA125, EMILIN, MDK, 97.585

3607 ips, CA125, MDK, , EGF, 96.733 EGF, IL1RA, HE4

GMCSF, HE4, *2 3634 mps, dps, CA125, EMILIN, MDK, 97.621

3608 ips, CA125, MDK, , EGF, IL1RA, 96.307 EGF, IL1RA, *2

HE4, *2 3635 mps, dps, CA125, EMILIN, MDK, 97.479

3609 ips, CA125, MDK, Ί, GMCSF, 96.697 EGF, HE4, *2

IL1RA, HE4, *2 3636 mps, dps, CA125, EMILIN, MDK, 97.763

3610 ips, CA125, MDK, EGF, GMCSF, 96.236 GMCSF, IL1RA, HE4

IL1RA, HE4, *2 3637 mps, dps, CA125, EMILIN, MDK, 97.621

3611 ips, CA125, *1, EGF, GMCSF, 94.354 GMCSF, IL1RA, *2

IL1RA, HE4, *2 3638 mps, dps, CA125, EMILIN, MDK, 97.585

3612 ips, EMILIN, MDK, Ί, EGF, 91.388 GMCSF, HE4, *2

GMCSF, IL1RA, HE4 3639 mps, dps, CA125, EMILIN, MDK, 97.869

3613 ips, EMILIN, MDK, Ί, EGF, 91.548 IL1RA, HE4, *2

GMCSF, IL1RA, *2 3640 mps, dps, CA125, EMILIN, Ί, EGF, 97.159

3614 ips, EMILIN, MDK, Ί, EGF, 90.874 GMCSF, IL1RA

GMCSF, HE4, *2 3641 mps, dps, CA125, EMILIN, Ί, EGF, 96.982

3615 ips, EMILIN, MDK, Ί, EGF, IL1RA, 91.371 GMCSF, HE4

HE4, *2 3642 mps, dps, CA125, EMILIN, Ί, EGF, 97.23

3616 ips, EMILIN, MDK, Ί, GMCSF, 91.584 GMCSF, *2

IL1RA, HE4, *2 3643 mps, dps, CA125, EMILIN, Ί, EGF, 97.23 IL1RA, HE4 3670 mps, dps, CA125, *1,EGF, 95.49

3644 mps, dps,CA125, EMILIN, Ί, EGF, 97.266 GMCSF, IL1RA, HE4

IL1RA, *2 3671 mps, dps, CA125, *1,EGF, 95.49

3645 mps, dps,CA125, EMILIN, Ί, EGF, 97.159 GMCSF, IL1RA, *2

HE4, *2 3672 mps, dps, CA125, *1,EGF, 95.455

3646 mps, dps,CA125, EMILIN, Ί, 97.124 GMCSF, HE4, *2

GMCSF, IL1RA, HE4 3673 mps, dps, CA125, , EGF, IL1RA, 95.49

3647 mps, dps,CA125, EMILIN, Ί, 97.195 HE4, *2

GMCSF, IL1RA, *2 3674 mps, dps, CA125, , GMCSF, 95.313

3648 mps, dps,CA125, EMILIN, Ί, 97.017 IL1RA, HE4, *2

GMCSF, HE4, *2 3675 mps, dps, CA125, EGF, GMCSF, 95.526

3649 mps, dps,CA125, EMILIN, Ί, 97.159 IL1RA, HE4, *2

IL1RA, HE4, *2 3676 mps, dps, EMILIN, MDK, Ί, EGF, 95.561

3650 mps, dps,CA125, EMILIN, EGF, 97.159 GMCSF, IL1RA

GMCSF, IL1RA, HE4 3677 mps, dps, EMILIN, MDK, Ί, EGF, 94.709

3651 mps, dps,CA125, EMILIN, EGF, 97.124 GMCSF, HE4

GMCSF, IL1RA, *2 3678 mps, dps, EMILIN, MDK, Ί, EGF, 95.17

3652 mps, dps,CA125, EMILIN, EGF, 97.195 GMCSF, *2

GMCSF, HE4, *2 3679 mps, dps, EMILIN, MDK, Ί, EGF, 95.739

3653 mps, dps,CA125, EMILIN, EGF, 97.39 IL1RA, HE4

IL1RA, HE4, *2 3680 mps, dps, EMILIN, MDK, Ί, EGF, 95.845

3654 mps, dps,CA125, EMILIN, 97.23 IL1RA, *2

GMCSF, IL1RA, HE4,*2 3681 mps, dps, EMILIN, MDK, Ί, EGF, 95.455

3655 mps, dps, CA125, MDK, , EGF, 96.68 HE4, *2

GMCSF, IL1RA 3682 mps, dps, EMILIN, MDK, Ί, 95.739

3656 mps, dps, CA125, MDK, , EGF, 96.52 GMCSF, IL1RA, HE4

GMCSF, HE4 3683 mps, dps, EMILIN, MDK, Ί, 95.774

3657 mps, dps, CA125, MDK, , EGF, 96.52 GMCSF, IL1RA, *2

GMCSF, *2 3684 mps, dps, EMILIN, MDK, Ί, 95.135

3658 mps, dps, CA125, MDK, , EGF, 96.484 GMCSF, HE4, *2

IL1RA, HE4 3685 mps, dps, EMILIN, MDK, *1 JURA, 95.881

3659 mps, dps, CA125, MDK, , EGF, 96.591 HE4, *2

IL1RA, *2 3686 mps, dps, EMILIN, MDK, EGF, 94.922

3660 mps, dps, CA125, MDK, , EGF, 96.555 GMCSF, IL1RA, HE4

HE4, *2 3687 mps, dps, EMILIN, MDK, EGF, 95.241

3661 mps, dps, CA125, ΜϋΚ,Ί, 96.733 GMCSF, IL1RA, *2

GMCSF, IL1RA, HE4 3688 mps, dps, EMILIN, MDK, EGF, 94.141

3662 mps, dps, CA125, ΜϋΚ,Ί, 96.768 GMCSF, HE4, *2

GMCSF, IL1RA, *2 3689 mps, dps, EMILIN, MDK, EGF, 95.348

3663 mps, dps, CA125, ΜϋΚ,Ί, 96.449 IL1RA, HE4, *2

GMCSF, HE4, *2 3690 mps, dps, EMILIN, MDK, GMCSF, 95.561

3664 mps, dps,CA125, MDK, *1, IL1RA, 96.733 IL1RA, HE4, *2

HE4, *2 3691 mps, dps, EMILIN, Ί, EGF, 94.709

3665 mps, dps, CA125, MDK, EGF, 96.449 GMCSF, IL1RA, HE4

GMCSF, IL1RA, HE4 3692 mps, dps, EMILIN, Ί, EGF, 95.064

3666 mps, dps, CA125, MDK, EGF, 96.52 GMCSF, IL1RA, *2

GMCSF, IL1RA, *2 3693 mps, dps, EMILIN, Ί, EGF, 93.75

3667 mps, dps, CA125, MDK, EGF, 96.378 GMCSF, HE4, *2

GMCSF, HE4, *2 3694 mps, dps, EMILIN, Ί, EGF, IL1RA, 95.241

3668 mps, dps, CA125, MDK, EGF, 96.502 HE4, *2

IL1RA, HE4, *2 3695 mps, dps, EMILIN, Ί, GMCSF, 95.241

3669 mps, dps, CA125, MDK, GMCSF, 96.52 IL1RA, HE4, *2

IL1RA, HE4, *2 3696 mps, dps, EMILIN, EGF, GMCSF, 94.709 IL1RA, HE4, *2 3723 mps, CA125, EMIUN, Ί, GMCSF, 96.857

3697 mps, dps, MDK, Ί, EGF, GMCSF, 93.75 IL1RA, HE4, *2

IL1RA, HE4 3724 mps, CA125, EMIUN, EGF, 96.733

3698 mps, dps, MDK, Ί, EGF, GMCSF, 94.318 GMCSF, IL1RA, HE4,*2

IL1RA, *2 3725 mps, CA125, MDK, , EGF, 96.165

3699 mps, dps, MDK, Ί, EGF, GMCSF, 93.999 GMCSF, IL1RA, HE4

HE4, *2 3726 mps, CA125, MDK, , EGF, 96.058

3700 mps, dps, MDK, , EGF, IL1RA, 94.247 GMCSF, IL1RA, *2

HE4, *2 3727 mps, CA125, MDK, , EGF, 95.881

3701 mps, dps, MDK, Ί, GMCSF, 94.176 GMCSF, HE4, *2

IL1RA, HE4, *2 3728 mps, CA125, MDK, , EGF, 96.271

3702 mps, dps, MDK, EGF, GMCSF, 93.146 IL1RA, HE4, *2

IL1RA, HE4, *2 3729 mps, CA125, MDK, Ί, GMCSF, 96.52

3703 mps, dps, , EGF, GMCSF, IL1RA, 90.838 IL1RA, HE4, *2

HE4, *2 3730 mps, CA125, MDK, EGF, GMCSF, 96.129

3704 mps, CA125, EMIUN, MDK, Ί, 97.408 IL1RA, HE4, *2

EGF, GMCSF, IL1RA 3731 mps, CA125, *1, EGF, GMCSF, 94.318

3705 mps, CA125, EMIUN, MDK, Ί, 97.266 IL1RA, HE4, *2

EGF, GMCSF, HE4 3732 mps, EMIUN, MDK, , EGF, 94.531

3706 mps, CA125, EMIUN, ΜϋΚ,Ί, 97.372 GMCSF, IL1RA, HE4

EGF, GMCSF, *2 3733 mps, EMIUN, MDK, , EGF, 94.993

3707 mps, CA125, EMIUN, MDK, Ί, 97.585 GMCSF, IL1RA, *2

EGF, IL1RA, HE4 3734 mps, EMIUN, MDK, , EGF, 94.815

3708 mps, CA125, EMIUN, MDK, Ί, 97.408 GMCSF, HE4, *2

EGF, IL1RA, *2 3735 mps, EMIUN, MDK, , EGF, 95.348

3709 mps, CA125, EMIUN, MDK, Ί, 97.159 IL1RA, HE4, *2

EGF, HE4, *2 3736 mps, EMIUN, MDK, , GMCSF, 95.17

3710 mps, CA125, EMIUN, MDK, Ί, 97.55 IL1RA, HE4, *2

GMCSF, IL1RA, HE4 3737 mps, EMIUN, MDK, EGF, GMCSF, 93.892

3711 mps, CA125, EMIUN, MDK, Ί, 97.656 IL1RA, HE4, *2

GMCSF, IL1RA, *2 3738 mps, EMIUN, Ί, EGF, GMCSF, 93.661

3712 mps, CA125, EMIUN, MDK, Ί, 97.408 IL1RA, HE4, *2

GMCSF, HE4, *2 3739 mps, MDK, Ί, EGF, GMCSF, 93.217

3713 mps, CA125, EMIUN, MDK, Ί, 97.585 IL1RA, HE4, *2

IL1RA, HE4, *2 3740 dps,CA125, EMIUN, MDK, Ί, 94.105

3714 mps, CA125, EMIUN, MDK, EGF, 97.195 EGF, GMCSF, IL1RA

GMCSF, IL1RA, HE4 3741 dps,CA125, EMIUN, MDK, Ί, 93.874

3715 mps, CA125, EMIUN, MDK, EGF, 97.266 EGF, GMCSF, HE4

GMCSF, IL1RA, *2 3742 dps,CA125, EMIUN, MDK, Ί, 94.247

3716 mps, CA125, EMIUN, MDK, EGF, 97.266 EGF, GMCSF, *2

GMCSF, HE4, *2 3743 dps,CA125, EMIUN, MDK, Ί, 94.176

3717 mps, CA125, EMIUN, MDK, EGF, 97.337 EGF, IL1RA, HE4

IL1RA, HE4, *2 3744 dps,CA125, EMIUN, MDK, Ί, 94.673

3718 mps, CA125, EMIUN, MDK, 97.479 EGF, IL1RA, *2

GMCSF, IL1RA, HE4,*2 3745 dps,CA125, EMIUN, MDK, Ί, 94.425

3719 mps, CA125, EMIUN, Ί, EGF, 96.697 EGF, HE4, *2

GMCSF, IL1RA, HE4 3746 dps,CA125, EMIUN, MDK, Ί, 94.212

3720 mps, CA125, EMIUN, Ί, EGF, 96.839 GMCSF, IL1RA, HE4

GMCSF, IL1RA, *2 3747 dps,CA125, EMIUN, MDK, Ί, 94.691

3721 mps, CA125, EMIUN, Ί, EGF, 96.733 GMCSF, IL1RA, *2

GMCSF, HE4, *2 3748 dps,CA125, EMIUN, MDK, Ί, 94.389

3722 mps, CA125, EMIUN, Ί, EGF, 96.964 GMCSF, HE4, *2

IL1RA, HE4, *2 3749 dps,CA125, EMIUN, MDK, Ί, 94.567 IL1RA, HE4, *2 3776 CA125, EMILIN, MDK, , EGF, 91.193

3750 dps, CA125, EMILIN, MDK, EGF, 93.466 GMCSF, IL1RA, HE4

GMCSF, IL1RA, HE4 3777 CA125, EMILIN, MDK, Ί, EGF, 91.264

3751 dps, CA125, EMILIN, MDK, EGF, 94.176 GMCSF, IL1RA, *2

GMCSF, IL1RA, *2 3778 CA125, EMILIN, MDK, , EGF, 90.838

3752 dps, CA125, EMILIN, MDK, EGF, 93.928 GMCSF, HE4, *2

GMCSF, HE4, *2 3779 CA125, EMILIN, MDK, , EGF, 91.104

3753 dps,CA125, EMILIN, MDK, EGF, 94.123 IL1RA, HE4, *2

IL1RA, HE4, *2 3780 CA125, EMILIN, MDK, , GMCSF, 91.797

3754 dps, CA125, EMILIN, MDK, 94.212 IL1RA, HE4, *2

GMCSF, IL1RA, HE4,*2 3781 CA125, EMILIN, MDK, EGF, 90.092

3755 dps, CA125, EMILIN, Ί, EGF, 92.685 GMCSF, IL1RA, HE4,*2

GMCSF, IL1RA, HE4 3782 CA125, EMILIN, Ί, EGF, GMCSF, 88.406

3756 dps, CA125, EMILIN, Ί, EGF, 92.898 IL1RA, HE4, *2

GMCSF, IL1RA, *2 3783 CA125, MDK, Ί, EGF, GMCSF, 89.471

3757 dps, CA125, EMILIN, Ί, EGF, 92.614 IL1RA, HE4, *2

GMCSF, HE4, *2 3784 EMILIN, MDK, Ί, EGF, GMCSF, 83.31

3758 dps, CA125, EMILIN, , EGF, 93.2 IL1RA, HE4, *2

IL1RA, HE4, *2 3785 ips, mps, dps, CA125, EMILIN, 98.189

3759 dps, CA125, EMILIN, Ί, GMCSF, 92.969 MDK, , EGF, GMCSF

IL1RA, HE4, *2 3786 ips, mps, dps, CA125, EMILIN, 98.153

3760 dps, CA125, EMILIN, EGF, 92.969 MDK, *1, EGF, IL1RA

GMCSF, IL1RA, HE4,*2 3787 ips, mps, dps, CA125, EMILIN, 98.189

3761 dps, CA125, MDK, , EGF, 94.318 MDK, *1, EGF, HE4

GMCSF, IL1RA, HE4 3788 ips, mps, dps, CA125, EMILIN, 98.118

3762 dps, CA125, MDK, , EGF, 94.283 ΜϋΚ,Ί, EGF,*2

GMCSF, IL1RA, *2 3789 ips, mps, dps, CA125, EMILIN, 98.26

3763 dps, CA125, MDK, , EGF, 94.247 MDK, Ί, GMCSF, IL1RA

GMCSF, HE4, *2 3790 ips, mps, dps, CA125, EMILIN, 98.118

3764 dps, CA125, MDK, , EGF, IL1RA, 94.318 MDK, , GMCSF, HE4

HE4, *2 3791 ips, mps, dps, CA125, EMILIN, 98.224

3765 dps, CA125, MDK, Ί, GMCSF, 94.176 MDK, , GMCSF, "2

IL1RA, HE4, *2 3792 ips, mps, dps, CA125, EMILIN, 98.189

3766 dps, CA125, MDK, EGF, GMCSF, 93.857 MDK, *1, IL1RA, HE4

IL1RA, HE4, *2 3793 ips, mps, dps, CA125, EMILIN, 98.224

3767 dps, CA125, *1, EGF, GMCSF, 91.726 MDK, Ί, I LIRA, *2

IL1RA, HE4, *2 3794 ips, mps, dps, CA125, EMILIN, 98.082

3768 dps, EMILIN, MDK, Ί, EGF, 89.844 ΜϋΚ,Ί, HE4,*2

GMCSF, IL1RA, HE4 3795 ips, mps, dps, CA125, EMILIN, 98.224

3769 dps, EMILIN, MDK, Ί, EGF, 90.518 MDK, EGF, GMCSF, IL1RA

GMCSF, IL1RA, *2 3796 ips, mps, dps, CA125, EMILIN, 98.153

3770 dps, EMILIN, MDK, , EGF, 90.341 MDK, EGF, GMCSF, HE4

GMCSF, HE4, *2 3797 ips, mps, dps, CA125, EMILIN, 98.082

3771 dps, EMILIN, MDK, Ί, EGF, 90.661 MDK, EGF, GMCSF, *2

IL1RA, HE4, *2 3798 ips, mps, dps, CA125, EMILIN, 98.438

3772 dps, EMILIN, MDK, Ί, GMCSF, 91.016 MDK, EGF, IL1RA, HE4

IL1RA, HE4, *2 3799 ips, mps, dps, CA125, EMILIN, 98.331

3773 dps, EMILIN, MDK, EGF, GMCSF, 88.352 MDK, EGF, IL1RA, *2

IL1RA, HE4, *2 3800 ips, mps, dps, CA125, EMILIN, 98.224

3774 dps, EMILIN, Ί, EGF, GMCSF, 87.464 MDK, EGF, HE4, *2

IL1RA, HE4, *2 3801 ips, mps, dps, CA125, EMILIN, 98.331

3775 dps, MDK, Ί, EGF, GMCSF, 90.057 MDK, GMCSF, IL1RA, HE4

IL1RA, HE4, *2 3802 ips, mps, dps, CA125, EMILIN, 98.331 MDK, GMCSF, IL1RA, *2 3829 ips.mps, dps, CA125, MDK, Ί, 97.976

3803 ips.mps, dps, CA125, EMIUN, 98.118 IL1RA, HE4, *2

MDK, GMCSF, HE4, *2 3830 ips, mps, dps, CA125, MDK, EGF, 97.798

3804 ips.mps, dps, CA125, EMIUN, 98.26 GMCSF, IL1RA, HE4

MDK, IL1RA, HE4,*2 3831 ips, mps, dps, CA125, MDK, EGF, 97.656

3805 ips.mps, dps, CA125, EMIUN, Ί, 98.047 GMCSF, IL1RA, *2

EGF, GMCSF, IL1RA 3832 ips, mps, dps, CA125, MDK, EGF, 97.834

3806 ips.mps, dps, CA125, EMIUN, Ί, 97.94 GMCSF, HE4, *2

EGF, GMCSF, HE4 3833 ips, mps, dps, CA125, MDK, EGF, 97.834

3807 ips.mps, dps, CA125, EMIUN, Ί, 97.976 IL1RA, HE4, *2

EGF, GMCSF, *2 3834 ips.mps, dps, CA125, MDK, 97.727

3808 ips.mps, dps, CA125, EMIUN, Ί, 98.26 GMCSF, IL1RA, HE4,*2

EGF, IL1RA, HE4 3835 ips.mps, dps, CA125, *1,EGF, 97.159

3809 ips.mps, dps, CA125, EMIUN, Ί, 98.224 GMCSF, IL1RA, HE4

EGF, IL1RA, *2 3836 ips.mps, dps, CA125, *1,EGF, 96.875

3810 ips.mps, dps, CA125, EMIUN, Ί, 98.047 GMCSF, IL1RA, *2

EGF, HE4, *2 3837 ips.mps, dps, CA125, *1,EGF, 96.946

3811 ips.mps, dps, CA125, EMIUN, Ί, 98.189 GMCSF, HE4, *2

GMCSF, IL1RA, HE4 3838 ips.mps, dps, CA125, *1,EGF, 97.053

3812 ips.mps, dps, CA125, EMIUN, Ί, 98.189 IL1RA, HE4, *2

GMCSF, IL1RA, *2 3839 ips, mps, dps, CA125, , GMCSF, 96.875

3813 ips.mps, dps, CA125, EMIUN, Ί, 98.118 IL1RA, HE4, *2

GMCSF, HE4, *2 3840 ips, mps, dps, CA125, EGF, 96.946

3814 ips.mps, dps, CA125, EMIUN, Ί, 98.26 GMCSF, IL1RA, HE4,*2

IL1RA, HE4, *2 3841 ips.mps, dps, EMIUN, MDK, Ί, 96.484

3815 ips.mps, dps, CA125, EMIUN, 98.118 EGF, GMCSF, IL1RA

EGF, GMCSF, IL1RA, HE4 3842 ips.mps, dps, EMIUN, MDK, Ί, 95.845

3816 ips.mps, dps, CA125, EMIUN, 98.1 EGF, GMCSF, HE4

EGF, GMCSF, IL1RA, *2 3843 ips.mps, dps, EMIUN, MDK, Ί, 95.952

3817 ips.mps, dps, CA125, EMIUN, 97.94 EGF, GMCSF, *2

EGF, GMCSF, HE4, *2 3844 ips.mps, dps, EMIUN, MDK, Ί, 96.697

3818 ips.mps, dps, CA125, EMIUN, 98.224 EGF, IL1RA, HE4

EGF, IL1RA, HE4, *2 3845 ips.mps, dps, EMIUN, MDK, Ί, 96.733

3819 ips.mps, dps, CA125, EMIUN, 98.118 EGF, IL1RA, *2

GMCSF, IL1RA, HE4,*2 3846 ips.mps, dps, EMIUN, MDK, Ί, 95.845

3820 ips.mps, dps, CA125, MDK, Ί, 97.798 EGF, HE4, *2

EGF, GMCSF, IL1RA 3847 ips.mps, dps, EMIUN, MDK, Ί, 96.68

3821 ips.mps, dps, CA125, MDK, Ί, 97.834 GMCSF, IL1RA, HE4

EGF, GMCSF, HE4 3848 ips.mps, dps, EMIUN, MDK, Ί, 96.413

3822 ips.mps, dps, CA125, MDK, Ί, 97.621 GMCSF, IL1RA, *2

EGF, GMCSF, *2 3849 ips.mps, dps, EMIUN, MDK, Ί, 95.756

3823 ips.mps, dps, CA125, MDK, Ί, 98.118 GMCSF, HE4, *2

EGF, IL1RA, HE4 3850 ips.mps, dps, EMIUN, MDK, Ί, 96.697

3824 ips.mps, dps, CA125, MDK, Ί, 97.834 IL1RA, HE4, *2

EGF, IL1RA, *2 3851 ips.mps, dps, EMIUN, MDK, EGF, 96.413

3825 ips.mps, dps, CA125, MDK, Ί, 98.011 GMCSF, IL1RA, HE4

EGF, HE4, *2 3852 ips.mps, dps, EMIUN, MDK, EGF, 96.484

3826 ips.mps, dps, CA125, MDK, Ί, 97.905 GMCSF, IL1RA, *2

GMCSF, IL1RA, HE4 3853 ips.mps, dps, EMIUN, MDK, EGF, 95.632

3827 ips.mps, dps, CA125, MDK, Ί, 97.834 GMCSF, HE4, *2

GMCSF, IL1RA, *2 3854 ips.mps, dps, EMIUN, MDK, EGF, 96.378

3828 ips.mps, dps, CA125, MDK, Ί, 97.834 IL1RA, HE4, *2

GMCSF, HE4, *2 3855 ips.mps, dps, EMIUN, MDK, 96.52 GMCSF, IL1RA, HE4,*2 3882 ips, mps, CA125, EMILIN, MDK, 98.757

3856 ips, mps, dps, EMILIN, , EGF, 96.058 EGF, IL1RA, HE4, *2

GMCSF, IL1RA, HE4 3883 ips, mps, CA125, EMILIN, MDK, 98.686

3857 ips, mps, dps, EMILIN, Ί, EGF, 95.969 GMCSF, IL1RA, HE4,*2

GMCSF, IL1RA, *2 3884 ips, mps, CA125, EMILIN, Ί, EGF, 98.366

3858 ips, mps, dps, EMILIN, Ί, EGF, 94.957 GMCSF, IL1RA, HE4

GMCSF, HE4, *2 3885 ips, mps, CA125, EMILIN, Ί, EGF, 98.366

3859 ips, mps, dps, EMILIN, Ί, EGF, 96.236 GMCSF, IL1RA, *2

IL1RA, HE4, *2 3886 ips, mps, CA125, EMILIN, Ί, EGF, 98.224

3860 ips, mps, dps, EMILIN, Ί, GMCSF, 96.271 GMCSF, HE4, *2

IL1RA, HE4, *2 3887 ips, mps, CA125, EMILIN, Ί, EGF, 98.473

3861 ips, mps, dps, EMILIN, EGF, 95.987 IL1RA, HE4, *2

GMCSF, IL1RA, HE4,*2 3888 ips, mps, CA125, EMILIN, Ί, 98.295

3862 ips, mps, dps, MDK, Ί, EGF, 95.419 GMCSF, IL1RA, HE4,*2

GMCSF, IL1RA, HE4 3889 ips, mps, CA125, EMILIN, EGF, 98.402

3863 ips, mps, dps, MDK, Ί, EGF, 95.33 GMCSF, IL1RA, HE4,*2

GMCSF, IL1RA, *2 3890 ips, mps, CA125, MDK, , EGF, 98.189

3864 ips, mps, dps, MDK, Ί, EGF, 95.011 GMCSF, IL1RA, HE4

GMCSF, HE4, *2 3891 ips, mps, CA125, MDK, , EGF, 98.047

3865 ips, mps, dps, MDK, Ί, EGF, 95.313 GMCSF, IL1RA, *2

IL1RA, HE4, *2 3892 ips, mps, CA125, MDK, , EGF, 98.118

3866 ips, mps, dps, MDK, Ί, GMCSF, 95.419 GMCSF, HE4, *2

IL1RA, HE4, *2 3893 ips, mps, CA125, MDK, , EGF, 98.047

3867 ips, mps, dps, MDK, EGF, GMCSF, 95.135 IL1RA, HE4, *2

IL1RA, HE4, *2 3894 ips, mps, CA125, ΜϋΚ,Ί, 98.082

3868 ips, mps, dps, , EGF.GMCSF, 93.43 GMCSF, IL1RA, HE4,*2

IL1RA, HE4, *2 3895 ips, mps, CA125, MDK, EGF, 97.976

3869 ips, mps, CA125, EMILIN, MDK, Ί, 98.509 GMCSF, IL1RA, HE4,*2

EGF.GMCSF, IL1RA 3896 ips,mps,CA125,*1, EGF.GMCSF, 97.088

3870 ips, mps, CA125, EMILIN, MDK, Ί, 98.295 IL1RA, HE4, *2

EGF.GMCSF, HE4 3897 ips, mps, EMILIN, MDK, Ί, EGF, 96.626

3871 ips, mps, CA125, EMILIN, MDK, Ί, 98.384 GMCSF, IL1RA, HE4

EGF, GMCSF, *2 3898 ips, mps, EMILIN, MDK, Ί, EGF, 96.733

3872 ips, mps, CA125, EMILIN, MDK, , 98.544 GMCSF, IL1RA, *2

EGF, IL1RA, HE4 3899 ips, mps, EMILIN, MDK, Ί, EGF, 96.058

3873 ips, mps, CA125, EMILIN, MDK, Ί, 98.58 GMCSF, HE4, *2

EGF, IL1RA, *2 3900 ips, mps, EMILIN, MDK, Ί, EGF, 96.626

3874 ips, mps, CA125, EMILIN, MDK, Ί, 98.438 IL1RA, HE4, *2

EGF, HE4, *2 3901 ips, mps, EMILIN, MDK, Ί, 96.555

3875 ips, mps, CA125, EMILIN, MDK, Ί, 98.615 GMCSF, IL1RA, HE4,*2

GMCSF, IL1RA, HE4 3902 ips, mps, EMILIN, MDK, EGF, 96.52

3876 ips, mps, CA125, EMILIN, MDK, Ί, 98.615 GMCSF, IL1RA, HE4,*2

GMCSF, IL1RA, *2 3903 ips, mps, EMILIN, Ί, EGF, 95.81

3877 ips, mps, CA125, EMILIN, MDK, Ί, 98.402 GMCSF, IL1RA, HE4,*2

GMCSF, HE4, *2 3904 ips, mps, MDK, Ί, EGF, GMCSF, 95.099

3878 ips, mps, CA125, EMILIN, MDK, Ί, 98.544 IL1RA, HE4, *2

IL1RA, HE4, *2 3905 ips, dps, CA125, EMILIN, MDK, Ί, 97.088

3879 ips, mps, CA125, EMILIN, MDK, 98.793 EGF.GMCSF, IL1RA

EGF.GMCSF, IL1RA, HE4 3906 ips, dps, CA125, EMILIN, MDK, , 96.911

3880 ips, mps, CA125, EMILIN, MDK, 98.686 EGF, GMCSF, HE4

EGF.GMCSF, IL1RA, *2 3907 ips, dps, CA125, EMILIN, MDK, , 96.982

3881 ips, mps, CA125, EMILIN, MDK, 98.509 EGF, GMCSF, *2

EGF, GMCSF, HE4, *2 3908 ips, dps, CA125, EMILIN, MDK, , 97.23 EGF, IL1RA, HE4 3935 ips, dps, EMILIN, MDK, Ί, EGF, 93.2

3909 ips, dps, CA125, EMILIN, MDK, , 97.514 GMCSF, HE4, *2

EGF, IL1RA, *2 3936 ips, dps, EMILIN, MDK, Ί, EGF, 93.501

3910 ips, dps, CA125, EMILIN, MDK, , 97.124 IL1RA, HE4, *2

EGF, HE4, *2 3937 ips, dps, EMILIN, MDK, Ί, 93.732

3911 ips, dps, CA125, EMILIN, MDK, , 97.124 GMCSF, IL1RA, HE4,*2

GMCSF, IL1RA, HE4 3938 ips, dps, EMILIN, MDK, EGF, 92.56

3912 ips, dps, CA125, EMILIN, MDK, , 97.301 GMCSF, IL1RA, HE4,*2

GMCSF, IL1RA, *2 3939 ips, dps, EMILIN, Ί, EGF, GMCSF, 92.152

3913 ips, dps, CA125, EMILIN, MDK, , 97.159 IL1RA, HE4, *2

GMCSF, HE4, *2 3940 ips, dps, MDK, Ί, EGF, GMCSF, 93.857

3914 ips, dps, CA125, EMILIN, MDK, , 97.266 IL1RA, HE4, *2

IL1RA, HE4, *2 3941 ips, CA125, EMILIN, MDK, Ί, EGF, 96.378

3915 ips, dps, CA125, EMILIN, MDK, 96.839 GMCSF, IL1RA, HE4

EGF, GMCSF, IL1RA, HE4 3942 ips, CA125, EMILIN, MDK, Ί, EGF, 96.52

3916 ips, dps, CA125, EMILIN, MDK, 97.266 GMCSF, IL1RA, *2

EGF, GMCSF, IL1RA, *2 3943 ips, CA125, EMILIN, MDK, Ί, EGF, 96.271

3917 ips, dps, CA125, EMILIN, MDK, 96.768 GMCSF, HE4, *2

EGF, GMCSF, HE4, *2 3944 ips, CA125, EMILIN, MDK, Ί, EGF, 96.733

3918 ips, dps, CA125, EMILIN, MDK, 97.408 IL1RA, HE4, *2

EGF, IL1RA, HE4, *2 3945 ips, CA125, EMILIN, MDK, Ί, 96.555

3919 ips, dps, CA125, EMILIN, MDK, 97.195 GMCSF, IL1RA, HE4,*2

GMCSF, IL1RA, HE4,*2 3946 ips, CA125, EMILIN, MDK, EGF, 96.378

3920 ips, dps, CA125, EMILIN, Ί, EGF, 96.342 GMCSF, IL1RA, HE4,*2

GMCSF, IL1RA, HE4 3947 ips, CA125, EMILIN, Ί, EGF, 94.922

3921 ips, dps, CA125, EMILIN, Ί, EGF, 96.342 GMCSF, IL1RA, HE4,*2

GMCSF, IL1RA, *2 3948 ips, CA125, MDK, , EGF, 96.697

3922 ips, dps, CA125, EMILIN, Ί, EGF, 96.129 GMCSF, IL1RA, HE4,*2

GMCSF, HE4, *2 3949 ips, EMILIN, MDK, Ί, EGF, 91.051

3923 ips, dps, CA125, EMILIN, Ί, EGF, 96.52 GMCSF, IL1RA, HE4,*2

IL1RA, HE4, *2 3950 mps, dps, CA125, EMILIN, MDK, 97.656

3924 ips, dps, CA125, EMILIN, Ί, 96.484 , EGF, GMCSF, IL1RA

GMCSF, IL1RA, HE4,*2 3951 mps, dps, CA125, EMILIN, MDK, 97.585

3925 ips, dps, CA125, EMILIN, EGF, 96.307 , EGF, GMCSF, HE4

GMCSF, IL1RA, HE4,*2 3952 mps, dps, CA125, EMILIN, MDK, 97.656

3926 ips, dps, CA125, MDK, , EGF, 97.088 , EGF, GMCSF, *2

GMCSF, IL1RA, HE4 3953 mps, dps, CA125, EMILIN, MDK, 97.763

3927 ips, dps, CA125, MDK, , EGF, 97.124 , EGF, IL1RA, HE4

GMCSF, IL1RA, *2 3954 mps, dps, CA125, EMILIN, MDK, 97.887

3928 ips, dps, CA125, MDK, , EGF, 96.839 , EGF, IL1RA, *2

GMCSF, HE4, *2 3955 mps, dps, CA125, EMILIN, MDK, 97.514

3929 ips, dps, CA125, MDK, Ί, EGF, 96.946 *1,EGF,HE4,*2

IL1RA, HE4, *2 3956 mps, dps, CA125, EMILIN, MDK, 97.621

3930 ips, dps, CA125, MDK, Ί, GMCSF, 96.839 , GMCSF, IL1RA, HE4

IL1RA, HE4, *2 3957 mps, dps, CA125, EMILIN, MDK, 97.692

3931 ips, dps, CA125, MDK, EGF, 96.804 , GMCSF, IL1RA, *2

GMCSF, IL1RA, HE4,*2 3958 mps, dps, CA125, EMILIN, MDK, 97.763

3932 ips, dps, CA125,*1, EGF, GMCSF, 95.739 Ί, GMCSF, HE4,*2

IL1RA, HE4, *2 3959 mps, dps, CA125, EMILIN, MDK, 97.869

3933 ips, dps, EMILIN, MDK, Ί, EGF, 93.058 *1,IL1RA, HE4,*2

GMCSF, IL1RA, HE4 3960 mps, dps, CA125, EMILIN, MDK, 97.585

3934 ips, dps, EMILIN, MDK, Ί, EGF, 93.537 EGF, GMCSF, IL1RA, HE4

GMCSF, IL1RA, *2 3961 mps, dps, CA125, EMILIN, MDK, 97.479 EGF, GMCSF, IL1RA, *2 3988 mps, CA125, EMILIN, MDK, Ί, 97.372

3962 mps, dps,CA125, EMILIN, MDK, 97.479 EGF, GMCSF, HE4, *2

EGF, GMCSF, HE4, *2 3989 mps, CA125, EMILIN, MDK, Ί, 97.727

3963 mps, dps,CA125, EMILIN, MDK, 97.763 EGF, IL1RA, HE4, *2

EGF, IL1RA, HE4, *2 3990 mps, CA125, EMILIN, MDK, Ί, 97.692

3964 mps, dps,CA125, EMILIN, MDK, 97.834 GMCSF, IL1RA, HE4,*2

GMCSF, IL1RA, HE4,*2 3991 mps, CA125, EMILIN, MDK, EGF, 97.266

3965 mps, dps,CA125, EMILIN, Ί, EGF, 97.088 GMCSF, IL1RA, HE4,*2

GMCSF, IL1RA, HE4 3992 mps, CA125, EMILIN, Ί, EGF, 96.626

3966 mps, dps,CA125, EMILIN, Ί, EGF, 97.23 GMCSF, IL1RA, HE4,*2

GMCSF, IL1RA, *2 3993 mps, CA125, MDK, , EGF, 96.236

3967 mps, dps,CA125, EMILIN, Ί, EGF, 97.053 GMCSF, IL1RA, HE4,*2

GMCSF, HE4, *2 3994 mps, EMILIN, MDK, , EGF, 94.709

3968 mps, dps,CA125, EMILIN, Ί, EGF, 97.283 GMCSF, IL1RA, HE4,*2

IL1RA, HE4, *2 3995 dps,CA125, EMILIN, MDK, Ί, 93.803

3969 mps, dps,CA125, EMILIN, Ί, 97.159 EGF, GMCSF, IL1RA, HE4

GMCSF, IL1RA, HE4,*2 3996 dps,CA125, EMILIN, MDK, Ί, 94.176

3970 mps, dps,CA125, EMILIN, EGF, 97.195 EGF, GMCSF, IL1RA, *2

GMCSF, IL1RA, HE4,*2 3997 dps,CA125, EMILIN, MDK, Ί, 94.105

3971 mps, dps, CA125, MDK, , EGF, 96.697 EGF, GMCSF, HE4, *2

GMCSF, IL1RA, HE4 3998 dps,CA125, EMILIN, MDK, Ί, 94.212

3972 mps, dps, CA125, MDK, , EGF, 96.768 EGF, IL1RA, HE4, *2

GMCSF, IL1RA, *2 3999 dps,CA125, EMILIN, MDK, Ί, 94.318

3973 mps, dps, CA125, MDK, , EGF, 96.573 GMCSF, IL1RA, HE4,*2

GMCSF, HE4, *2 4000 dps, CA125, EMILIN, MDK, EGF, 93.857

3974 mps, dps, CA125, MDK, , EGF, 96.839 GMCSF, IL1RA, HE4,*2

IL1RA, HE4, *2 4001 dps,CA125, EMILIN, Ί, EGF, 92.685

3975 mps, dps, CA125, ΜϋΚ,Ί, 96.839 GMCSF, IL1RA, HE4,*2

GMCSF, IL1RA, HE4,*2 4002 dps,CA125, MDK, Ί, EGF, 94.247

3976 mps, dps, CA125, MDK, EGF, 96.591 GMCSF, IL1RA, HE4,*2

GMCSF, IL1RA, HE4,*2 4003 dps, EMILIN, MDK, Ί, EGF, 90.057

3977 mps, dps, CA125,*1,EGF, 95.49 GMCSF, IL1RA, HE4,*2

GMCSF, IL1RA, HE4,*2 4004 CA125, EMILIN, MDK, , EGF, 90.945

3978 mps, dps, EMILIN, MDK, Ί, EGF, 95.526 GMCSF, IL1RA, HE4,*2

GMCSF, IL1RA, HE4 4005 ips, mps, dps, CA125, EMILIN, 98.295

3979 mps, dps, EMILIN, MDK, Ί, EGF, 95.668 MDK, Ί, EGF, GMCSF, IL1RA

GMCSF, IL1RA, *2 4006 ips, mps, dps, CA125, EMILIN, 98.224

3980 mps, dps, EMILIN, MDK, Ί, EGF, 94.886 MDK, Ί, EGF, GMCSF, HE4

GMCSF, HE4, *2 4007 ips, mps, dps, CA125, EMILIN, 98.153

3981 mps, dps, EMILIN, MDK, Ί, EGF, 95.792 ΜϋΚ,Ί, EGF, GMCSF, *2

IL1RA, HE4, *2 4008 ips, mps, dps, CA125, EMILIN, 98.295

3982 mps, dps, EMILIN, ΜϋΚ,Ί, 95.668 MDK, , EGF, IL1RA, HE4

GMCSF, IL1RA, HE4,*2 4009 ips, mps, dps, CA125, EMILIN, 98.295

3983 mps, dps, EMILIN, MDK, EGF, 95.17 MDK, , EGF, IL1RA, *2

GMCSF, IL1RA, HE4,*2 4010 ips, mps, dps, CA125, EMILIN, 98.189

3984 mps, dps, EMILIN, Ί, EGF, 95.064 MDK, , EGF, HE4, *2

GMCSF, IL1RA, HE4,*2 4011 ips, mps, dps, CA125, EMILIN, 98.295

3985 mps, dps, MDK, Ί, EGF, GMCSF, 94.176 MDK, Ί, GMCSF, IL1RA, HE4

IL1RA, HE4, *2 4012 ips, mps, dps, CA125, EMILIN, 98.224

3986 mps, CA125, EMILIN, MDK, Ί, 97.621 MDK, Ί, GMCSF, IL1RA, *2

EGF, GMCSF, IL1RA, HE4 4013 ips, mps, dps, CA125, EMILIN, 98.224

3987 mps, CA125, EMILIN, MDK, Ί, 97.55 MDK, Ί, GMCSF, HE4, *2

EGF, GMCSF, IL1RA, *2 4014 ips, mps, dps, CA125, EMILIN, 98.402 MDK, *1, IL1RA, HE4, *2 4041 ips, mps, CA125, EMIUN, MDK, Ί, 98.58

4015 ips, mps, dps, CA125, EMIUN, 98.295 EGF, GMCSF, IL1RA, HE4

MDK, EGF, GMCSF, IL1RA, HE4 4042 ips, mps, CA125, EMIUN, MDK, Ί, 98.58

4016 ips, mps, dps, CA125, EMIUN, 98.242 EGF, GMCSF, IL1RA, *2

MDK, EGF, GMCSF, IL1RA, *2 4043 ips, mps, CA125, EMIUN, MDK, Ί, 98.438

4017 ips, mps, dps, CA125, EMIUN, 98.153 EGF, GMCSF, HE4, *2

MDK, EGF, GMCSF, HE4,*2 4044 ips, mps, CA125, EMIUN, MDK, , 98.651

4018 ips, mps, dps, CA125, EMIUN, 98.438 EGF, IL1RA, HE4, *2

MDK, EGF, IL1RA, HE4, *2 4045 ips, mps, CA125, EMIUN, MDK, Ί, 98.722

4019 ips, mps, dps, CA125, EMIUN, 98.295 GMCSF, IL1RA, HE4,*2

MDK, GMCSF, IL1RA, HE4,*2 4046 ips, mps, CA125, EMIUN, MDK, 98.828

4020 ips, mps, dps, CA125, EMIUN, Ί, 98.047 EGF, GMCSF, IL1RA, HE4, *2

EGF, GMCSF, IL1RA, HE4 4047 ips, mps, CA125, EMIUN, Ί, EGF, 98.331

4021 ips, mps, dps, CA125, EMIUN, Ί, 98.224 GMCSF, IL1RA, HE4,*2

EGF, GMCSF, IL1RA, *2 4048 ips, mps, CA125, MDK, , EGF, 98.189

4022 ips, mps, dps, CA125, EMIUN, Ί, 97.94 GMCSF, IL1RA, HE4,*2

EGF, GMCSF, HE4, *2 4049 ips, mps, EMIUN, MDK, Ί, EGF, 96.662

4023 ips, mps, dps, CA125, EMIUN, Ί, 98.153 GMCSF, IL1RA, HE4,*2

EGF, IL1RA, HE4, *2 4050 ips, dps, CA125, EMIUN, MDK, , 96.875

4024 ips, mps, dps, CA125, EMIUN, Ί, 98.047 EGF, GMCSF, IL1RA, HE4

GMCSF, IL1RA, HE4,*2 4051 ips, dps, CA125, EMIUN, MDK, , 97.195

4025 ips, mps, dps, CA125, EMIUN, 98.011 EGF, GMCSF, IL1RA, *2

EGF, GMCSF, IL1RA, HE4, *2 4052 ips, dps, CA125, EMIUN, MDK, , 96.946

4026 ips, mps, dps, CA125, MDK, Ί, 97.834 EGF, GMCSF, HE4, *2

EGF, GMCSF, IL1RA, HE4 4053 ips, dps, CA125, EMIUN, MDK, , 97.23

4027 ips, mps, dps, CA125, MDK, Ί, 97.834 EGF, IL1RA, HE4, *2

EGF, GMCSF, IL1RA, *2 4054 ips, dps, CA125, EMIUN, MDK, , 97.195

4028 ips, mps, dps, CA125, MDK, Ί, 97.94 GMCSF, IL1RA, HE4,*2

EGF, GMCSF, HE4, *2 4055 ips, dps, CA125, EMIUN, MDK, 97.053

4029 ips, mps, dps, CA125, MDK, Ί, 98.011 EGF, GMCSF, IL1RA, HE4, *2

EGF, IL1RA, HE4, *2 4056 ips, dps, CA125, EMIUN, , EGF, 95.916

4030 ips, mps, dps, CA125, MDK, Ί, 97.905 GMCSF, IL1RA, HE4,*2

GMCSF, IL1RA, HE4,*2 4057 ips, dps, CA125, MDK, Ί, EGF, 97.017

4031 ips, mps, dps, CA125, MDK, EGF, 97.798 GMCSF, IL1RA, HE4,*2

GMCSF, IL1RA, HE4,*2 4058 ips, dps, EMIUN, MDK, Ί, EGF, 93.217

4032 ips, mps, dps, CA125, *1,EGF, 96.928 GMCSF, IL1RA, HE4,*2

GMCSF, IL1RA, HE4,*2 4059 ips, CA125, EMIUN, MDK, Ί, EGF, 96.307

4033 ips, mps, dps, EMIUN, MDK, Ί, 96.449 GMCSF, IL1RA, HE4,*2

EGF, GMCSF, IL1RA, HE4 4060 mps, dps, CA125, EMIUN, MDK, 97.727

4034 ips, mps, dps, EMIUN, MDK, Ί, 96.52 , EGF, GMCSF, IL1RA, HE4

EGF, GMCSF, IL1RA, *2 4061 mps, dps, CA125, EMIUN, MDK, 97.834

4035 ips, mps, dps, EMIUN, MDK, Ί, 95.739 , EGF, GMCSF, IL1RA, *2

EGF, GMCSF, HE4, *2 4062 mps, dps, CA125, EMIUN, MDK, 97.585

4036 ips, mps, dps, EMIUN, MDK, Ί, 96.697 , EGF, GMCSF, HE4, *2

EGF, IL1RA, HE4, *2 4063 mps, dps, CA125, EMIUN, MDK, 97.905

4037 ips, mps, dps, EMIUN, MDK, Ί, 96.555 , EGF, IL1RA, HE4, *2

GMCSF, IL1RA, HE4,*2 4064 mps, dps, CA125, EMIUN, MDK, 97.763

4038 ips, mps, dps, EMIUN, MDK, EGF, 96.378 , GMCSF, IL1RA, HE4, *2

GMCSF, IL1RA, HE4,*2 4065 mps, dps, CA125, EMIUN, MDK, 97.585

4039 ips, mps, dps, EMIUN, Ί, EGF, 95.934 EGF, GMCSF, IL1RA, HE4, *2

GMCSF, IL1RA, HE4,*2 4066 mps, dps, CA125, EMIUN, Ί, EGF, 97.195

4040 ips, mps, dps, MDK, Ί, EGF, 95.455 GMCSF, IL1RA, HE4,*2

GMCSF, IL1RA, HE4,*2 4067 mps, dps, CA125, MDK, , EGF, 96.697 GMCSF, IL1 RA, HE4, *2 MDK, EGF, GMCSF, IL1 RA. HE4,

4068 mps, dps, EMILIN, MDK, , EGF, 95.419

GMCSF, IL1 RA, HE4, *2 4077 ips, mps, dps, CA125, EMILIN, Ί , 98.082

4069 mps, CA125, EMILIN, MDK, Ί , 97.585 EGF, GMCSF, IL1RA, HE4, *2

EGF, GMCSF, IL1 RA, HE4, *2 4078 ips, mps, dps, CA125, MDK, Ί , 97.798

4070 dps, CA125, EMILIN, MDK, *1 , 93.892 EGF, GMCSF, IL1RA, HE4, *2

EGF, GMCSF, IL1 RA, HE4, *2 4079 ips, mps, dps, EMILIN, MDK, Ί, 96.325

4071 ips, mps, dps, CA125, EMILIN, 98.366 EGF, GMCSF, IL1RA, HE4, *2

MDK, Ί , EGF, GMCSF, IL1 RA, 4080 ips, mps, CA125, EMILIN, MDK, Ί , 98.615 HE4 EGF, GMCSF, IL1RA, HE4, *2

4072 ips, mps, dps, CA125, EMILIN, 98.295 4081 ips, dps, CA125, EMILIN, MDK, , 97.088 MDK, Ί , EGF, GMCSF, IL1 RA, *2 EGF, GMCSF, IL1RA, HE4, *2

4073 ips, mps, dps, CA125, EMILIN, 98.26 4082 mps, dps, CA125, EMILIN, MDK, 97.621 MDK, Ί , EGF, GMCSF, HE4, *2 , EGF, GMCSF, IL1 RA, HE4, *2

4074 ips, mps, dps, CA125, EMILIN, 98.402 4083 ips, mps, dps, CA125, EMILIN, 98.402 MDK, , EGF, IL1 RA, HE4, *2 MDK, Ί , EGF, GMCSF, IL1RA,

4075 ips, mps, dps, CA125, EMILIN, 98.438 HE4, *2

MDK, Ί , GMCSF, IL1 RA, HE4, *2

4076 ips, mps, dps, CA125, EMILIN, 98.366

Reference documents

1. Johnson WE, Li C, Rabinovic A. Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics. 2007; 8:118-127

2. Everitt, B. The Cambridge Dictionary of Statistics. Cambridge, UK New York: 1998;

Cambridge Universit Press.

3. Kohavi R, and John GH. Wrappers for feature subset selection. Artificial Intelligence 1997; 97(1 -2):273-324.

4. Breiman L. Random forests. Machine Learning, 2001 ; 45(1):5-32.

5. Liaw A. Documentation for R package randomForest (PDF), h ttp ://cran . r-project.

Org/web/packages/randomForest/randomForest.pdf, 16 October 2012, Retrieved: 7 April 2015.

Golland P, Liang F, Mukherjee S, and Panchenko D. Permutation tests for classification. In Annual Conference on Learning Theory, 2005; pages 501-515

Claims

1. A computer-implemented in vitro method of determining a subject's diagnostic state, the method comprising:

in a machine-learning phase:

- preparing a set of decision trees, each decision tree comprising at least a root node and a plurality of leaf nodes;

- wherein each node which is not a leaf node is associated with a feature and at least one threshold value for the feature;

- and wherein each feature indicates a level of a biomarker and/or clini- cal variable;

- and wherein each leaf node indicates a likelihood for the subject to have a disease;

in a diagnostic phase:

- processing levels of biomarkers and/or clinical variables obtained from the subject, wherein said processing comprises:

- traversing each of a subset of the set of decision trees from the root node to one of its leaf nodes;

- while traversing, at each node which is not a leaf node, comparing the threshold of the feature of the node with the level of the biomarker and/or clinical variable obtained from the subject and continuing traversing towards one of the leaf nodes based on said comparison;

- when said traversing ends at a leaf node, obtaining a likelihood value for the subject to have the disease from the leaf node at which said traversing ends;

- after traversing all decision trees in the subset, combining the likelihood values obtained from the leaf nodes.

2. The method of claim 1 , wherein said preparing the set of decision trees comprises executing a computer-executed process, which comprises:

- preparing a search space of multiple candidate feature subsets;

- using a machine-learning search process, wherein a heuristic function guides the search to find feature subsets with highest-scoring evaluated functions; and wherein an accuracy estimate is used as both the heuristic function and the evaluator function.

3. The method of claim 2, wherein repeated cross-validation is used as the evaluator function.

4. The method of any one of the preceding claims, further comprising using bootstrap aggregation with random subsets of features to fit the decision trees to training data, to thereby reduce overfitting with training data.

5. The method of any one of the preceding claims, wherein at least some decision trees of the subset comprise one or more intermediate nodes between the root node and the leaf nodes.

6. The method of any one of the preceding claims, wherein at least some of the features indicate clinical variables selected from a group which consists of the subject's general information, surgical information, medical history, obstetric history, and symptoms of one or more pains.

7. The method of any one of the preceding claims, wherein at least some of the features indicate clinical variables, which comprise qualitative assessments) of one or more pains, wherein the pains are selected from a group consisting of intercourse pain, menstrual pain and defecation pain.

8. The method of any one of the preceding claims, wherein at least some of the features indicate levels of biomarkers, wherein the biomarkers comprise one or more biomarkers selected from a group consisting of CA125, MDK, EMILIN1 , GM-CSF, PC ae C38:1 , PC ae C38:2, EGF, IL-1 Ra, IL-17, and HE4.

9. The method of any one of the preceding claims, wherein said disease is a disease associated with lower abdominal pain.

10. The method according to claim 9, wherein said disease is selected from a group consisting of endometriosis, endometrial cancer, ovarian cancer, colon cancer, ulcerative colitis, irritable bowel disease, irritable bowel syndrome and Crohn's disease.

11. A processor comprising:

- memory for storing program code instructions and data;

- one or more processing units for executing the program code instructions; - means for accessing clinical variables and biomarkers with respect to one or more subjects;

- wherein executing the program code instructions on the one or more processing units causes the processor to carry out the steps of the method of claim 1.

12. A tangible non-transitory memory, comprising the program code instructions as defined in claim 11.

13. A method of determining a subject's endometriosis state, said method comprising:

a) assessing levels of biomarkers comprising CA125,MDK, and EMIL-

IN1 in a sample obtained from said subject,

c) responsive to the comparison, determining the subject's endometri- osis state,

14. The method according to claim 13, wherein the biomarkers further comprise at least one biomarker selected from the group consisting of GM-CSF, PC ae C38:1 , PC ae C38:2, and any combination thereof.

15. The method according to claim 14, wherein the biomarkers further comprise at least one biomarker selected from the group consisting of EGF, IL- 1 Ra, IL-17, and any combination thereof.

16. The method according to any one of claims 13-15, wherein the biomarkers further comprise HE4.

17. The method according to any one of claims 13-16, wherein the method further comprises assessing at least one clinical variable selected from the group consisting of the subject's general information, surgical information, medical history, obstetric history, and pain symptoms.

18. The method according to claim 17, wherein said pain symptom comprises at least one pain symptom selected from the group consisting of menstrual pain, intercourse pain, and defecation pain.

19. The method according to any one of claims 13-18, wherein determining the endometriosis state comprises diagnosing, testing for, prognosing or monitoring endometriosis state, risk of endometriosis, response to treatment of endometriosis, recurrence or relapse of endometriosis, or risk of recurrence or relapse of endometriosis.

20. The method according to any one of claims 13-18, wherein the method is used for excluding the presence or risk of a lower abdominal pain-associated disease other than endometriosis.

21. The method according to claim 20, wherein said lower abdominal pain- associated disease is selected from the group consisting of endometrial can- cer, ovarian cancer, colon cancer, ulcerative colitis, irritable bowel disease, irritable bowel syndrome and Crohn's disease.

22. The method according to any one of claims 13-21 , wherein said sample is selected from the group consisting of urine, blood, serum, plasma, biopsy and tissue samples.

23. The method according to any one of claims 12-22, wherein said comparison of biomarker levels and determination of the endometriosis state are performed by a processor of a computing device.

24. An in vitro screening kit comprising reagents for determining a biological sample for the level of biomarkers comprising CA125, MDK, and EMILIN1.

25. The kit according to claim 24, further comprising reagents for determining the level of at least one biomarker selected from the group consisting of GM- CSF, PC ae C38:1 , PC ae C38:2, and any combination thereof.

26. The kit according to claim 24 or 25, further comprising reagents for determining the level of at least one biomarker selected from the group consisting of EGF, IL-1 Ra, IL-17, and any combination thereof.

27. The kit according to any one of claims 24-26, further comprising reagents for determining the level of HE4.

28. Use of a biomarker combination comprising CA125, MDK, and EMILIN1 for determining a subject's endometriosis state.

29. The use according to claim 28, wherein said combination further comprises at least one biomarker selected from the group consisting of, GM-CSF, PC ae C38:1 , PC ae C38:2, and any combination thereof.

30. The use according to claim 28 or 29, wherein said combination further comprises at least one biomarker selected from the group consisting of EGF, IL-1 Ra, IL-17, and any combination thereof.

31. The use according to any one of claims 28-30, wherein said combination further comprises HE4.